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SUMMARY 
HIV related facial lipoatrophy is a common complication of the treatment of 
HIV infection with highly active antiretroviral therapy (HAART). It is characterized 
by loss of fat in the face, arms and legs sometimes accompanied by increased 
central fat. The complication is stigmatising for patients and is linked to decreased 
quality of life, and poor adherence to HIV treatment. The exact compartmental 
changes in facial fat have not been defined and there is no established method for 
measuring these changes for use in clinical research. The aim of this research was to 
evaluate methods for measuring facial and whole body fat changes, and to apply 
these to investigate changes in a cohort of HIV infected patients receiving HAART. 
A cross-sectional study of facial fat volume by volumetric MRI was 
performed in HIV infected patients with lipoatrophy and controls with and without 
wasting. Facial fat depletion in lipoatrophy was found to be substantial 
(approximately 50% volume loss) and involved superficial and deep fat (buccal fat 
pad). A subsequent longitudinal study over one year was performed and showed that 
lipoatrophy patients had significant superficial facial fat decrease by 20% over 
one-year of HAART treatment.  
Body composition was measured in HIV-infected patients with 
lipodystrophy and non-lipodystophy controls on two DEXA machines (Lunar and 
Hologic). We found DEXA machines from different manufacturers give major 
differences in measurements of body fat content and distribution, and this might 
affect the ability to distinguish patients with lipodystrophy from those without 
 xii
lipodystrophy. Standardization of DEXA technology is needed before widespread 
application in the clinical diagnosis of lipodystrophy. 
Facial fat change assessed by three-dimensional laser scanning (LS) 
method was developed. Studies were conducted to evaluate its accuracy and 
reproducibility using a mannequin model and healthy subjects, and the method was 
then validated against MRI for its ability to detect lipoatrophy changes over time. 
LS was found to be an accurate and reproducible method for estimating cheek 
surface volume (CSV) changes and valid for measurement of facial fat volume 
changes over time. As a further refinement, a cheek surface point-displacement (CPD) 
method of analysis of scan data was validated against MRI facial fat volume and 
changes. CPD was found to be a valid method for detecting cheek volume changes. 
We found that it might also be a useful method in the diagnosis of facial lipoatrophy 
based on a single scan. 
These methods were then applied to a cohort of HIV infected patients to 
investigate the effect of HAART on facial fat and regional body composition 
changes over time. LS and DEXA were conducted both at study entry and repeated 
after 12 months of follow up. LS estimated CSV changes and CPD and its changes 
were calculated. Laser scanning could detect facial lipoatrophy changes in a 
longitudinal study, and could clearly detect the effects of individual drugs. Laser 
scan change was only partly related to limb fat changes. This potentially 
represented an objective and reliable method to assess facial fat change in future 
clinical trials. 
 xiii
In summary, this work had developed and evaluated facial and whole body 
fat change measurement techniques and applied these techniques to address relevant 
clinical questions about lipodystrophy in patients receiving HIV treatment.  
 xiv
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AIMS OF THIS THESIS 
 
The overall aims of the work are  
 
1. To quantify the magnitude and location of facial fat loss in lipoatrophy  
 
2. To develop an objective, reliable and affordable method for assessing 




AIMS OF THIS THESIS 
 
Strategy to achieve the aims 
 
1. To quantify the volume and anatomical location of facial fat in patients 
with lipoatrophy using the volumetric MRI scanning and to compare the 
pattern of soft tissue depletion with that seen in patients without 
lipoatrophy  
 
2. To quantify the volume change of facial fat in patients with lipoatrophy 
over one year follow up using volumetric MRI scanning 
 
3. To compare measurements of fat distribution between two different DEXA 
machines and to determine the impact of differences on lipodystrophy 
diagnosis 
 
4. To evaluate the accuracy and reproducibility of a standardised method for 
estimating cheek volume changes using laser scanning in a mannequin 




5. To validate laser scanning cheek surface volume estimation and cheek 
surface point-displacement measurement by MRI measurement for facial 
fat changes in HIV infected patients with lipoatrophy 
 
6. To assess the facial fat changes over time by cheek surface volume 
estimation and cheek surface point-displacement measurement in a cohort 
of HIV-infected patients taking combination antiretroviral therapy 
 
 
CHAPTER 1 INTRODUCTION 
 
1.1 Human immunodeficiency virus (HIV) infection 
 
1.1.1 Prevalence and transmission of HIV infection 
Human immunodeficiency virus (HIV) infection and the acquired 
immunodeficiency syndrome (AIDS) were first recognized in the early 1980s, and 
since then the number of people living with HIV has increased steadily resulting in 
a global pandemic (UNAIDS and WHO, 2005). The 2006 Report on the Global 
AIDS Epidemic by the Joint United Nations Programme on HIV/AIDS (UNAIDS) 
estimates that globally there are 38.6 million people living with HIV at the end of 
2006 (Joint United Nations Programme on HIV/AIDS, 2006). In 2005 alone, 
about 4.9 million people became infected with HIV, and about 3.1 million died of 
AIDS. Of all the HIV infected population, two thirds are in Africa, where the 
epidemic exploded during the 1990s, and one fifth is in Asia, where the epidemic 
has been growing rapidly in recent years. Adult HIV prevalence is lower in Asian 
countries than in countries in sub-Saharan Africa, and the epidemic in most Asian 
countries is attributable primarily to various high-risk behaviors (e.g., unprotected 
sexual intercourse with sex workers, injection drug users, or males who have sex 
with males (MSM)). Of the 8.3 million HIV-infected persons in Asia, 5.7 million 
live in India. Approximately 80% of HIV infections in India are acquired 
heterosexually(Kumar et al., 2006). In China, injecting drug users account for 
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approximately half of the 650,000 persons living with HIV infection (Ministry of 
Health China and UNAIDS and WHO, 2006; Ruan et al., 2005). In contrast, the 
epidemics in Thailand and Cambodia have been driven largely by commercial sex. 
In Thailand, HIV prevalence in pregnant women declined from 2.4% in 1995 to 
1.2% in 2003; however, HIV prevalence among MSM in Bangkok increased from 
17% in 2003 to 28% in 2005 (CDC, 2006).  
In Singapore, there are 2852 people reported with HIV infection/AIDS till 
the end of June of 2006 since the first case was reported in 1985. In 2005, 317 
people were newly confirmed with HIV infection, the figure was 149 for the first 6 
months in 2006. The majorities of HIV/AIDS cases were between 20-49 years and 
were predominantly male. The male to female ratio was 7.7:1. Among males, the 
highest proportion of HIV/AIDS cases was in the age group 30-39 years followed 
by those in the age group 40-49 years. Among the females, the majority was aged 
20-29 years followed by 30-39 years. The main mode of HIV transmission among 
all the HIV infected people was through sexual contact, representing 90.2% of 
cases in 2005, heterosexual transmission accounted for 58.4% of all cases in 2005 
while homosexual and bisexual transmission accounted for 31.9% (MOH 
Singapore, 2006).  
HIV is found in blood, semen, spinal fluid, breast milk, vaginal secretions, 
saliva and tears of human beings. The predominant mode of transmission of HIV 
worldwide is through unprotected sexual intercourse between men and women 
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(Steinbrook, 2004). Other routes of transmission include sexual intercourse 
between men, intravenous injections of drugs, transfusion of blood or blood 
products, tattooing, and sharing razor blades between individuals without 
sterilization. HIV infected mothers can also pass the virus on to their fetuses in 
utero or to infants via breast milk. HIV cannot spread by routine touch, kissing, 
shaking hands or by staying together with HIV-infected people. Also, HIV cannot 
be transmitted through insect bite, food or water. 
 
1.1.2 Pathogenesis of HIV infection 
HIV is a member of lentivirus subfamily of human retrovirus, 
characterized the presence of the enzyme RNA-dependent DNA polymerase 
(reverse transcriptase). The most common type is HIV-1 which was found in 1983 
and is the infectious agent that has led to the worldwide AIDS epidemic. There is 
also an HIV-2 which was found in 1984, and is much less common and less 
virulent, but eventually produces clinical findings similar to HIV-1 (Stevenson, 
2003).  
When HIV infects a cell, the reverse transcriptase enzyme transcribes its 
RNA to host cell proviral DNA, in which form it can integrate into the cellular 
genome. The proviral DNA directs the cell to produce additional HIV virions. 
Once infected, the cell can remain in a latent state, or it can actively produce viral 
RNA and proteins, leading to the release of infectious progeny which 
subsequently infect other cells. The usual route of infection is via Langerhans cells 
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in mucosal epithelial surfaces. Mucosal ulceration and inflammation which are 
caused by other sexually transmitted diseases also increase the chances of HIV 
infection through epithelial surfaces. The CD4 T-lymphocytes have surface 
receptors to which HIV can attach to promote entry into the cell. The human body 
responds to HIV infection by producing antibodies, some of which can neutralize 
the virus, although they are not protective once infection has taken place. The 
cellular immune system is also activated and there is evidence that cytotoxic T 
lymphocytes play an impartment role in controlling the virus, at least during 
primary infection (Koup and Ho, 1994).  
During acute HIV-1 infection, the virus replicates extensively in the absence 
of any detectable adaptive immune response, reaching levels of over 100 million 
copies HIV-1 RNA/ml. The above-mentioned pathogenic processes are thought to 
be occurred during this initial cycle of viral replication. These also include the 
seeding of virus to a range of tissue reservoirs and the destruction of CD4 
T-lymphocytes, especially within the lymphoid tissues of the gut. Hoverer, the very 
high levels of HIV-1 viremia are normally short-lived, indicating that the host is 
able to generate an immune response to control the viral replication. Viremia 
declines by several orders of magnitude over the following weeks before reaching a 
viral setpoint, which the production of new viral particles matches the rate of loss of 
virus particles. This setpoint, following resolution of the acute infection, is a strong 
predictor of long-term disease progression rates (Mellors et al., 1995). 
Accompanying the ongoing viral replication there is progressive depletion of CD4 
 4
lymphocytes (Roederer, 1995) that, if left unchecked, leads to progressive loss of 
immunological function. When the CD4 lymphocyte count drops below 200 cells 
/mm3, there is a much increased risk of developing the characteristic opportunistic 
infections and neoplasms of AIDS appear. Thus, measurement of viral load, which 
representative of the productively infected cells in the body and bears close 
relationship with survival from HIV disease (Mellors et al., 1995), plus the 
traditional surrogate marker of CD4 count provides accurate prognostic information 
and forms the foundation on which antiviral therapy is based. 
 
1.1.3 Clinical course of HIV infection 
The course of HIV infection can be divided into a number of phases 
(Bartlett and Finkbeiner, 1998). The first phase of HIV infection is acute infection. 
It lasts for a few weeks and is often accompanied by a short flu-like illness, the 
so-called seroconversion-illness which occurs usually 2 to 4 weeks following 
infection (Cooper et al., 1985). The most common symptoms are fevers, sweats, 
malaise, lethargy, anorexia, nausea, myalgia, arthralgia, headaches, sore throat, 
diarrhoea, generalised lymphadenopathy, a macular erythematous truncal eruption, 
and thrombocytopenia. In about 20% of people the symptoms are serious enough 
to lead them to consult a doctor, but the diagnosis is frequently missed. The viral 
load is high at this time. From 6 to 12 weeks after HIV infection, a variety of HIV 
antibodies can be measured in the blood, and remain detectable thereafter. This 
forms the basis of the commonly used methods for diagnosing HIV infection. 
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Following seroconversion, there is a clinically asymptomatic period, which may 
last for many years. The infected person shows no symptoms, although sometimes 
there may be swollen lymph nodes. Although the disease is clinically latent, the 
virus is actively replicating and there is a continuous destruction of CD4 cells 
(Perelson et al., 1997). This period is also called CDC stage A disease. After a 
period of time at equilibrium, the CD4 cell count starts to decline more rapidly. 
Three main reasons are proposed. First, the lymph nodes and tissues become 
damaged or 'burnt out' because of the years of over production. Second, HIV 
mutates and becomes more pathogenic, leading to more T helper cell destruction. 
Third, the body fails to keep up with replacement of the T helper cells that are lost. 
When the CD4 count declines to around 350 cells /mm3, patients often enter a 
symptomatic phase of infection. Initially many of the symptoms are mild, but as 
the immune system deteriorates the symptoms worsen. Mucocutaneous conditions, 
such as oral candidiasis and oral leukoplakia, are often the earliest indicators of 
immunological failure. This period is also called CDC stage B. The final phase of 
HIV infection is progression to AIDS (or CDC stage C disease). This is defined by 
the presence of one or more AIDS-defining opportunistic infections or 
malignancies such as PCP, cytomegalovirus virus colitis or Kaposi’s sarcoma 
(CDC, 1992). These usually occur when the CD4 cell count has fallen below 200 
cells /mm3. Until the recent advent of effective therapy (see section 1.1.3), AIDS 
was invariably fatal within a few years. 
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1.1.4 Treatment of HIV infection 
In the early 1980s, most patients with AIDS died within 2 years 
(Rothenberg et al., 1987). Therapy was limited to the treatment of opportunistic 
infections, which were often the proximate cause of death in patients with AIDS. 
By 1993, AIDS had become the number one killer of young adults in the US 
(CDC, 1996).  
In the early 1990s, zidovudine and didanosine, nucleoside analogues 
reverse transcriptase inhibitors (NNRTI) with the ability to block the action of 
HIV reverse transcriptase enzyme, were first used to treat HIV infection (Gershon, 
1991). However, when used as monotherapy the effect of these drugs was 
recognized to be brief and limited (Concorde Coordinating Committee, 1994; 
Volberding et al., 1995). There was rapid emergence of resistant viral strains 
associated with single point mutations in the reverse transcriptase gene with the 
monotherapy (Saag et al., 1993).  
In 1995, protease inhibitors (PI), which inhibit the HIV protease enzyme, 
became available as a new class of drug treatment. Combining two nucleosides 
with a PI to form a triple combination therapy, or highly active antiretroviral 
therapy (HAART), was found to markedly reduce mortality (Hammer et al., 1997) 
and was able to induce viral load suppression (Hirsch et al., 1999). Also, sustained 
suppression of HIV-1 titers could minimize viral replication, which would, in turn, 
deter the development of resistance to the new agents and allow for immune 
reconstitution (Gulick et al., 2000; Sterling et al., 2003).  
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A further important advance was the development of non-nucleoside 
reverse transcriptase inhibitors (NNRTIs) which could be used in place of the PI in 
combination with two NRTIs, and this triple combination was also very effective 
in suppressing HIV-1 replication (Staszewski et al., 1999). Recent comparative 
studies have shown that NNRTIs performed better than PIs when used in first line 
combinations (Chou et al., 2006; Miro et al., 2005) and the combination of two 
NRTIs plus one NNRTI is now the preferred initial HAART regimen. HAART 
had dramatically changed the effect of AIDS in the developed world by 
significantly reducing morbidity and mortality, as well as decreasing health-care 
and drug-use costs for treating AIDS patients (Sendi et al., 2001). The cohort 
studies that had been conducted in developing countries had also shown similar 
dramatic effects of HAART (Braitstein et al., 2006; Ivers et al., 2005; Laurent et 
al., 2005). However, in many developing countries, where antiretroviral therapy is 
not yet available HIV treatment is still limited to the treatment of complications 
and prophylaxis of other infections. In the last few years, there has been a 
significant increase in the political priority given to HAART delivery by many 
governments, and much new funding has been made available. In 2003, the World 
Health Organization (WHO) and UNAIDS “3 by 5” campaign set the target of 
providing antiretroviral treatment to three million people living with AIDS in 
developing countries and those in transition by the end of 2005 (World Health 
Organization, 2004). Based on WHO and UNAIDS report 2006, a total of 1.3 
million people in resource-limited and middle-income countries were receiving 
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antiretroviral therapy for HIV infection at the end of 2005. Although the target 
was not reached, major lessons from the initiative learned. The lessons included 
the utility of country-owned targets in mobilizing efforts and promoting 
accountability, the need for extensive partnerships to scale up activities, the 
importance of identifying and resolving health systems constraints, the challenges 
of ensuring equity, and the synergy between treatment initiatives and a 
simultaneous scaling-up of HIV prevention (World Health Organization, 2006).  
In 2005, G8 leaders made a commitment to “working with WHO, 
UNAIDS and other international bodies to develop and implement a package of 
HIV prevention, treatment and care, with the aim of coming as close as possible to 
universal access to treatment for all those who need it by 2010” (G8 Summit, 
2005). Five strategic priorities had been defined that would require a refocusing of 
WHO’s efforts and the mobilization of new resources. First, to recognize that 
wider access to HIV testing and counseling was essential; second, to deliver 
prevention to people living with HIV and their families; thirdly, to achieve 
universal access; fourthly, to tackle health system challenges brought to light by 
the “3 by 5” initiative with vigorous efforts; finally, to gather, analyze, interpret 
and disseminate strategic information about the scaling-up of HIV/AIDS 
programmes in the health sector (G8 Summit, 2005). 
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1.2 HIV-related lipodystrophy  
 
1.2.1 Clinical features and definition of terms  
From 1997, a number of reports began to emerge of HIV-treated patients 
who were experiencing changes in body appearance. The earliest studies reported 
patients on indinavir, a PI, for several months were found with abdominal weight 
gain (Viraben and Aquilina, 1998). Other studies reported neck/buffalo hump (Lo 
et al., 1998). Others reported peripheral lipoatrophy (Saint-Marc et al., 1999). In 
summary, the following signs of changes in body fat have been described:  
1. Increased waist size 
2. Increased breast size 
3. 'Buffalo hump' (fat accumulation around the neck and upper back) 
4. Fat deposits in other locations 
5. Facial wasting, especially of the cheeks 
6. Loss of subcutaneous fat in all parts of the body, most visibly in the 
limbs 
7. Wasting of the buttocks 
8. Prominent leg veins 
Others subsequently reported associations with insulin resistance (Dube et 
al., 2001; Mulligan et al., 2000; Thiebaut et al., 2000) and hypercholesterolemia 
(Grunfeld et al., 1989; Grunfeld et al., 1992) and attempted to unify these features 
into a single syndrome (see section 1.2.5.3, page 32) (Carr et al., 2003). 
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Considerable confusion arises from the imprecise nature of the terms used and 
their definitions. In this thesis, wherever possible, specific terms will be used to 
refer to individual manifestations e.g. facial lipoatrophy. When more general terms 
are needed the following definitions will be used:  
HIV-related lipoatrophy refers specifically to the loss of fat occurring in 
the face, arms, legs, buttocks or abdomen.  
HIV-related lipodystrophy will be used to refer to a process that may 
include either or both of HIV related lipoatrophy and accumulation of fat in the 
face, arms, legs, chest or abdominal areas.  
Lipodystrophy syndrome will be used to refer to a process that includes 
HIV-related lipodystrophy and that may also include cholesterol or triglyceride 
disturbances, insulin resistance and other abnormalities such as lactic acidosis.  
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1.2.2 Prevalence of HIV-related lipodystrophy  
Wide variations have been reported in the prevalence of body fat changes 
among people taking HAART. In a French APROCO cohort study of 624 patients 
who had been taking at least one PI for an average of 18 months, Saves et al found 
that 85% had experienced at least one physical change during that time. The most 
common changes were increased abdominal wall thickness, enlargement of veins 
in the legs and arms, increased waist size, wasting of the lower limbs and/or 
buttocks (Saves et al., 2002). In a cross-sectional French study of 685 
HIV-infected people, Boufassa et al found 59% had lipodystrophy including 63 
who had never received a PI (Boufassa et al., 2001). In a study of 1035 
participants, Heath et al found that 50% of patients self-reported abnormalities of 
body fat, with 36% reporting fat wasting, 33% increased abdominal girth, and 6% a 
buffalo hump (Heath et al., 2001). In an Australian survey of 724 patients 
conducted in 2000, Miller et al found that the most frequently affected body parts 
were the face (45%), the legs (43%), the abdomen (39%), the arms (38.5%) and 
the buttocks (36%) (Miller et al., 2000a). In another cross-sectional study of 581 
people on treatment, Thiebaut et al found that 38% of them had lipodystrophy 
(Thiebaut et al., 2000). In another German cohort of 221 HIV-infected patients on 
antiretroviral therapy followed for three years, Mauss et al found 34% of them 
developed lipodystrophy (Mauss et al., 2002). In the Lipodystrophy Italian 
Multicenter Study (LIMS) of 2258 subjects, fat maldistribution was present in 
33.2% of cases (Galli et al., 2000b). In the French Aquitaine cohort of 581 subjects, 
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the prevalence of lipodystrophy was 38%. The prevalence of fat wasting was 16%, 
fat accumulation 12%, and mixed syndrome 10% (Thiebaut et al., 2000). In the 
HIV Outpatient Study (HOPS) cohort, 49% of 1077 subjects developed 
manifestations of fat maldistribution (13% lipoatrophy, 13% fat accumulation, and 
23% mixed syndrome) (Lichtenstein et al., 2001). In the Multicenter AIDS Cohort 
Study of 868 HIV infected patients and a HIV-negative control group, Kingsley et 
al found that 25-35% of HIV patients had lost fat in the face, arms and legs 
compared to 2% of the HIV-negative group. No difference was found on fat 
accumulation in both groups (Kingsley et al., 2001a). In a study of 410 HIV 
infected patients conducted in Singapore, Dr Paton reported 46% of patients with 
peripheral fat loss, 32% with central fat gain, and 8% with a mixed clinical 
presentation (Paton et al., 2002). However, a retrospective review of over 1,600 
HIV-infected children on PIs found that only 1% had visibly recognizable changes 
in their body shape and composition (Babl et al., 1999). Table 1.1 shows the 
summary of the prevalence of HIV-related lipodystrophy reported in different 
studies. 
In summary, the prevalence of lipodystrophy in reported studies varied 
widely ranging from 1% to 85%. Lack of standardized objective case definition, 
variability in the way different physicians clinically assess fat distribution, 
selection bias, and extract of data from chart reviews are the common reason 
which might explain the wide discrepancy in prevalence (Sattler, 2003). Also, no 
HIV-negative control groups were used in some of the studies.  
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 Table 1.1. Prevalence of HIV-related lipodystrophy in different studies 
Author & year Study country Total patients Lipodystrophy 
Saves et al., 2002 France 624 85% 
Boufassa et al., 2001 France 685 59% 
Miller et al., 2000a Australia 724 51% 
Heath et al., 2001 Canada 1035 50% 
Lichtenstein et al., 2001 USA 1077 49% 
Thiebaut et al., 2000 France 581 38% 
Mauss et al., 2002 Germany 221 34% 
Galli et al., 2000b Italy 2258 33% 
Kingsley et al., 2001a USA 868 33% 
Babl et al., 1999 USA 1644 1% 
Paton et al., 2002 Singapore 410 54% 
 




1.2.3 Impact of HIV-related lipodystrophy 
Patients who have lipodystrophy may suffer considerable psychosocial and 
clinical symptoms related to these stigmatizing body changes. Firstly, patients 
may experience stigmatization from society as their appearance changes makes it 
difficult for patients to hide the presence of their underlying medical condition, 
and leads to the feelings of low self-esteem and distress. This is particularly the 
case with facial lipoatrophy. The psychological morbidity will also affect patients’ 
adherence to antiretroviral therapy regimens and thus increase the risk of treatment 
failure (Carrieri et al., 2001). Some patients may decide not to initiate or quit 
treatment for fear of developing HIV-related lipodystrophy and facial lipoatrophy 
in particular. However, there is increasing availability of drug combinations that 
reduce the risk of this complication as will be discussed below (Echavez and 
Horstman, 2005; Martinez et al., 2001a; Power et al., 2003; Talmor et al., 2002). 
The lipoatrophic risk of particular antiretroviral drugs influences the selection of 
new antiretroviral regimens (Gazzard, 2005). 
Also, endocrinological disturbances such as lipid and sugar metabolism 
suggest a greater risk of cardiovascular disease, with some patients experiencing 
high lactic level even lactic acidosis and accompanying abdominal pain, lethargy 
and neuromuscular weakness (Maggi et al., 2000). Fat accumulation may also 
cause clinical symptoms such as neck pain, respiratory difficulty, umbilical hernia, 
pain associated with breast enlargement in women, and gastroesophageal reflux.  
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1.2.4 Risk factors and pathogenesis of HIV-related lipodystrophy 
 
1.2.4.1 Risk factors of HIV-related lipodystrophy 
Many studies have been conducted to investigate the risk factors associated 
with lipodystrophy including central fat accumulation and peripheral fat loss. Carr 
reviewed the potential risk factors associated with lipodystrophy based on several 
large cross-sectional studies and two prospective cohort studies (Carr, 2003). 
Increasing age, current use and total duration of antiretroviral therapy, including 
NRTIs and PIs, but not NNRTIs have been recognized as risk factors that are seen 
consistently in cohorts. Other factors such as gender, AIDS diagnosis, greater CD4 
lymphocyte and HIV RNA responses to antiretroviral treatment, low body weight 
pre-therapy, use of the dual protease inhibitor combination ritonavir–saquinavir, 
were shown to have less clear associations. It was also not clear whether there was 
a definite hierarchy of responsible drugs as this had not been disentangled from 
the duration of therapy with each drug and class (Bogner et al., 2001; Boubaker et 
al., 2001; Carr, 2003; Carr et al., 2000; Heath et al., 2001; Lichtenstein et al., 2001; 
Martinez et al., 2001b; Miller et al., 2000b; Thiebaut et al., 2000). The following 
are some of the factors associated with body fat changes: 
 
Increasing age: 
The Australian Lipodystrophy Prevalence Survey found that the risk of 
body fat changes increased with age (Miller et al., 2000b). Individuals aged 40-49 
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had a two fold increased risk compared with those below 40, and the risk 
increased four fold in those over 50 years old (Lichtenstein et al., 2001). This 
pattern has been reflected in most other studies of risk factors for lipodystrophy. 
 
Gender  
Several studies have found that women were more likely to experience fat 
accumulation, or to experience more severe accumulation of fat, whereas men 
were more likely to have severe fat depletion (Galli et al., 2000a; Heath et al., 
2002; Martinez et al., 2001b; Wanke et al., 2000). However, race cut across this 
gendered effect; African American men and women were found to be less likely to 
experience fat accumulation (Wanke et al., 2000). Men also seem more likely to 
experience metabolic abnormalities. Unfortunately, the reasons for these gender 
differences are not understood, many aetiological studies have not included 
substantial numbers of female subjects or have not assessed gender as an 
independent variable. Furthermore, some studies with limited power constraints 
could not find increased risk among women (Boufassa et al., 2001; Mallal et al., 
2000; Rakotoambinina et al., 2001). 
 
Race 
Race may impact on lipodystrophy. African Americans were found to be 
less likely to experience body fat changes than other races (Lichtenstein et al., 
2001; Wanke et al., 2000). White race was found to associate with a greater 
 17
prevalence of lipodystrophy compared with Asian and African races in an 
Australian study (Mallal et al., 2000). Also, in a cross-sectional study of 156 
Korean subjects including 57 HIV-infected subjects receiving HAART, 42 
HAART-naive subjects, and 57 healthy controls, Chang et al found only 3.5% of 
the patients receiving HAART developed lipodystrophy (Chang et al., 2002). 
However, a prospective study of 12 black (mainly African) and 11 white men in 




The development and severity of lipodystrophy have been positively 
associated with the duration of HIV infection, negatively associated with previous 
HIV viral load, and both positively and negatively associated with blood CD4 
lymphocyte counts in various studies (Arpadi et al., 2001; Chen et al., 2002; 
Rakotoambinina et al., 2001). CD4 count prior to PI treatment was a predictor of 
current total fat mass, as was duration of time on PIs and weight prior to treatment 
(Carr et al., 2001). Poor CD4 cell reconstitution was associated with fat loss; those 
with CD4 cell increases of less than 100 cells/mm3 after two years of follow-up 
were more likely to have lipoatrophy (Lichtenstein et al., 2002). The mechanism 




Fat accumulation appears to be more common among people who are 
overweight, or have a high body mass index, before starting therapy, whereas fat 
depletion is more likely to be experienced by people with a lower body mass index 
(Galli et al., 2000a; Muurahainen et al., 2000; Raffi et al., 2000). However, more 
recent data suggested that higher baseline BMI and limb fat predict greater loss of 
limb fat at week 96 (Calmy et al., 2006).  
 
Current use and total duration of antiretroviral therapy,  
PI and lipodtsrophy 
The type and duration of antiretroviral therapy may be an important factor in 
determining what type of body fat and metabolic disorders an individual may 
experience. For example, various studies had found ritonavir/saquinavir, ritonavir, 
indinavir and saquinavir were associated with lipodystrophy. Indinavir had been 
particularly linked to abdominal fat accumulation (Boubaker et al., 2001; 
Lichtenstein et al., 2002; Lichtenstein et al., 2001). However, these studies might 
underestimate the incidence rate at all stages because they were carried out in the 
last quarter of 1998, when PIs had been standard therapy for less than two years in 
the USA (Lichtenstein et al., 2002; Lichtenstein et al., 2001). 
The emergence of physical changes had been associated with the length of 
time on PIs and NRTIs in some studies (Carr et al., 2001; Lichtenstein et al., 2001). 
However, the prevalence of body fat changes stabilized in the large MACS study 
after two years of treatment, which might suggest that some individuals were not at 
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risk of lipodystrophy no matter how long they stayed on treatments (Kingsley et al., 
2001b).  
 
NRTI and lipodystrophy 
Protease inhibitor therapy is not the only factor associated with body fat 
changes. There are a lot of case reports of lipodystrophy in people taking anti-HIV 
therapy that did not include PIs. Subsequent data confirmed earlier reports linking 
nucleoside analogues to lipodystrophy, lipoatrophy and metabolic irregularities 
(Carr et al., 2000; Galli et al., 2002). 
Stavudine is one of the NRTIs that is more strongly associated with body fat 
changes, specifically fat loss (lipoatrophy) (Chene et al., 2002; Dube et al., 2002; 
Nolan et al., 2002). Several large longitudinal studies also supported this conclusion 
(Bernasconi et al., 2002; Cohen et al., 2002a; Mallal et al., 2000; Mauss et al., 
2002).  
 
Combination of NRTI and PI and lipodystrophy 
Treatment with nucleoside analogues in combination with PIs was also 
found to dramatically increase the risk of lipodystrophy. In a 6-year study of 66 
patients, Cohen et al found the common morphological abnormalities (MoAs) at 
year 5 were buttock wasting and thinning of cheeks respectively. Body composition 
was examined after three years on treatment, and at year 4, and showed that whilst 
23% of those who had intensified treatment had developed three or more body fat 
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abnormalities, none of those who received treatment solely with PIs had developed 
severe lipodystrophy (Cohen et al., 2002b). In the Lipodystrophy Italian 
Multicenter Cohort Study (LIMS) of 2258 subjects, the risk was greater in subjects 
treated with a combined regimen of NRTIs and PIs (OR, 2.1 [95% CI, 1.6-2.9]) 
compared with patients treated only with NRTIs (OR, 1.0) (Galli et al., 2000b).  
 
NNRTI and lipodystrophy 
Although studies found that NRTI treatment was associated with 
lipodystrophy or lipoatrophy, little evidence of association was found between 
NNRTIs and lipodystrophy, even though efavirenz has been associated with 
elevated lipid levels. In a 3 year prospective, cross-sectional, multicentre, 
observational, cohort study of 221 ART naïve HIV-positive patients commencing 
antiretroviral therapy, Mauss et al found that stavudine use was associated with an 
increased risk for the lipodystrophy development (OR 2.1), NNRTI treatment was 
associated with a reduced risk (OR 0.2, CI 0.04-0.87) (Mauss et al., 2002). 
Prolonged treatment with an NNRTI-based combination has been associated with 
reduced risk of lipodystrophy when compared with prolonged PI treatment 
(Lichtenstein, 2005; Mauss et al., 2002). 
In summary, clinical studies have demonstrated that NRTI therapy alone 
provides sufficient conditions for the development of lipoatrophy (Carr et al., 2000; 
Madge et al., 1999; Saint-Marc et al., 1999). NRTI therapy is an independent risk 
factor for its occurrence in HAART-treated individuals (Mallal et al., 2000; 
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Saint-Marc et al., 2000; van der Valk et al., 2001). Clinical trials data have also 
supported the findings of observational cohort studies (John et al., 2001) that 
stavudine (stavudine) therapy is associated with an approximately two fold 
increased risk of lipoatrophy compared with zidovudine, in that the risk of clinical 
apparent lipoatrophy over 30 months is approximately 10-20% in zidovudine 
treated individuals and 40-50% among those treated with stavudine (Amin et al., 
2003; Chene et al., 2002; Joly et al., 2002). Lastly, switching NRTI therapy from 
stavudine to abacavir (Carr et al., 2002; Lafeuillade et al., 2003; Saint-Marc et al., 
1999) has been associated with significant improvement in fat atrophy. In contrast, 
over 30 trials investigating PI discontinuation as a therapeutic strategy have failed 
to demonstrate beneficial effects on fat atrophy, although metabolic abnormalities 
such as dyslipidaemia and insulin resistance showed a modest improvement at 48 
weeks (Drechsler and Powderly, 2002). 
Recently, Lichtenstein summarized statistically significant risk factors 
identified after a literature search of epidemiologic studies published or reported 
as of February 2005 and employed multivariate analysis using lipoatrophy and 
lipohypertrophy as dependent variables (Lichtenstein, 2005). Table 1.2 shows the 
statistically significant risk factors for lipoatrophy and lipohypertrophy in 
published or reported studies by multiple regression analysis. The most common 
statistically significant risk factors for lipoatrophy were exposure to and duration 
of thymidine analogues-most commonly stavudine (stavudine) (6/9), age (5/9), 
presence of markers of disease severity (CD4/HIV RNA) (5/9), duration of therapy 
 22
(3/9), and white race (3/9) in the 9 studies assessing lipoatrophy (Bogner et al., 
2001; Heath et al., 2002; Joly et al., 2002; Lichtenstein et al., 2003; Lichtenstein et 
al., 2001; Martinez et al., 2001b; Miller et al., 2003; Saves et al., 2002; Thiebaut et 
al., 2000). An additional nonrandomized, prospective study in 40 HIV-positive 
patients beginning their first antiretroviral therapy reported results after a mean of 
96 weeks of therapy. In multivariate analysis, treatment with stavudine was the 
strongest independent factor associated with rate of lipoatrophy (P=0.05) (Mallon 
et al., 2003). In the 8 studies assessing lipohypertrophy, the most common 
statistically significant risk factors were duration of therapy (3/8), markers of 
disease severity (3/8), age (3/8), and protease inhibitor use (4/8) (Bogner et al., 
2001; Heath et al., 2002; Joly et al., 2002; Lichtenstein et al., 2001; Martinez et al., 
2001b; Miller et al., 2003; Saves et al., 2002; Thiebaut et al., 2000). A further 
study in 2258 HIV-positive patients assessed adipose tissue alterations by gender 
(Galli et al., 2003). Logistic regression analysis demonstrated that men had a 
significantly lower adjusted risk of presenting with any alteration than women 
(OR: 0.47; 95% CI: 0.38-0.58; P<0.0001) and a significantly lower risk of 
lipohypertrophy (P=0.0022) and mixed fat redistribution (P<0.0001), whereas risk 
of lipoatrophy was similar between genders (Galli et al., 2003). The author 
suggested to use rigorous multivariate analyses controlling for numerous variables 
to reveal multiple risk factors, and the pathogenic mechanisms for fat 
redistribution revealed by the analysis might be that complex interactions between 
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host, disease, and drug factors might lead to the fat redistribution (Brinkman, 2005; 
Lichtenstein, 2005).  
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Age CD4/Viral load White race Tx duration D4T PI 
Author & year 
LA LH LA LH LA LH LA LH LA LH LA LH 
Miller et al., 2003 √ √ √ √     √ √ √ √ 
Lichtenstein et al., 2003   √  √        
        √ √  √ 
√   √     √   √ 
√      √      
 √       √    
√  √  √  √ √    √ 
  √ √     √   √ 
Lichtenstein et al., 2001 √ √ √ √ √    √    
Heath et al., 2001 
Saves et al., 2001 
Thiebaut et al., 2000 
Martinez et al., 2002       √ √ √    
Joly et al., 2000b 
Bogner et al., 2001a 
Paton et al., 2002 
Tx duration, treatment duration; LA, lipoatrophy; LH, lipohypertrophy; D4T, Stavudine; PI, protease inhibitor 
Ö indicated statistically significant risk factor for lipoatrophy or lipohypertrophy. 
Table 1.2 Statistically significant risk factors for lipoatrophy and lipohypertrophy in published or reported  
studies by multiple regression analysis 
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1.2.4.2 Pathogenesis of HIV-related lipodystrophy 
Based on the observational data, several pathogenic mechanisms for 
lipodystrophy in HIV had been hypothesized. Possible mechanisms including 
mitochondrial toxicity, adipocyte apoptosis mediated by proinflammatory 
cytokines such as tumor necrosis factor (TNF-α), impairment of adipocyte 
differentiation, and dysregulation of 11-β-hydroxysteroid dehydrogenase 
(11-β-HSD) had been proposed.  
 
Mitochondrial toxicity 
In 1999, Brinkman et al postulated a mechanism for the relationship 
between NRTIs and lipodystrophy, suggesting that mitochondrial toxicity of 
nucleoside analogs played an essential part in the development of lipodystrophy 
(Brinkman et al., 1999). The body composition changes observed in HIV-infected 
patients were similar to changes seen in patients with multiple symmetrical 
lipomatoses and the lipomatoses were associated with mutations in mitochondrial 
DNA (Hengel et al., 1997; Teplitsky and Halabe, 1999). Also, nucleosides 
inhibited mitochondrial DNA polymerase-γ (Berkovic et al., 1991). Thus, these 
two situations might share the same mechanism in causing the various 
morphologic changes, particularly the fat redistribution syndrome. Based on this 
mechanism, they hypothesized that NRTIs might play an important role in the 
pathogenesis of lipodystrophy with mitochondrial dysfunction through the 
inhibition of DNA polymerase gamma (Brinkman et al., 1999).   
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A number of subsequent studies had lent support to the hypothesis that 
toxicity to mitochondrial DNA might contribute to fat redistribution. In a group of 
23 HIV infected patients with lipoatrophy who had received ART for more than 6 
months, Shikuma et al found depleted mitochondrial DNA content in 
subcutaneous fat tissue from the neck, abdomen, and thigh in 19 of 23 (82.6%) 
compared with 2 of 20 (10%), 0 of 15, and 0 of 20 specimens from HIV patients 
without lipoatrophy, from ART naïve HIV patients, and from HIV seronegative 
patients, respectively (all P<0.001). No large mitochondrial DNA deletions or 
additions were noted in the patients with lipoatrophy, suggesting that a 
mitochondrial dysfunction is the result of reduced DNA content rather than DNA 
deletions (Shikuma et al., 2001). Similarly, Walker et al found that mean 
mitochondrial DNA content was 39% lower in buttock fat biopsies from patients 
with lipoatrophy (n=11) than in patients without lipoatrophy (n=13; P=0.02). Also, 
NRTI-treated patients (n=19) had a 44% lower mitochondrial DNA content than 
patients not on NRTI (n=5; P=0.01). No mitochondrial DNA point mutations or 
deletions were observed (Walker et al., 2002). In 28 patients treated with 
stavudine-containing regimens (n=17) or zidovudine-containing regimens (n=11), 
Van der Valk et al found that lower mitochondrial DNA content per adipocyte 
from subcutaneous thigh biopsies was correlated with severity of lipodystrophy (P 
= 0.007) (van der Valk et al., 2004). Shiramizu et al also found that mitochondrial 
DNA depletion was greatest in patients with lipoatrophy (50% depletion relative 
to seronegative adults), moderate in antiretroviral-experienced patients who did 
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not have lipoatrophy (40% depletion), and least in antiretroviral-naive patients 
(16% depletion) (Shiramizu et al., 2001).  
An NRTI switching study also provided supporting evidence for the 
hypothesis. Increased mitochondrial DNA (copies per adipocyte) 48 weeks after 
switching from a stavudine-containing regimen to abacavir- or zidovudine-based 
therapy along with some improvement in arm, leg, and trunk fat was observed 
(Thompson et al., 2003).  
In addition to the increased mtDNA depletion, Hammond et al also found 
evidence of mitochondrial dysfunction. Adipocytes from 6 out of 7 patients 
demonstrated cytochrome C oxidase (COX) activity reduced from baseline, 
correlating positively with mitochondrial DNA levels, Three patients also showed 
reduced expression of COX subunit I (Hammond et al., 2004). In a 48-week 
longitudinal study of 16 participants (on stavudine for more than 3 years; with 
lipoatrophy and/or hyperlactatemia), McComsey et al found that mtDNA was 
depleted at study entry in muscle, adipose tissue and PBMC but levels rebounded 
with respective mean increases of 141%, 146%, and 369% at week 48 after 
switching away from stavudine. Mean values for seven mitochondrial enzyme 
activities assays at entry indicated substantial loss of function (48% to 85% of 
controls) with significant improvement of complex I activity by week 48 
(McComsey et al., 2005b).  
Furthermore, results from other studies have suggested that mitochondrial 
toxicity is multifactorial, with both a disease and drug component. In a study of 24 
 28
HIV negative controls, 47 HIV-infected asymptomatic patients who had never 
been treated with antiretroviral drugs, and 8 HIV-infected patients who were 
receiving antiretroviral drugs and had symptomatic hyperlactatemia, Cote et al had 
noted differences in the ratio of mitochondrial to nuclear DNA in HIV negative 
controls (1.28±0.38), asymptomatic HIV-infected subjects who had never received 
antiretroviral therapy (0.72±0.19), and HIV-infected subjects with symptomatic 
mitochondrial toxicity while on therapy (0.28±0.06) (Cote et al., 2002). The 
abnormal values in the untreated HIV group suggests that mitochondrial DNA 
toxicity may be multifactorial, with both a disease and drug component (Brinkman, 
2005; Cote et al., 2002; Lichtenstein, 2005). 
 
Adipocyte apoptosis  
Adipocyte apoptosis mediated by proinflammatory cytokines such as 
TNF-α might be another explanation for lipodystrophy. Studies found increased 
expression of TNF-α, a cytokine known to induce apoptosis of adipocytes, in 
lipoatrophic tissue from HIV patients. In a study of 56 subjects, Johnson et al 
found elevated TNF-α expression in HIV-positive patients with fat redistribution 
(n=28) compared with HIV-positive patients controls (n=16), the author suggested 
that HIV infection or its treatment might be involved in the pathogenesis of 
lipoatrophy (Johnson et al., 2002). In a study of 131 patients with HIV infection, 
Vigouroux et al found markedly elevated levels of TNF-α and its soluble receptor, 
sTNFR1. In a subset analysis of patients with lipohypertrophy, lipoatrophy, and 
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mixed syndrome, sTNFR1 was significantly elevated in patients with lipoatrophy 
(P<0.05) and mixed syndrome (P<0.05) but not in patients with lipohypertrophy 
(Vigouroux et al., 2003). Similarly, levels of sTNFR2 were significantly higher in 
HIV-infected patients with lipodystrophy than in HIV-infected patients without 
lipodystrophy (Mynarcik et al., 2000). Furthermore, a significant difference 
between groups in the frequency of polymorphism -238 in the promoter region of 
the TNF-α gene (P=0.01) in a genetic case-control study conducted in 
HIV-positive patients both with (n=61) and without (n=35) lipodystrophy (Maher 
et al., 2002). HAART deregulates the homeostasis of TNF-α synthesis, a 
proinflammatory cytokine involved in lipid metabolism (Ledru et al., 2000), were 
also reported.  
Increased subcutaneous adipocyte apoptosis was also reported in clinical 
observation in lipoatrophic areas of HIV infected patients with lipodystrophy on 
antiretroviral therapy (Domingo et al., 1999). In a study of 15 HIV infected 
patients with lipoatrophy, Cherry et al found increased apoptosis in fat samples 
from patients with lipoatrophy treated with stavudine compared with 
HIV-uninfected controls. Also, the observed apoptosis improves toward normal 
within 48 weeks of switching away from stavudine to abacavir or zidovudine, 
suggesting a causative role for stavudine in this process (Cherry et al., 2005).  
Furthermore, several studies have found that adipocytes from patients with 
lipodystrophy treated with NRTIs and PIs had higher levels of 
sterol-regulatory-element-binding-protein-1 (SREBP1c, an adipocyte transcription 
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factor) and higher expression of TNF-α than did adipocytes from healthy controls. 
The adipocytes in HIV patients were also smaller and tended to cluster (Bastard et 
al., 2002). These data suggest that NRTIs may also have an effect in impairing 
adipocyte differentiation despite the increase in SREBP1c protein. The 
transcription factor for SREBP1c might be sequestered in an inactive form in the 
nuclear membrane, a phenomenon seen in vitro when adipocytes are treated with 
protease inhibitors (Bastard et al., 2002; Lichtenstein, 2005).   
 
Enzyme 11-β-hydroxysteroid dehydrogenase (11-β-HSD1) and fat accumulation 
Studies found that enzyme 11-β-HSD1 might also potentially play a role in 
fat redistribution syndromes. Enzyme 11-β-HSD1 participated in the catalyzing 
the conversion of inactive cortisone to cortisol, which is required for adipocyte 
differentiation. It was found to express to a higher degree in visceral fat than in 
subcutaneous fat and was elevated in the presence of cortisol. The differential 
expression of 11-β-HSD1 in visceral fat, its association with cortisol, and the 
well-established prevalence of elevated cortisol levels in HIV suggested that this 
enzyme might play a role in the pathogenesis of central fat accumulation in HIV 
(Chen and Garg, 1999).  
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1.2.5 Methods of assessing HIV-related lipodystrophy 
Although lipodystrophy is often obvious in clinical practice, for research 
studies it is necessary to have methods for quantifying the progression of this 
condition. Clinical assessment as well as more objective assessments has been 
used, as described below.  
 
1.2.5.1 Subjective clinical assessment  
In many studies, lipodystrophy had been assessed by patients’ report of 
peripheral fat wasting (face, arms, buttocks, or legs) or central abdominal fat 
accumulation, and confirmed by physical examination. Patients’ self-report of 
lipodystrophy was assessed by questionnaire. Patients and physicians 
independently recorded any lipoatrophy, diffuse fat accumulation, in the face, neck, 
dorso-cervical spine, arms, breasts, abdomen, buttocks, or legs, as well as the 
presence, site, and number of any lipomata (focal accumulations of fat). The degree 
of lipoatrophy, diffuse fat accumulation, or lipomatosis at every site on the body 
was rated as absent (score of 0), mild (noticeable on close inspection, score of 1), 
moderate (readily noticeable by patient or physician, score of 2), or severe (readily 
noticeable to a casual observer, score of 3) (Carr et al., 2003; Lichtenstein et al., 
2001). Patients classed as lipodystrophy had at least one moderate or severe feature 
of lipoatrophy, diffuse fat accumulation, or lipomatosis arising since the diagnosis 
of HIV infection, and that had been independently confirmed by physical 
examination to be moderate or severe—for example, a patient’s report of moderate 
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facial lipoatrophy and severe facial lipoatrophy on physical examination by the 
physician. Weight change without peripheral fat wasting or central adiposity was 
not classified as lipodystrophy (Carr et al., 2003; Lichtenstein et al., 2001).  
 
1.2.5.2 Objective assessment methods 
 
Dual-energy x-ray absorptiometry (DEXA) 
DEXA is a reference method for body composition measurement. DEXA 
measurement is based on three-compartment model that divides the body into fat 
tissue, lean tissue, and bone mass. DEXA emits X-rays at two different energy 
levels and a detector measures the attenuation of the energy through the body. As 
different tissues absorb the energy differently, the composition of soft tissue can be 
calculated. DEXA is highly reliable, and has good agreement with 
hydrodensitometry (Friedl et al., 1992; Prior et al., 1997). Also, DEXA estimates of 
body composition appear to be less affected by fluctuations in total body water 
(TBW) compared to hydrodensitometry and hydrometry (Kohrt, 1995). 
Furthermore, DEXA provides segmental and regional measures of body 
composition.  
However, some limitations also exist for the DEXA measurement. First, 
anteroposterior thickness of the subject and variation in fat distribution may affect 
the accuracy of DEXA estimates of soft tissue (Lohman, 1996). Second, DEXA is 
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good for measurement of whole body and peripheral fat, but it is no use in 
measurement of facial fat due to the surrounding skull; the facial fat has to be 
assumed (Brownbill and Ilich, 2005). Third, DEXA results vary with different 
machines and different software versions used, even those from the same 
manufacturer (Paton et al., 1995). In spite of its inability to assess facial fat, DEXA 
has gained widespread use in studies of HIV-related lipodystrophy.  
 
CT and MRI 
Computed tomography (CT) and magnetic resonance imaging (MRI) may 
be useful for the objective assessment of HIV-related lipodystrophy. These are 
possibly the most accurate and useful method of measuring percentage, 
distribution and actual amounts of all the main body composites (Sjostrom et al., 
1986; Tokunaga et al., 1983). MRI gives valid estimates of the amount and 
distribution of body fat, as tested both by comparisons with computerized 
tomography (Seidell et al., 1990) and by validation studies with cadaver analysis 
both in humans (Abate et al., 1994) and in pigs (Fowler et al., 1992). In the study 
of fat redistribution and metabolic change in HIV infection (FRAM) with 425 HIV 
infected male patients and 152 male non HIV infected controls, MRI of 
measurement of regional adipose tissue volumes were found to be able to separate 
patients with/without peripheral lipoatrophy and controls (Bacchetti et al., 2005).  
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MRI measurement methodology has also been used in the assessment of 
change in autologous fat grafting over time in both non-HIV and HIV infected 
patients. Goehde et al reported increase in facial fat after autologous fat grafting in 
a non-HIV infected patients with facial lipoatrophy by MRI (Goehde et al., 2005). 
In another study of 53 patients with facial defect, Horl et al reported facial fat 
change over time by repeated MRI measurements with good reproducibility (Horl 
et al., 1991). In a study of 15 HIV infected patients with facial lipoatrophy, MRI 
measured facial subcutaneous fat thickness at the level of the dental apices had 
been used to assess the Lipostructuring, the re-injection of autologous fatty tissue 
for correction of facial lipoatrophy with satisfactory results both clinically and by 
MRI assessment (Levan et al., 2002).  
CT measurement has also been used to measure facial fat. In a study of 13 
cadaver heads that were examined with spiral CT, Cavalcanti et al found that good 
reproducibility in head soft tissue measurement in interobserver and intraobserver 
measurements or between imaging and physical measurements in both 
3-dimentional CT protocols (Cavalcanti et al., 2004). Furthermore, single sliced 
CT scan (at the level of upper lip) of measurement of adipose tissue area in 61 
HIV infected patients were found to be able to separate patients with facial 
lipoatrophy and without facial lipoatrophy. There was a good correlation between 
clinical assessment of facial lipoatrophy and adipose tissue area. The method also 
presented with good inter-observer and intra-observer reproducibility (Padilla et 
al., 2004).  
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Long scan times and extremely high cost have limited the widespread use 
of CT and MRI in clinical studies of lipodystrophy. Radiation exposure with CT 
scan is another limitation, especially for longitudinal studies requiring repeat 
measurements. There have been no published longitudinal studies using these 
imaging methods to follow changes of lipodystrophy, although the FRAM cohort 
has plans for repeated whole body MRI scans 4 years after the baseline study 
(Tien et al., 2006).  
 
1.2.5.3 Lipodystrophy syndrome case definition model 
Lipodystrophy diagnosis has met with difficulties in trying to define the 
confusing set of interrelated disorders without clear distinguishing or diagnostic 
features. In 1999, the European Medicines Evaluation Agency (EMEA) convened 
a group of researchers to conduct a study to develop a case definition for 
HIV-associated lipodystrophy (Carr et al., 2003). The aim of the lipodystrophy 
case definition (LDCD) study was to provide an objective case definition that 
might facilitate estimates of disease prevalence and incidence and allow 
comparisons between studies. Four hundred and seventeen lipodystrophy cases 
and 371 HIV infected controls in 32 study sites were recruited into the study. 
Cases and controls were defined by self-reported morphological changes and 
confirmed by study physician. One half of the study group was used for 
construction of the model, and the other half was used to test the model. The 
parameters included in the study were dietary, metabolic, clinical, and exercise 
history; antiretroviral and metabolic drug history; and anthropometry and body 
composition data. Logistic regression models were used to develop the case 
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definition model. Finally, age, gender, disease duration, disease stage, waist:hip 
ratio, anion gap, high-density lipoprotein (HDL) cholesterol, trunk:limb fat ratio, 
intra-abdominal:extra-abdominal fat ratio, and leg fat percentage were included in 
the model. A model was developed in which a total lipodystrophy score could be 
derived by adding the relevant individual score for each parameter and then 
subtracting 43 (the constant). A final score for a given patient of ≥0 means 
presence of lipodystrophy and a score <0 means no lipodystrophy. This model had 
79% (95% confidence interval [CI], 70 to 85) sensitivity and 80% (95% CI, 71 to 
87) specificity (Carr and Law, 2003). Table 1.3 shows the detailed components of 
the model. As a further refinement, based on quartiles of physician-rated severity, 
the LDCD scores were categorized as absent (LDCD score < 0), grade 1 (0-9.9), 
grade 2 (10-14.9), grade 3 (15-22.9), and grade 4 (> or =23) as the severity of 
lipodystrophy (Carr and Law, 2003). In contrast to DEXA and CT, it is also 
gender independent. It could be used as an objective grading scale in future 
cross-sectional study and longitudinal studies.  
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Parameter Unit OR P value Lipodystrophy score† 
Demographic 
Male 1  0    Sex 
Female 9.33 < .001 22 
</= 40 years 1  0    Age 
> 40 years 2.02 0.008 7 
</= 4 years 1  0 
   Duration of HIV 
infection 
> 4 years 3.11 < .001 11 
A 1  0 
B 1.32 0.361 3 
   CDC category 
C 1.92 0.043 7 
Clinical 
   Waist-to-hip ratio 0.1 1.34 0.014 Multiply value by 29 
Metabolic 
   HDL cholesterol 0.1 mmol/L 0.87 < .001 Multiply value by 214 
   Anion gap 1 mmol/L 1.101 0.001 Multiply value by 1 
Body composition 
< 0.45 1  0 
0.45 - 0.83 0.82 0.613 22 
0.83 - 1.59 1.4 0.416 3 
   VAT-to-SAT ratio 
> 1.59 3.7 0.007 13 
   Trunk-to-limb fat ratio 1 1.72 0.014 Multiply value by 5 
> 21.4 1  216 
14.5 - 21.4 1.27 0.559 214 
8.8 - 14.5 2.32 0.051 28 
   Leg fat percentage 
< 8.8 5.04 0.001 0 
OR, odds ratio; HDL, high-density lipoprotein; VAT, visceral adipose tissue; SAT, subcutaneous adipose tissue. 
*The model has a sensitivity of 79% (95% confidence interval [CI], 70 to 85) and specificity of 80% (95% CI, 71 
to 87). †A total lipodystrophy score is derived by adding the relevant individual score for each parameter and then  
subtracting 43 (the constant). A final score greater than or equal to zero for a given patient constitutes presence of  
lipodystrophy; a score less than zero constitutes no lipodystrophy. 
Reprinted from Carr A et al. Lancet. 2003;361:726-735 
Table 1.3 HIV lipodystrophy case definition and scoring system* 
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1.2.5.4 Limitation of the lipodystrophy case definition model 
This LDCD model provides one intriguing way to define and categorize 
the complex features that were considered to be part of a single syndrome (Carr 
and Law, 2003). However, several shortcomings in the definition have limited its 
widespread clinical and research use. First, although facial lipoatrophy is probably 
the most important component of the “lipodystrophy syndrome” for patients, the 
LDCD model fails to assess the facial fat loss in patients with lipodystrophy due to 
the lack of an appropriate and objective measurement method. Secondly, the 
LDCD diagnostic model requires CT or MRI for assessment of visceral fat and 
DEXA scan for assessment of extremity fat. These methods are not available to 
the general HIV population for purposes of the diagnosis of HIV lipodystrophy 
because of their inconvenience, cost, and (in the case of CT) radiation exposure. 
Also, it is known that DEXA results vary with manufacturers, as well as with 
hardware and software versions used. Studies using DEXA instruments at various 
clinical research centers revealed considerable inter-machine differences, even 
among machines from the same manufacturer (Paton et al., 1995). Thirdly, there is 
an increasingly large body of evidence that points to the fact that lipoatrophy and 
lipohypertrophy and other proposed manifestations of the syndrome, might not be 
linked to each other, and might represent particular toxicities of individual drugs 
used in combination ART regimens (Bacchetti et al., 2005; Kotler, 2002; Palella et 
al., 2004; Tien et al., 2003). Thus, the case definition needs to be used in caution. 
Also, this case definition study did not distinguish lipoatrophy with true 
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HIV-associated wasting and these two manifestations might be overlapping with 
each other in some patients.  
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1.3 Treatment of HIV-related lipodystrophy 
Currently, there is no adequate treatment to resolve lipodystrophy. Many 
strategies have been attempted to address this problem including, diet adjustment, 
physical exercise, recombinant human growth hormone (rhGH), switching 
antiretroviral drugs, discontinuing all antiretroviral therapy, and surgical 
correction (Milinkovic and Martinez, 2005).  
 
1.3.1 Diet adjustment and physical exercise 
One study found no beneficial effect on lipodystrophy with diet adjustment, 
unless dietary abnormalities were present (Batterham et al., 2000). Exercise may 
lead to some beneficial effect in decreasing central fat accumulation and 
triglyceride levels, but may also lead to worsening of peripheral fat wasting 
(Roubenoff et al., 1999; Smith et al., 2001).  
 
1.3.2 Recombinant human growth hormone (rhGH) 
Recombinant human growth hormone (rhGH) has also been tested for 
lipodystrophy treatment. One study found that the hormone could be useful in 
patients with increased visceral abdominal fat and/or buffalo hump, but it may also 
lead to decreasing in peripheral fat. Furthermore, adverse reactions to high doses 
of rhGH might affect the long-term efficacy and drug safety (Bickel et al., 2005; 
Engelson et al., 2002; Lo et al., 2001).  
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1.3.3 NRTI switching strategy 
Switching particular lipoatrophy-associated NRTIs (especially stavudine) 
to less toxic drugs has been associated with periphery fat gain in several clinical 
trials. In the MITOX study, 111 patients with lipoatrophy were randomized to 
either switching the thymidine analogue to abacavir or continuing their previous 
regimen. Peripheral fat mass measured by DEXA showed a modest improvement 
(0.4 kg increase over baseline) 6 months after the switch. However, no subjective 
improvement and no correlations between subjective severity scores and objective 
data were noted (Carr et al., 2002). 
Additional analyses showed a median gain of 36% from baseline in limb 
fat 2 years after switching treatment (Martin et al., 2004). The benefit of switching 
stavudine to abacavir has been supported in other studies (McComsey et al., 2005a; 
McComsey et al., 2004).  
Although switching from a thymidine analogue does confer an increase in 
peripheral fat, the effect is relatively modest and slow. Extended follow-up of the 
GS 903 study gave some insight into the rate of limb fat gain possible (Zhong et 
al., 2005). At the end of the GS 903 study, which was a randomized comparison of 
tenofovir vs. stavudine on a background of lamivudine and efavirenz in naive 
subjects, patients in the stavudine arm were offered the option of switching to 
tenofovir. The study found a considerable increase in subcutaneous fat as 
measured by DEXA scan after 1 year of switching in a substudy of 74 patients 
who switched their stavudine to tenofovir, even though patients still had 
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considerable lipoatrophy. Interestingly, patients had a decline in mean limb fat 
from approximately 5.0 kg to 4.6 kg before switching; whereas, limb fat had 
increased back to a mean of 5 kg after 1 year stopping of stavudine. The results 
suggested that these patients had regained the fat they had lost in the previous year 
on stavudine. Even if complete reversibility of lipoatrophy might be possible and 
the rate of limb fat recovery remains constant over time, the time required for the 
limb fat to be completely regained may be as long as the length of time the patient 
was previously on stavudine. Many patients may not want to wait if they do not 
notice the change during the first year or more of recovery, even though objective 
improvements may be confirmed by DEXA (Zhong et al., 2005).  
 
1.3.4 Structured treatment interruption (STI) 
Discontinuing all antiretroviral therapy had also been proposed as a 
strategy. However, very little data is available about the evolution of lipid 
abnormalities and body fat change. Preliminary data obtained from a group of 
well-controlled patients with primary HIV infection have shown gain of total and 
regional fat during consecutive cycles of structured treatment interruptions (STIs) 
(Milinkovic et al., 2003). However, unfavorable consequences, such as HIV drug 
resistance emergence, and immunological and virological disease progression 
might limit the use of this strategy. Patients have had to be closely monitored and 
only selected patients with better immune preservation could stand the prolonged 
STI strategy (Maggiolo et al., 2004). Recent data from the SMART study showed 
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clear detrimental effects of treatment interruption, including inferior outcomes on 
metabolic and other parameters related to drug toxicity (El-Sadr et al., 2006), so 
this is not a reasonable strategy for treating lipodystrophy at present.  
 
1.3.5 Thiazolidinediones and leptin treatment 
Thiazolidinediones and leptin have been used in non-HIV-infected patients 
with familial and autoimmune lipodystrophy with good results (Arioglu et al., 
2000; Oral et al., 2002; Petersen et al., 2002). Preliminary pilot study also 
suggested that rosiglitazone might contribute to fat gain in HIV-infected patients 
regardless of ongoing antiretroviral therapy (Gelato et al., 2002). However, 
randomized, placebo-controlled studies have failed to show body fat improvement 
in HIV lipoatrophy, and the glitazones may even worsen dyslipidaemia despite the 
improvement of insulin sensitivity (Carr et al., 2004; Sutinen et al., 2003). 
Similarly, randomized, placebo-controlled, double-blinded, crossover study of 7 
HIV infected patients with lipoatrophy also failed to show body fat improvement, 
although improved insulin resistance, high-density lipoprotein, and increased 
truncal fat mass were noted over time (Lee et al., 2006). The reason for the 
disappointing results might be the continued exposure to thymidine analogue 
therapy (Mallon et al., 2005).  
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1.3.6 Plastic surgical intervention 
Plastic surgical intervention such as liposuction and breast reduction for 
the treatment of local fat hypertrophy has been successfully performed, but 
appears to be associated with an increased risk of secondary infection, and 
recurrence of the fat accumulation is possible (Piliero et al., 2003).  
As for the treatment of facial lipoatrophy, repeated subcutaneous injection 
of substances such as poly-L-lactic acid (PLLA), a resorbable molecule that 
promotes collagen formation, has been effectively used in HIV patients (Cattelan 
et al., 2006; Lafaurie et al., 2005; Mest and Humble, 2004; Valantin et al., 2003). 
Although plastic surgery can help some people with lipodystrophy, the treatments 
are expensive and in the centers where the treatment is carried out there are often 
waiting lists of one year or more. In some cases, the improvements are only 




In summary, facial and whole body fat changes occur during the entire 
course of HIV infection and its treatment. Body fat changes, especially facial fat 
changes cause emotional distress, and significantly affect patients’ self-esteem, 
treatment adherence and quality of life. Development of methods for measuring 
body fat changes, especially facial fat changes, in clinical research is essential for 
understanding the development of the disease and for assessing potential 
interventions in clinical trials.  
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CHAPTER 2 MRI FACIAL FAT AND BODY COMPOSITION 




Lipodystrophy is a common complication of the treatment of HIV disease. 
It is usually characterized by atrophy of fat in the face, arms and legs and 
sometimes by fat accumulation in central areas. These changes are often 
accompanied by hyperlipidaemia and insulin resistance (Carr et al., 2003). Facial 
lipoatrophy is the most distressing manifestation for patients, and the resulting 
stigma and psychological morbidity may affect adherence to treatment (Collins et 
al., 2000; Martinez et al., 2001). Although the aetiology of lipoatrophy is 
uncertain, it is most likely related to mitochondrial toxicity caused by nucleoside 
analogue medication (Brinkman et al., 1999).  
In spite of its importance to patients, and the efforts that have been made in 
developing treatments, there have been few studies that have properly quantified 
the extent and location of facial fat depletion in HIV related lipoatrophy. It has 
been suggested by some authors that there is widespread loss of fat in the buccal, 
parotid and pre-auricular fat pads (Pujol et al., 2000; Viraben and Aquilina, 1998), 
although these conclusions have been based on clinical observation only.   
The aim of the study was to quantify the volume and anatomical location 
of facial fat in patients with lipoatrophy using the volumetric MRI scanning and to 






We recruited 45 male HIV infected patients (confirmed by ELISA and 
Western Blot assay) from the outpatient clinics of the Communicable Disease 
Centre, Tan Tock Seng Hospital, the national referral center for HIV infection in 
Singapore. Patients were classified and recruited into lipoatrophy, controls with 
wasting and controls without wasting groups as described below. Patients with 
lipoatrophy were required to have evidence of at least moderate facial lipoatrophy 
(i.e. readily noticeable by patient or physician) reported both by patient and study 
physician (Carr and Law, 2003), and to have been on antiretroviral therapy for at 
least 1 year. In order to distinguish from wasting, they were required to be free 
from opportunistic infection for at least 1 year, to have a body weight at least 90% 
of their usual weight at time of study and not to have experienced recent weight 
loss (defined as more than 5% over the previous 6 months). 
Control patients with wasting were required to have experienced an 
opportunistic infection within the previous 6 months that was associated with 
>10% weight loss, and to have a body weight that was less than 90% of their usual 
body weight at the time of study. To further distinguish from lipoatrophy, wasting 
patients were also required to have received less than 12 months of antiretroviral 
therapy and not to have previous report of lipodystrophy prior to opportunistic 
infection.   
Control patients without wasting were required to have no report of 
lipodystrophy (facial or other body region) by patient or physician, to be free from 
opportunistic infection for at least 1 year, to have a body weight at least 90% of 
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their usual weight at time of study and not to have experienced recent weight loss 
(defined as more than 5% over the previous 6 months). Duration of antiretroviral 
therapy was not specified for this group.  
Exclusion criteria for recruitment to all groups were concomitant use of 
systemic corticosteroids, pregnancy or breast-feeding, any serious facial injury, 
any patients received cosmetic surgery for lipoatrophy and any of the standard 
contraindications for MRI scanning. All patients gave written informed consent 
and the protocol was approved by the Ethics Committee of Tan Tock Seng 
Hospital. 
 
2.2.2 Clinical characteristics 
A standard questionnaire was administered to all subjects. The 
questionnaire asked about any loss of fat or accumulation of fat in the face, neck, 
dorso-cervical spine, arms, breasts, abdomen, buttocks, or legs, as well as the 
presence, site, and number of any lipomata (focal accumulation of fat). The degree 
of lipoatrophy, diffuse fat accumulation, or lipomatosis at every site on the body 
was rated as absent (score of 0), mild (noticeable on close inspection, score of 1), 
moderate (readily noticeable by patient or physician, score of 2), or severe (readily 
noticeable to a casual observer, score of 3). Positive findings were confirmed by a 
study physician. We classified patients as lipodystrophy if they had at least one 
confirmed moderate or severe feature of lipoatrophy, diffuse fat accumulation, or 
lipomatosis that had arisen since the diagnosis of HIV infection (Carr et al., 2003). 
Clinical information including the result of the most recent CD4 count, viral load, 
and details of the antiretroviral treatment history were abstracted from the medical 
case records. Body weight was measured to the nearest 0.1 kg using electronic 
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scales (SECA, Model 7700, Vogel & Halke, Hamburg, Germany) and height was 
measured to the nearest 0.5 cm using a stadiometer. Body mass index (BMI) was 
calculated as the weight in kilograms divided by the height squared in metres. 
 
2.2.3 MRI measurements 
MR imaging was performed on a clinical 1.5T MR system (Signa NVi, 
GE Medical Systems, Wisconsin, MI) using a standard quadrature head coil. 
Patients were positioned in the magnet in a supine position, with arms relaxed by 
their side. The entire head volume was scanned using contiguous axial 1.5mm 
thick slices with no interslice gap. High resolution spoiled gradient recalled echo 
(SPGR) 3D T1-weighted MR images were obtained with parameters of 
TR/TE/flip angle 8.9/4.2/15°; field of view 240 x 190 mm; matrix 256x256; 
number of excitation 2; scan time 5 min 4 sec.  
MR images were transferred to a SUN Sparc 10 workstation (SUN 
Microsystems, Mountain View, CA) for analysis using in house MRreg v.1.6.2 
software (Lemieux et al., 2000). Each fat or muscle region of interest (ROI) was 
manually traced using a mouse-driven cursor. Different contrast settings 
optimized for facial fat and muscle were used in the display panels. The regions of 
interest were temporal fat and cheek fat (separated at zygomatic arch level), 
periorbital fat, the buccal fat pad, orbital fat, and the masseter and temporalis 
muscles. Figure 2.1 shows T1-weighted MRI scans from one patient with buccal 
fat pad traced for volume measurement. All constituent tissues within the ROI 
were assessed bilaterally. The volume of ROI per slice was calculated by counting 
the 3D pixels (voxels) within a traced area, multiplying the selected area by the 
slice thickness in mm. The volumetric function of the MRreg software summed 
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the selected slice volumes to compute a total volume. Superficial fat volume was 
defined as the sum of the temporal, cheek and periorbital fat compartments. Total 
facial fat was defined as the sum of all the measured fat compartment volumes. In 
addition to the above volume analysis, the fat and muscle areas were recorded for 
a standard single slice. The position of this slice was located at 2.4cm (16 cuts) 
below the maximum prominence of the zygomatic level, placing it approximately 
in the center of the cheek for most patients.  
Tracing and analysis of soft tissue volumes were performed for all the 
patients by a trained reader blinded to the patients’ grouping. The entire image 
analysis per patient took approximately one hour to perform. Reproducibility of 
the measurements was evaluated by performing repeat analysis of 10 randomly 
selected scans. The coefficient of variations of repeated measurements were 4.3%, 
6.8%, 8.3%, 9.2%, 7.5%, 4.0%, 6.8%, 7.9% and 5.5% for total facial fat, temporal 
fat, cheek fat, periorbital fat, buccal fat pad, orbital fat, superficial fat, temporalis 








Buccal fat pad 
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2.2.4 DEXA measurements 
Whole body composition was measured in each patient with a Lunar DEXA 
machine (Lunar Prodigy, software version 6.50; Lunar Corporation, Madison, 
Wisconsin, USA). Patients were scanned wearing light indoor clothing. Scans 
were performed and analyzed by the same operator (blinded to subject grouping) 
following manufacturer’s instructions, and using standardized cut-offs for regional 
measurements. The machine was regularly calibrated for quality control purposes 
according to procedures specified by the manufacturer. The measurements were 
performed on the same day as the MRI measurement. The coefficient of variation 
of DEXA fat measurements at our centre is 1.8%, 3.1%, and 3.2% for limb fat, 
trunk fat and total fat respectively by repeated measurements of 3 healthy and 5 
HIV infected volunteers. 
 
2.2.5 Statistical analysis 
MRI facial fat and muscle volumes, single sliced fat or muscle areas and 
body composition parameters were compared among the three groups of patients 
by ANOVA, with post-hoc Scheffe test. Pearson’s correlation coefficients were 
calculated to show the relationship between MRI volumes and DEXA 
measurements, and between MRI volumes and single slice MRI areas. All P 
values were two sided and p<0.05 was considered statistically significant. The 





2.3.1 Demographic characteristics and clinical data  
The demographic and clinical characteristics of the 45 patients (all Asian, 
predominantly Chinese) are shown in Table 2.1. All 15 patients with lipoatrophy 
reported facial, arm, and leg atrophy, and 2 had central adiposity. All were taking 
HAART at the time of the study, and the mean duration of antiretroviral therapy 
was almost 5 years. None had received any facial implant or injections to correct 
the facial atrophy. The mean BMI was in the normal range, total lean tissue was 
no different from controls without wasting, but total fat and limb fat were lower 
than controls without wasting. Controls with wasting all had advanced HIV 
disease and the mean CD4 count was 84 cells. Only 3 were receiving antiretroviral 
therapy. The BMI in the controls with wasting was significantly lower than 










wasting (n=15) P 
Age, years 40.4±7.6 41.6±5.9 42.3±7.1 0.741
Chinese, n 15 12 10 0.056
HIV duration, months 42.7±33.4 80.5±29.2 a 41.4±40.2 b  0.004
Stage C disease, n 6 7 15 0.001
CD4 lymphocytes, cells/mm3 386.3±184.7 522.7±292.5 a 84.3±106.4 a b <0.001
Viral load, log10 copies/ml 3.57±1.47 2.75±1.48 5.00±0.00 b 0.012
Viral load <400 log10 copies/ml, n 3 / 12 10 / 15 0 / 2 <0.001
ART Duration, months 18.5±25.7 58.1±21.8 a 2.0±3.5 b <0.001
Current use of HAART, n 7 15 3 <0.001
   D4T/3TC/NVP 3 10 2 0.003
   D4T/SAQ/RIT 2 3 0 0.207
   Others 2 2 1 0.799
     
Height, cm 167.1±7.4 168.2±6.0 167.3±7.6 0.908
Weight, kg 68.3±10.5 63.5±10.5 a 52.1±10.8 a b <0.001
BMI, kg/m2 24.5±3.9 22.4±2.8 a 18.6±3.4 a b  <0.001
ART, antiretroviral treatment; BMI, body mass index. Data shown are mean ±SD, except for
Chinese race, disease stage, viral load <400 log10 copies/ml, current use of highly active  
antiretroviral therapy (HAART) and HAART regimens, which are absolute numbers.  
Means are compared among groups by one-way ANOVA followed by post hoc Scheffe tests 
and proportions are compared by Fisher's exact test. 
 a p<0.05 vs. controls, b P<0.05 vs. lipoatrophy  
 
Table 2.1 Demographic and clinical data of HIV infected patients (n=45) 
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2.3.2 MRI facial fat and muscle volume 
The MRI measurements of facial fat and muscle volumes in the three 
groups of patients are shown in Table 2.2. Patients with lipoatrophy had lower fat 
volume in the temporal region, (8.9±9.4 vs. 20.5±7.2ml; p<0.001), cheek region 
(25.6±24.9 vs. 55.5±15.0ml; p<0.001) periorbital region (1.9±1.0 vs 2.7±1.0ml; P 
= 0.09) and buccal fat pad (13.4±9.4 vs. 21.8±9.8ml; p=0.003) compared with 
controls without wasting. Patients with wasting had temporal, cheek, peri-orbital 
and buccal fat pad volumes (10.4±6.7ml, 34.0±14.8ml, 1.4±1.1ml, and 
13.1±4.6ml respectively) that were lower than controls without wasting (all 
p<0.01), but did not differ from those of lipoatrophy patients (all p>0.5). Orbital 
fat showed no significant difference between controls without wasting, 
lipoatrophy patients and controls with wasting (Table 2.2). There was no 
difference between lipoatrophy patients and controls without wasting in the 
volume of the masseter muscle (47.8±9.7 vs. 49.1±12.4ml) or the temporalis 
muscle (59.8±12.2 vs. 60.3±13.4ml). However, patients with wasting had 
masseter and temporalis muscle volumes (35.6±6.8ml and 45.3±11.1ml) that were 
significantly lower than both controls without wasting and lipoatrophy patients 
(all p<0.05). Figure 2.2 shows T1-weighted MRI scans of facial fat and muscle in 
3 HIV-infected patients. 
Comparison of the three groups for fat and muscle area obtained from the 
single cheek slice measurement revealed significant differences among the groups 
in the same direction and to the same extent as was seen with the full face volume 
measurements (Table 2.2). 
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 Figure 2.2 T-1 weighted MRI scans to show facial fat and muscle in 3 HIV-
infected patients 
 
Panel A, controls without wasting: 48-year-old man, no lipodystrophy and wasting, 
BMI 24.7, HIV positive since Dec 2001, not start ART, CD4 370 cells/mm
3, viral 
load 237000 copies/ml, no opportunistic infection within 6 months. MRI image 
showed normal masseter and temporalis muscle, and normal facial fat.  
Panel B, 40-year-old man, diagnosed severe lipoatrophy without weight loss of 
more than 5% over the past 6 months, BMI 20.9, HIV positive since Sep 1992, on 
HAART since Feb 1998 including d4T, CD4 393 cells/mm
3, viral load <50 
copies/ml, no opportunistic infection within 6 months. MRI image showed 
decreased facial fat including buccal fat pad, but normal masseter and temporalis 
muscle.  
Panel C, controls with wasting, 38-year-old man, diagnosed wasting without 
previous diagnosis of lipodystrophy, BMI 17.8, HIV positive since Oct 2000, not 
on ART, CD4 5 cells/mm
3, no viral load result, has pneumocystis carinii 
pneumonia within 6 months. MRI image showed decreased facial fat including 






wasting (n=15) Lipoatrophy (n=15) 
Controls with 
wasting (n=15) P 
Temporal fat, ml 20.5±7.2  8.9±9.4 a 10.4±6.7 a <0.001 
Cheek fat, ml 55.5±15.0  25.6±24.9 a 34.0±14.8 a <0.001 
Periobital fat, ml 2.7±1.0  1.9±1.0  1.4±1.1 a 0.006 
Buccal fat pad, ml 21.8±9.8  13.4±9.4 a 13.1±4.6 a 0.009 
Orbital fat, ml 16.5±4.9  16.1±7.2  14.3±4.1 0.51 
     
Total superficial facial fat, ml 78.7±20.7  36.3±34.1 a 45.8±20.8 a <0.001 
Total facial fat, ml  116.9±30.3  65.8±48.1 a 73.2±26.0 a <0.001 
     
Temporalis muscle, ml 60.3±13.4 59.8±12.2 45.3±11.1 a b 0.001 
Masseter muscle, ml 49.1±12.4 47.8±9.7 35.6±6.8 a b 0.001 
     
Single slice cheek fat area, cm2 11.1±2.2  4.8±4.6 a 6.9±3.0 a <0.001 
Single slice cheek muscle area, cm2 9.2±1.9 8.8±1.6 7.0±2.2 a b 0.006 
Volumes are sum of left and right sides. Total superficial facial fat is the sum of temporal fat, cheek fat, and  
periorbital fat. Single-slice is positioned at 2.4cm below zygomatic arch level. Groups are compared by  
ANOVA with post-hoc Scheffe tests. a p<0.05 vs. controls, b P<0.05 vs. lipoatrophy 
 
Table 2.2 Comparison of MRI-measured facial soft tissue volumes and single-slice cheek fat and muscle area between 
patients with lipoatrophy and controls with and without wasting 
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 2.3.3 DEXA body composition 
The DEXA measurements of body composition results in the three groups 
of patients are shown in Table 2.3. Patients with lipoatrophy had lower total body 
fat (9.8±5.9 vs. 16.9±5.1kg; p= 0.008) compared with controls without wasting. 
Patients with wasting had total fat (9.0±6.8kg) that were lower than controls 
without wasting (p=0.003) but similar to lipoatrophy patients (p>0.9). As for 
regional body fat change, patients with lipoatrophy had lower fat in limb (2.9±2.0 
vs. 6.1±1.8kg; p=0.002) and trunk (6.5±3.9 vs. 10.2±3.5kg; p=0.030) compared 
with controls without wasting. Patients with wasting had limb and trunk fat 
(3.6±3.0kg and 5.0±3.8kg respectively) that were lower than controls without 
wasting (all p<0.05) but similar to lipoatrophy patients (all p>0.5). Patients with 
lipoatrophy had higher trunk-to-limb fat ratio (2.5±0.9) and trunk-to-limb fat 
percent ratio (2.1±0.8) compared with controls without wasting  (1.7±0.3, 1.4±0.2) 
and controls with wasting (1.4±0.5, 1.1±0.4; all p<0.01); no difference was found 
between controls with and without wasting (all p>0.05).  
Patients with lipoatrophy had similar total body lean (51.2±5.6 vs. 
49.1±6.4kg; p= 0.571) compared with controls without wasting. Patients with 
wasting had total body lean (40.1±5.0kg) that was lower than controls without 
wasting and lipoatrophy patients (all p<0.001). As for regional body lean tissue 
change, patients with lipoatrophy had similar lean in limb (22.6±3.0 vs. 
22.1±3.0kg) and trunk (24.7±2.6vs. 23.1±3.2kg, all p>0.3) compared with controls 
without wasting. Patients with wasting had limb and trunk lean (16.2±2.7kg and 
20.5±2.7kg respectively) that were lower than controls without wasting and 










wasting (n=15) P 
Total Fat (kg) 16.9±5.1 9.8±5.9 a 9.0±6.8 a 0.001
Total Fat (%) 24.3±5.0 14.6±6.6 a 16.0±9.0 a 0.001
Total Lean (kg) 49.1±6.4 51.2±5.6 40.1±5.0 a b <0.001
     
Arm Fat (kg) 1.4±0.5 0.8±0.6 a 0.7±0.7 a 0.007
Arm Fat (%) 17.8±4.5 10.2±5.9 a 11.9±7.8 a 0.004
Leg Fat (kg) 4.7±1.4 2.1±1.4 a 2.8±2.2 a 0.001
Leg Fat (%) 21.1±4.0 10.0±5.5 a 16.4±8.5 a <0.001
Limb Fat (kg) 6.1±1.8 2.9±2.0 a 3.6±3.0 a 0.001
Limb Fat (%) 20.3±3.9 10.1±5.6 a 15.3±8.3  <0.001
Trunk Fat (kg) 10.2±3.5 6.5±3.9 a 5.0±3.8 a 0.001
Trunk Fat (%) 29.3±6.6 19.1±8.1 a 17.5±10.6 a 0.001
Trunk-to-limb fat ratio 1.7±0.3 2.5±0.9 a 1.4±0.5 b <0.001
Trunk-to-limb fat % ratio 1.4±0.2 2.1±0.8 a 1.1±0.4 b <0.001
     
Arm lean (kg) 5.8±0.8 5.9±0.9 4.3±0.8 a b <0.001
Leg lean (kg) 16.2±2.4 16.7±2.3 11.9±2.0 a b <0.001
Limb lean (kg) 22.1±3.0 22.6±3.0 16.2±2.7 a b <0.001
Trunk lean (kg) 23.1±3.2 24.7±2.6 20.5±2.7 a b 0.001
Means are compared among groups using one-way ANOVA and followed by post hoc  
Scheffe tests. a p<0.05 vs. controls, b P<0.05 vs. lipoatrophy 
 
Table 2.3 DEXA body composition results of all patients (n=45) 
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 2.3.4 Correlation between facial fat volume and DEXA body composition 
parameters 
The relationship between superficial facial fat volume measured by MRI 
and limb fat measured by DEXA is shown in Figure 2.3 (for all patients) and 
Figure 2.4 (for lipoatrophy patients only). There was a high and statistically 
significant correlation between superficial facial fat and limb fat for the overall 
group of 45 patients (r=0.78, p<0.001) and the relationship was even closer 
between these two parameters when the analysis was performed on just the 
patients with lipoatrophy (r=0.91, p<0.001).  
The fat area from the single cheek slice was strongly correlated with total 
facial fat volume (r=0.90, P<0.001) for all patients and (r=0.96, P<0.001) for just 




Figure 2.3 Correlation between superficial fat volume (ml) and limb fat (kg) 















Figure 2.4 Correlation between superficial fat volume (ml) and limb fat (kg) 














 2.4 Discussion 
 
2.4.1 Facial fat loss in lipoatrophy 
This is the first study to quantify objectively the extent and anatomical 
distribution of facial fat depletion in patients with HIV-related lipoatrophy. We 
found that facial fat was reduced by more than 50% in patients with lipoatrophy 
compared with controls, with all areas of superficial facial fat (temporal, cheek 
and peri-orbital) affected. The very close relationship (high correlation 
coefficient) between volume of superficial facial fat and limb fat measurements in 
the patients with lipoatrophy suggested that superficial facial fat depletion 
occurred in proportion to a generalized process of peripheral lipoatrophy. The 
mean difference in superficial facial fat between lipoatrophy and controls without 
wasting was greater than 20ml on each side, which is a surprisingly large amount 
given that volume change of only a few ml of facial fat is necessary to bring about 
a noticeable change in facial appearance (Stuzin et al., 1990). Although 
improvements in appearance of facial lipoatrophy have been obtained with the use 
of submalar silicone implants (Talmor et al., 2002) and injections of polylactic 
acid (Lafaurie et al., 2005; Valantin et al., 2003), the magnitude and widespread 
distribution of fat loss we have observed in this study indicate that complete 
restoration of normal appearance is unlikely to be possible by surgical correction 
methods. The focus should therefore remain on strategies for the early detection 
and prevention of severe facial lipoatrophy  
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 2.4.2 Deep facial fat loss in lipoatrophy 
The buccal fat pad is located deep in the cheek, and it has been unclear 
previously whether this was affected in the process of HIV-related facial 
lipoatrophy. The buccal fat pad is a specialized type of fat termed syssarcosis, a 
type of fat that enhances intermuscular motion, and it has a distinct appearance 
from the subcutaneous fat of the cheek (Stuzin et al., 1990). The buccal fat pad 
appears to be less metabolically active than other fat, with less numerous vesicles 
and smaller mitochondria, (Kahn et al., 2000) and has been previously noted to be 
preserved even in very cachectic patients (Kahn et al., 2000). Thus, given its 
unique nature, it is conceivable that the buccal fat pad might be spared by the 
process of lipodystrophy. Indeed, the only previous study that have formally 
attempted an evaluation of the buccal fat pad (by visual inspection prior to 
surgery) concluded that it was not affected by lipoatrophy (Talmor et al., 2002). 
However, our study has clearly demonstrated that the buccal fat pad is 
significantly depleted in lipoatrophy, although the extent of depletion (to 60% of 
controls without wasting) appears less than that of superficial fat depletion (to 
45% of controls without wasting). In 4 patients the buccal fat pad was reduced to 
extremely low values (0.6 to 5.7 ml), well below the lowest value (8.6 ml) seen in 
patients with wasting. The function of the buccal fat pad is to assist the muscles of 
mastication, although whether there are any functional consequences of such 
extreme depletion is unclear. However, orbital fat (a deep fat compartment) was 
relatively well preserved in both patients with lipoatrophy and those with wasting. 
This is consistent with the observation that orbital fat is the last area of fat to be 
lost in patients with severe emaciation due to anorexia nervosa (Okamoto et al., 
2001).  
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 2.4.3 Facial fat and muscle change in lipoatrophy 
Loss of facial fat in lipoatrophy and wasting gives rise to a cachectic 
appearance that is stigmatizing and makes it difficult for patients to hide the 
presence of their underlying medical condition. One of the aims of this study was 
to examine whether the pattern of facial fat loss in lipodystrophy was distinct from 
the pattern seen in wasting. This is a plausible hypothesis, given the likely 
different aetiology of fat depletion in these two processes. Whereas lipodystrophy 
is thought to be due to mitochondrial toxicity, wasting is caused by restriction of 
energy intake leading to reduction of fat as well as lean tissue to meet energy 
requirements (Paton et al., 1997). In fact we found that the distribution and extent 
of fat depletion did not differ between lipoatrophy and wasting patients. Of note, 
we also found depletion of the buccal fat pad occurred in wasted patients, even 
though it has previously been thought to be preserved even in very cachectic 
patients (Kahn et al., 2000). In contrast to patients with lipoatrophy, wasting 
patients had a significant reduction in facial muscle volume that may make a 
further contribution to their cachectic appearance. The pattern of loss of fat tissue 
with preservation of muscle tissue in the face might prove helpful in the diagnosis 
of lipodystrophy. The differences between measured muscle volumes in the two 
groups also suggest that the stringent inclusion criteria we used were effective in 
separating wasting and lipoatrophy patients, although in clinical practice the two 
conditions may sometimes overlap.   
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 2.4.4 Whole body and regional fat changes in lipoatrophy 
This study is also the first to compare regional and whole body 
composition changes among HIV infected patients with lipoatrophy, controls with 
and without wasting. We found that patients with lipoatrophy and wasting lost a 
significant amount of total body fat (approximately 40% to 50% of controls) 
compared with controls without wasting. Surprisingly, even with a higher mean 
body weight (by 10%) than patients with wasting, patients with lipoatrophy had 
lesser total body fat (about 10%) than wasting patients. As for the regional body 
composition changes, although HIV infected patients with lipoatrophy or wasting 
lost fat all over the body, patients with lipoatrophy lost more fat from limb (50%) 
than trunk region (30%), whereas patients with wasting lost more fat from trunk 
(40%) than limb region (25%). The study results were in agreement with the 
results from other large studies of HIV infected patients. The first study, a cross 
sectional study found that lipoatrophy both peripherally and centrally 
predominates in HIV infected men compared with healthy controls of similar age 
(Gripshover et al., 2003). The subcutaneous fat loss was also confirmed by direct 
MRI measurement of regional body fat in the same groups of subjects (Saag et al., 
2003). Another study, a prospective study also found that lipoatrophy both 
peripherally and centrally predominates in HIV infected women compared with 
control women at risk for HIV (Tien et al., 2003). Disproportional preservation of 
fat in the trunk region in patients with lipoatrophy was offered as an explanation 
for this phenomenon (Saag et al., 2003). Other studies also found relatively 
preserved visceral fat compared to healthy controls in HIV infected man with or 
without clinical evidence of truncal enlargement (Engelson et al., 1999; Kosmiski 
et al., 2003), HIV infected children (Brambilla et al., 2001), and even in HIV 
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 infected patients before potent HAART first become widely available (Kotler et 
al., 1999). However, some earlier studies had also suggested that central 
lipohypertrophy was the predominant form of lipodystrophy in women (Dong et 
al., 1999; Gervasoni et al., 1999; Herry et al., 1997). In contrast to the fat tissue 
change in patients with lipoatrophy, patients with wasting lost more fat from trunk 
than limb region. Preferential abdominal fat loss was also shown in army rangers 
undergoing weight reduction (Nindl et al., 1996) and TB-associated wasting 
patients (Paton and Ng, 2006). So the patients with lipoatrophy had trunk-to-limb 
fat percent ratio higher than controls without wasting and almost doubled 
compared to patients with wasting. These results highlighted the difference in the 





 2.5 Summary 
The volume and anatomical distribution of facial fat depletion in HIV 
related lipoatrophy have not been properly quantified. The objective of this study 
was to determine the extent and distribution of facial fat loss in HIV-infected 
patients with lipoatrophy and whether this differed from wasting and to compare 
the regional and whole body composition changes among patients with 
lipoatrophy, controls with/without wasting.   
We studied HIV-infected patients with clinically defined moderate to 
severe lipoatrophy without wasting (n=15), clinically defined controls with 
wasting (>10% weight loss and recent opportunistic infection) with no previous 
reported lipodystrophy (n=15), and controls without wasting (n=15). Facial MRI 
scans were performed, and areas of fat were manually traced bilaterally in all 
individual image slices and summed to calculate volume in anatomically defined 
regions of interest. Whole body composition was measured by DEXA.   
Patients with lipoatrophy had lower fat volumes in temporal region 
(8.9±9.4 vs. 20.5± 7.2ml; p<0.001), cheek region (25.6±24.9 vs. 55.5±15.0ml; 
p<0.001), periorbital region (1.9 ± 1.0 vs. 2.7 ± 1.0ml; P = 0.09) and buccal fat 
pad (13.4±9.4 vs. 21.8±9.8ml; p=0.030) compared with controls without wasting. 
Patients with wasting had temporal, cheek, periorbital and buccal fat pad volumes 
(10.4±6.7ml, 34.0±14.8ml, 1.4 ± 1.1ml and 13.1±4.6ml respectively) that were 
lower than controls without wasting (all p<0.01) but similar to lipoatrophy 
patients (all p>0.7). Patients with lipoatrophy had lower fat in limb (3.0±1.9 vs. 
6.1±1.8 kg; p=0.013), trunk (6.6±3.6 vs. 10.2±3.5kg; p<0.001) and total body 
(10.0±5.5 vs. 16.9±5.1kg; p=0.005) compared with controls without wasting. 
Patients with wasting had limb, trunk and total body fat (3.6±3.0kg, 5.0±3.8kg and 
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 9.0±6.8kg respectively) that were lower than controls without wasting (all p<0.05) 
but similar to LD patients (all p>0.4). Lipoatrophy patients had higher trunk-to-
limb fat percent ratio (2.1±0.8) than controls without wasting (1.4±0.2) and with 
wasting (1.1±0.4) (all p<0.01). Patients with wasting had lower limb, trunk and 
total lean tissue compared with controls without wasting and lipoatrophy patients 
(all p<0.05 except for trunk lean); no difference was found between lipoatrophy 
and controls without wasting (all p>0.7).  
Facial fat depletion in lipoatrophy is substantial (approximately 50% 
volume loss) and involves superficial and deep fat (buccal fat pad). Similarly, fat 
depletion in lipoatrophy is also substantial (approximately 50% loss) and occurred 
in the whole body; but it was more prominent in limb than in trunk region. The 
distribution and volume of fat change in lipoatrophy is similar to that seen in 
wasting, but with relative preservation in trunk fat. Given the extent of the 
changes, complete surgical correction is unlikely to be possible and hence 
emphasis should be placed on prevention of lipoatrophy.  
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CHAPTER 3 LONGITUDINAL CHANGES IN FACIAL FAT IN 
HIV-INFECTED PATIENTS WITH LIPOATROPHY 
 
3.1 Introduction 
Changes in facial appearance are one of the most stigmatizing aspects of 
HIV disease. In the pre-antiretroviral therapy (ART) era, facial atrophy was 
usually caused by severe weight loss that was driven by decreases in energy intake 
that accompanied bouts of opportunistic infection (wasting). In the current era, 
facial atrophy is usually the result of lipodystrophy, a selective loss of body fat 
that occurs as a side effect of ART, principally thymidine analogue drugs. The 
resulting stigma and psychological morbidity may affect adherence to treatment 
(Collins et al., 2000; Martinez et al., 2001).  
Currently, few studies have attempted to define precisely the alterations in 
facial soft tissue compartments that underlie these changes in appearance. Such 
knowledge is essential however for developing appropriate objective measurement 
tools for use in clinical trials and for refining approaches to cosmetic correction of 
defects. This information may also shed light on pathogenesis of the facial soft 
tissue changes. In the cross sectional study using MRI measurements of facial fat 
described in Chapter 2 (see section 2.3.2, page 52), we found evidence of 
substantial facial fat depletion in lipoatrophy, but that the distribution and volume 
of fat change was similar to that seen in wasting. In this study we extend these 
data by using MRI to measure changes in facial soft-tissue compartments over 
time. The aims were to define the progressive change over time in facial fat 
compartments that underlie the appearance of facial lipoatrophy, and to determine 
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whether the compartmental changes could be differentiated from those that 






The patients participating in this longitudinal study were drawn mostly 
from the group of HIV infected patients enrolled in the cross-sectional study to 
compare facial fat compartment volumes in lipoatrophy and wasting reported 
previously in Chapter 2 (see section 2.3.1, page 51). Patients with lipoatrophy at 
baseline were invited to participate in the follow-up study if they remained on 
ART, had not experienced a systemic opportunistic infection and did not have 
more than 5% weight change in the period between the two scans. The patients 
classified as controls with wasting (weight loss with opportunistic infection with 
no evidence of lipoatrophy) or controls without wasting (neither wasting nor 
lipoatrophy) at baseline were invited to participate in the follow-up study if their 
weight had increased by 10% (weight gain group) or decreased by 10% (weight 
loss group) from the baseline value.  
All patients gave written informed consent and the protocol was approved 
by the Ethics Committee of Tan Tock Seng Hospital. 
 
3.2.2 Clinical characteristics 
A standard questionnaire about changes in appearance was administered to 
all patients both at the study entry and follow up visit, and any changes were 
classified as mild, moderate or severe (Carr et al., 2003). Clinical information 
including the result of the most recent CD4 count, viral load, and details of the 
antiretroviral treatment history were abstracted from the medical case records. 
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Body weight was measured to the nearest 0.1 kg using electronic scales (SECA, 
Model 7700, Vogel & Halke, Hamburg, Germany) at each visit.   
 
3.2.3 MRI measurements 
MRI measurement was performed as described in section 2.2.3 (page 46). 
Tracing and analysis of all soft tissue volumes was performed both at baseline and 
at follow up by the single experienced reader, who was blinded to subject 
grouping 
 
3.2.4 DEXA measurements 
Whole body composition was measured in each patient with a Lunar 
DEXA machine (Lunar Prodigy, software version 6.50; Lunar Corporation, 
Madison, Wisconsin, USA) using the method described in section 2.2.4 (page 49). 
All Scans were performed and analyzed by the same operator following 
manufacturer’s instructions, and using standardized cut-offs for regional 
measurements. The measurements were performed on the same day as the MRI 
measurement. 
 
3.2.5 Statistical analysis 
MRI facial fat and muscle volumes, single-slice fat or muscle areas and 
DEXA body composition parameters were compared between baseline visit and 
follow up visit within groups by Wilcoxon Signed Ranks Test. Changes of greater 
than 15% from baseline in superficial facial fat (about 2 times of the coefficient of 
variation for repeat measurements of superficial fat volume) were regarded as 
indicative of substantial change in an individual patient. Pearson’s correlation 
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coefficients were calculated to determine the relationship between MRI facial fat 
volume changes and DEXA measurement changes. All P values were two sided 
and p<0.05 was considered statistically significant. The data analyses were 






Twenty-four patients had scans performed at baseline and after a mean of 
10.0±2.4 months. The mean age of the patients was 44±7 years. Nineteen of the 
patients were of Chinese ethnicity, 4 were Indian and 1 was Malay and most 
reported high risk heterosexual contact as the main risk factor for HIV-1 
acquisition.   
Twelve studies were performed in patients with moderate to severe 
lipoatrophy at baseline who continued to take stable ART regimens during follow-
up (stavudine, lamivudine and nevirapine in 8; stavudine, ritonavir and saquinavir 
in 2; thymidine-analogue-sparing regimens in 2 patients).  
Five studies were performed in patients who lost weight (a median of 
7.7kg loss, or 17% decrease from baseline). All these patients had CD4 counts less 
than 200 at baseline, did not take ART during follow up, and developed new 
opportunistic infections around the time of the weight loss (Pneumocystis jiroveci 
pneumonia at 4 and 5 months, disseminated mycobacterium avium complex at 6 
months, disseminated tuberculosis at 7 months, and oesophageal candidiasis at 9 
months after baseline).  
Seven studies were performed in patients who gained weight (a median of 
9.7kg increase, or 16% increase from baseline). Five of these had wasting at 
baseline associated with recent opportunistic infection (pneumocystis carinii 
pneumonia in four, and disseminated mycobacterium avium complex in one 
patient). The other two patients who gained weight had normal nutritional status at 
baseline, and remained clinically stable throughout. All seven patients took stable 
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ART regimens during follow-up (stavudine, lamivudine and nevirapine in 5; 
stavudine, ritonavir and saquinavir 1; zidovudine, lamivudine and efavirenz in 1 
patient).    
 
3.3.2 Longitudinal facial fat changes in patients with lipoatrophy 
Clinical and body composition data for the 12 patients in the lipoatrophy 
group and the 12 patients with 10% weight changes are shown in Table 3.1 and 
Table 3.2. Superficial facial fat decreased by a median of 5.2ml (P=0.03). Eight of 
the 12 patients showed a substantial decrease in superficial facial fat (i.e. more 
than 15% change from baseline). Five of these 8 had severe facial lipoatrophy at 
baseline and follow-up, and 3 had moderate lipoatrophy at baseline that 
progressed to severe during follow up. All were taking a stavudine-containing 
regimen during the interval between the scans. Figure 3.1 shows T1-weighted 
MRI scans of facial fat and muscle in one HIV-infected patient at baseline and 
after one-year follow up.  
Of the 4 patients who did not show a substantial change decrease in 
superficial facial fat, 1 had severe lipoatrophy at baseline and follow-up and 3 had 
moderate lipoatrophy that did not progress during follow-up. Two of these four 
appeared to show small increases in facial fat, and these were the only two 
patients who were not currently receiving stavudine (but had extensive prior 












interval (m)  
Clinical LA 
assessment MRI superficial fat volume (ml)  DEXA limb fat 
            Baseline Repeat Baseline Repeat  % Change Baseline Repeat % Change 
34.5 446 <50 65 D4T/3TC/NVP 12.3 Severe Severe 5.9 2.1 -64.2 0.88 0.87 -1.4 
46.5 484 <50 38 D4T/3TC/NVP 12.1 Severe Severe 16.5 5.1 -68.8 1.67 1.52 -9.4 
30.3 1113 <50 41 D4T/3TC/NVP 11.8 Severe Severe 19 14.3 -24.9 2.12 1.97 -7.4 
52.4 532 <50 38 D4T/3TC/NVP 12.8 Severe Severe 20 14.5 -27.7 3.83 3.45 -10.1 
50.8 309 34,905 43 D4T/3TC/NVP 8.6 Severe Severe 8.3 6.6 -21.4 1.02 0.92 -9.5 
42.7 594 <50 40 D4T/3TC/NVP 11.3 Moderate Severe 23.8 12.1 -49 1.8 1.48 -17.5 
46.9 958 <50 25 D4T/3TC/NVP 11.8 Moderate Severe 88.6 58.5 -34.1 4.74 3.82 -19.5 
38.7 422 <50 91 D4T/RIT/SAQ 12.5 Moderate Severe 85 51.6 -39.3 5.19 4.74 -8.7 
41.2 442 <50 41 D4T/3TC/NVP 9 Severe Severe 11.3 11 -2.7 1.4 1.4 0.1 
35.3 349 707 60 D4T/RIT/SAQ 7.9 Moderate Moderate 101.4 90.9 -10.4 7.79 7.66 -1.7 
40.1 193 <50 67 IDV/RIT 11.6 Moderate Moderate 49.7 56.2 13.1 4.61 4.84 4.8 
41.4 719 <50 95 ABC/NVP/RIT/SAQ 11.4 Moderate Moderate 69.1 73.4 6.2 3.49 3.27 -6.1 
D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; RIT, ritonavir; SAQ, saquinavir, ABC, abacavir 
Table 3.1 Clinical and body composition data of HIV-infected patients with facial lipoatrophy at baseline and follow up (n=12) 
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interval (m) Body weight, kg MRI superficial fat volume (ml)  DEXA limb fat 
            Baseline Repeat Baseline Repeat  % Change Baseline Repeat 
% 
Change 
38 74 100000 0 - 7.5 53.4 44.4 68.7  34.1  -50.4  3.73  1.78  -52.2  
42 57 - 16 3TC/Kaletra 9.3 53.7 47.8 3.8  3.5  -7.1  1.05  0.80  -23.1  
50 11 57300 15 D4T/3TC/NVP 13.1 60.2 49.6 55.0  52.3  -4.9  5.08  2.93  -42.3  
53 120 - 12 - 14.3 57.1 45.7 13.7  7.7  -44.0  1.29  0.76  -41.1  
48 27 - 0 - 6.8 44.4 38 40.8  25.3  -38.0  1.00  1.00  0.9  
              
48 22 - 6 D4T/3TC/NVP 7.2 45.9 52.2 22.5  43.5  93.2  0.86  3.00  250.5  
57 228 - 5 D4T/3TC/NVP 8.3 57.4 63.1 56.4  68.2  20.8  5.32  5.10  -4.1  
49 73 - 0 3TC/AZT/EFV 6.8 60.4 70.1 73.9  102.3  38.4  4.84  7.00  44.7  
42 186 49 51 D4T/3TC/NVP 10 60.4 71.4 95.7  115.9  21.1  4.75  8.06  69.7  
37 361 - 16 D4T/3TC/NVP 9.6 87.9 98.7 72.6  83.4  14.8  8.19  7.93  -3.2  
56 69 - 0 D4T/3TC/NVP 7.9 39 45.9 28.4  36.5  28.8  1.79  2.26  26.3  
37 28 - 2 D4T/3TC/Kaletra 5.3 54.8 65.6 54.5  77.6  42.5  3.07  5.40  76.0  
D4T, stavudine; 3TC, lamivudine; NVP, nevirapine; Kaletra, lopinavir+ritonavir, EFV, efavirenz 
 




Figure 3.1 T-1 weighted MRI scans to show facial fat and muscle in one HIV-
infected patient at baseline and after one-year follow up 
 
This patient is a 47-year-old man with moderate clinical LA at baseline, who had 
been on HAART for 25months at baseline. During the 12 months follow up, he 
was on HAART regimen D4T/3TC/NVP, had stable body weight, clinical 
assessed facial lipoatrophy was progressed from moderate to severe facial 
lipoatrophy. The picture shows superficial facial fat decrease from baseline (left 
panel) to one year later (right panel), with reduced buccal fat but masseter and 
temporalis muscles show no change overtime. 
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The individual measurements of absolute change in superficial facial fat 
and change in limb fat (measured by DEXA) were strongly associated (r=0.8, 
P=0.002) as shown in Figure 3.2.  
 81 
  
Figure 3.2 Correlation between changes in superficial facial fat volume (ml) 
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3.3.3 Comparison of compartmental changes between patients with 
lipoatrophy and patients undergoing weight change 
The changes in facial fat and muscle compartments, in body weight and in 
DEXA parameters for the lipoatrophy, weight loss and weight gain groups are 
shown in Table 3.3. Superficial facial fat decreased by a median of 6.0ml (P=0.04) 
in patients with weight loss and increased by a median of 20.2ml (P=0.02) in 
patients with weight gain. However, there were clear differences in the pattern of 
individual soft tissue compartment changes between patients in lipoatrophy and 
weight change groups. In the lipoatrophy group, there was a significant decrease 
in cheek fat volume (4.6 ml), with minimal change in other fat and muscle 
compartment volumes. In the weight loss group, there were significant decreases 
in cheek fat (3.7ml), temporal fat (1.9ml) and buccal fat (0.5ml), together with 
significant decreases in temporalis muscle (12.1ml) and masseter muscle (6.0ml). 
In the weight gain group, there were significant increases in cheek fat (7.0ml), 
temporal fat (7.6ml), together with significant increases in temporalis muscle 
(4.4ml) and masseter muscle (6.1ml).  
 
 83 
    Lipoatrophy (n=12) Weight loss (n= 5) Weight gain (n =7) 
  Baseline Change Baseline Change Baseline Change 
Temporal fat, ml 4.8 (1.9, 18.5) -0.5 (-1.4, 0.0) 5.5 (4.5, 7.9) -1.9 (-3.6, -0.4)* 12.2 (8.4, 20.3) 7.6 (4.3, 11.0)* 
Cheek fat, ml 17.2 (12.2, 46.2) -4.6 (-10.7, -1.4)* 34.3 (8.1, 44.2) -3.7 (-11.5, -0.9)* 44.6 (32.8, 50.2) 7.0 (6.4, 11.6)* 
Periobital fat, ml 1.8 (1.2, 2.4) -0.1 (-0.5, 0.3) 1.1 (1.0, 1.8) -0.4 (-0.7,  -0.3) 1.1 (0.8, 2.6) 0.2 (0.1, 0.3) 
Buccal fat pad, ml 13.6 (10.8, 15.6) -1.0 (-1.0, 0.6) 10.6 (9.6, 12.1) -0.5 (-1.8, -0.3)* 18.6 (14.5, 21.6) 2.9 (1.2, 3.5) 
Orbital fat, ml 14.1 (12.1, 23.2)  0.5 (-0.3, 1.3) 12.3 (7.8, 12.4) -1.3 (-2.3, -0.3) 14.2 (12.9, 20.9) -0.2 (-0.9, 0.4) 
       
Total superficial facial fat, ml 21.9 (15.2, 73.0) -5.2  (-11.4, -1.4)* 40.8 (13.7, 55.0) -6.0 (-15.5, -2.7)* 56.4 (41.4, 73.3) 20.2 (11.3, 22.1)*
Total facial fat, ml  48.9 (38.6, 119.0) -4.3 (-14.0, -1.0) 63.6 (33.5, 79.5) -9.4 (-19.6, -5.6) 91.2 (68.1, 114.2)  22.9 (14.1, 24.7)*
       
Temporalis muscle, ml 57.7 (51.5, 69.2) -1.1 (-2.1, 1.7) 51.7 (51.5, 69.2) -12.1 (-15.1, -11.0)* 53.1 (44.4, 54.8) 4.4 (3.2, 8.7)* 
Masseter muscle, ml 46.3 (38.4, 55.8) 0.5 (-1.3, 1.5) 42.5 (36.5, 43.6) -6.0 (-8.1, -5.8)* 43.1 (36.6, 46.5) 6.1 (3.7, 7.0)* 
       
Single-slice cheek fat area, cm2 3.5 (2.4, 8.1) -1.1 (-2.1, -0.3)* 6.8 (1.7, 8.8) -0.8 (-1.5, 0.0)  8.7 (6.5,10.0) 1.1 (1.0, 2.3)* 
       
Single-slice cheek muscle area, 
cm2 8.5 (7.6, 10.2) -0.1 (-0.9, 1.0) 7.5 (6.7, 7.6) -1.5 (-1.6, -0.7)* 8.7 (7.6, 10.4) 1.5 (0.3, 2.1)* 
       
Weight  64.4 (60.6, 69.6) -0.2 (-1.7, 1.0) 53.7 (53.4, 57.1) -7.7 (-10.6, -6.4)* 57.4 (50.4, 60.4) 9.7 (6.6, 10.8)* 
       
Total fat by DEXA, kg 9.5 (6.2, 14.5) -0.4 (-1.1, 0.2) 4.7 (4.0, 12.4) -2.2 (-7.2, -2.0)* 10.6 (6.3, 13.1) 4.6 (3.2, 6.4)* 
Limb fat by DEXA, kg 2.8 (1.6, 4.6) -0.2 (-0.3, -0.1)* 1.4 (1.0, 3.7) -0.5 (-1.9, -0.2) 4.7 (2.4, 5.1) 2.1 (0.1, 2.2) 
Total lean by DEXA, kg 53.1 (48.6, 53.5) 0.1 (-0.3, 0.3) 41.8 (40.7, 46.7) -3.8 (-4.3, -3.2)* 43.5 (40.8, 45.8) 3.7 (2.2, 4.7)* 
Values are medians with inter-quartile range in parentheses. * P < 0.05 for within-group change from baseline tested by Wilcoxon Signed Ranks Test 
  
Table 3.3 Comparison of MRI-measured facial soft tissue volume change among lipoatrophy, weight loss and weight gain patients
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 The single slice measurements showed an overall pattern of fat and muscle 
losses and gains in the 3 groups that were similar to the changes seen in the 
multiple slice technique. For patients in the lipoatrophy group, there was a close 
correlation between the change in fat area obtained using the single slice 





3.4.1 Facial fat changes over time in lipoatrophy patients   
In this study, we found that patients with moderate to severe facial 
lipoatrophy who continued on thymidine-analogue based regimens had evidence 
of substantial ongoing loss of superficial facial fat over a 12-month follow-up 
period. Although continuing losses of peripheral fat have been documented by 
serial DEXA-measurement in patients who have many years of prior thymidine 
analogue use (Martin et al., 2004a), this is the first longitudinal study to 
demonstrate ongoing severe facial fat loss using MRI, the gold-standard soft-
tissue imaging method. The close relationship we demonstrated between facial fat 
change and limb fat change confirms that facial fat loss occurs as part of a 
widespread syndrome of peripheral fat loss. This extends the findings of the Study 
of Fat Redistribution and Metabolic Change in HIV Infection (FRAM) that used 
whole-body MRI measurements to show that fat loss in HIV infection occurred in 
all regions of the body (Bacchetti et al., 2005), but did not include sufficiently 
detailed MRI measurements of the head to demonstrate that the process also 
extended to facial fat. Although our study was not intended to assess the changes 
in facial fat following thymidine analogue withdrawal, it is noteworthy that the 
only two patients with baseline lipoatrophy who did not continue a thymidine 
analogue during follow-up, were the only two to show increases in facial fat. This 
is consistent with studies that have shown reversibility of peripheral fat changes 
(but without objective measurement of facial fat changes) (Bergersen et al., 2005; 
Carr et al., 2002; Martin et al., 2004b; McComsey et al., 2004; Moyle et al., 2003) 
and one study that found an increase in the thickness of the malar fat pad 
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measured by ultrasound (Ribera et al., 2005) in patients discontinuing thymidine 
analogue therapy.  
 
3.4.2 MRI as a tool in assessment of facial fat changes over time 
This study shows that MRI may be a useful technique for detecting facial 
fat changes in clinical research studies that compare interventions for treatment of 
lipoatrophy, and suggest that the technique may also be of value for following 
changes in individual patients. In the majority of patients the decreases in 
superficial facial fat exceeded 15% over 1 year, a difference that is more than 
twice the coefficient of variation of measurement (see section 2.2.3, page 46), and 
that is therefore unlikely to be due to measurement error. As well as the strong 
association with DEXA-measured peripheral fat change, MRI measurements of 
facial fat change were also consistent with the subjective clinical assessment of 
facial lipoatrophy. Of the 6 patients with moderate lipoatrophy at baseline, the 3 
who had clinical progression to severe lipoatrophy at follow-up showed 
substantial decreases in superficial facial fat, and the 3 who did not progress in 
clinical stage had relatively small or no changes detected by MRI. Our findings 
support the validity of the clinical classification, but also clearly demonstrate the 
additional value provided by MRI in detecting progressive change in those who 
already have clinical severe lipoatrophy as well as the advantages provided by 
increased objectivity and having a quantitative measurement.  
Although facial lipoatrophy is probably the most important component of 
the “lipodystrophy syndrome” for patients, it has been difficult to investigate in 
clinical studies due to the lack of an appropriate and objective measurement 
method. The MRI analysis method we used in this study is precise (i.e. gives 
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reproducible measurements, with a coefficient of variation of 6.8% for analysis of 
superficial fat volume). Given the large magnitude of the differences seen in 
lipoatrophy in relation to the precision, the method is clearly suitable for detecting 
lipoatrophy changes in small groups of patients. Analysis of scans could easily be 
centralised to preserve precision in a clinical trial setting. The major disadvantages 
of MRI are the cost and inconvenience of scanning and analysis. As a potential 
approach to reduce the scanning and analysis time, we also evaluated the use of a 
single slice scan to measure fat area in the cheek. We found this to be reproducible 
and were also able to detect the soft tissue differences among the groups, and this 
approach may therefore be of some practical use. Spiral CT can also provide a 
good measure of facial volume soft-tissue volumes (Cavalcanti et al., 2004) but 
shares the disadvantages with MRI of cost and inconvenience with the added 
disadvantage of radiation exposure which would limit its use in longitudinal 
studies. A single-slice CT approach has been shown to be reproducible and to be 
able to differentiate patients with lipoatrophy from controls (Padilla et al., 2004).  
 
3.4.3 Facial soft tissue changes in lipoatrophy and weight change patients 
We sought to look at the pattern of facial soft tissue compartment changes 
over time to determine whether there is a pattern of change that is characteristic of 
lipoatrophy. We therefore included two other groups for comparison of changes; a 
group of patients who lost weight during follow-up (wasting) caused by decreased 
energy intake associated with episodes of opportunistic infections, and a group 
who gained weight during follow-up that was associated with recovery from 
opportunistic infections and/or institution of antiretroviral therapy. Whereas the 
only substantial change in the lipoatrophy group was loss of cheek fat, the weight 
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loss group showed more disseminated fat loss involving temporal, cheek and 
buccal fat pads. The wasting patients could also be distinguished from lipoatrophy 
patients by their substantial losses of temporalis and masseter muscle volume, 
which is consistent with body composition studies showing that wasting 
comprises invariably a mixture of whole body lean and fat tissue depletion (Paton 
et al., 1997). In the weight gain group, large increases were seen in temporal as 
well as cheek fat, and these were accompanied by gains in masseter and temporal 
muscle volumes, thereby restoring values of all compartments to those of non-
lipodystrophic, non-wasted control patients that we have documented in Chapter 2 
(see section 2.3.2, page 52). Thus we have demonstrated that there are distinct 
changes in facial soft tissue compartments that differentiate lipoatrophy from 
changes due to wasting or weight gain.   
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3.5 Summary 
Changes in facial fat occurring over time in patients with HIV related 
lipoatrophy have not been properly quantified. The aims of this study were to 
define the longitudinal changes in facial fat compartments in patients with 
lipoatrophy and to compare these with changes accompanying wasting or weight 
gain.  
Facial MRI scans were performed at baseline and repeated after a median 
of 10 months in 12 patients with moderate to severe lipodystrophy continuing 
antiretroviral therapy, in 5 patients who lost weight and in 7 patients who gained 
weight (more than 10% weight change).  
Superficial facial fat decreased by a median of 5.2ml (P=0.03) in patients 
with lipoatrophy, and 8 of 12 individuals showed more than 15% decrease (all of 
whom were taking stavudine). The decrease was mainly cheek fat. Superficial 
facial fat decreased by 6.0ml in patients with weight loss (P=0.04) and increased 
by 20.2ml (P=0.02) in patients with weight gain, and changes occurred in cheek 
fat, temporal fat, masseter muscle and temporalis muscle compartments.   
MRI can detect substantial ongoing changes in facial fat in patients with 
facial lipoatrophy, and a characteristic pattern of compartmental change 
distinguishes lipoatrophy from wasting and weight recovery. MRI should be 
considered for use in clinical trials of interventions to prevent or treat lipoatrophy, 
and may be useful for documenting changes in individual patients during clinical 
follow-up. This information should be considered when designing future clinical 
intervention studies. 
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CHAPTER 4 EVALUATION OF DEXA IN ASSESSMENT OF 
LIPODYSTROPHY IN HIV INFECTED PATIENTS 
 
4.1 Introduction 
Substantial variations in the prevalence (20-80%), incidence, severity and 
risk factors for lipodystrophy have been reported which are likely to arise in part 
due to differences in diagnostic criteria for lipodystrophy (Carr et al., 2003; Carr 
et al., 1999; Heath et al., 2001; Lichtenstein et al., 2003; Paton et al., 2002; 
Thiebaut et al., 2000). DEXA has been advocated as a useful objective tool in the 
diagnosis and evaluation of lipodystrophy (Carr et al., 2003). The technique can 
detect differences in fat distribution between lipodystrophy and non-lipodystrophy 
patients, and DEXA measurements of leg fat percent and trunk to limb fat percent 
ratio made a significant contribution to a diagnostic model for a case definition of 
lipodystrophy (Carr et al., 2003; Carr et al., 1999). However, it is known that 
DEXA results vary with manufacturers, as well as with hardware and software 
versions used (Kistorp and Svendsen, 1997; Pritchard et al., 1993; Tothill et al., 
1994). Studies using DEXA instruments at various clinical research centers 
revealed considerable inter-machine differences (Economos et al., 1997), even 
among machines from the same manufacturer (Lantz et al., 1999; Paton et al., 
1995; Tataranni et al., 1996). Lipodystrophy is probably the first situation in 
which DEXA soft tissue measurements have been applied as a clinical diagnostic 
tool. However the impact of inter-machine differences on the assessment and 
diagnosis of lipodystrophy has not been assessed.  
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The aim of this study was to compare measurements of fat distribution 
between two different DEXA machines and to determine the impact of differences 






Twenty-four HIV infected patients (confirmed by ELISA and Western 
Blot assay) were recruited from the outpatient clinics of the Communicable 
Disease Centre, Tan Tock Seng Hospital, the national referral center for HIV 
infection in Singapore. Subjects were required to have lipodystrophy (12 subjects, 
see below for details of diagnosis) or no lipodystrophy (12 subjects). Exclusion 
criteria were wasting (defined as weight loss of more than 10% of their usual body 
weight during the past 6 months), concomitant use of diuretics, systemic 
corticosteroids, pregnancy or breast-feeding. All subjects gave written informed 
consent and the protocol was approved by the Ethics Committee of Tan Tock 
Seng Hospital.   
 
4.2.2 Clinical lipodystrophy assessments 
Standard questionnaire (same as used in section 2.2.2, page 45) about 
changes in appearance was administered to all patients, and any changes were 
classified as mild, moderate or severe (Carr et al., 2003). 
 
4.2.3 Clinical characteristics 
Medical records were reviewed and clinical information was abstracted 
including CD4 counts, viral load, and antiretroviral treatment history. Body weight 
was measured to the nearest 0.1 kg using electronic scales (SECA, Model 7700, 
Vogel & Halke, Hamburg, Germany) and height was assessed to the nearest 0.5 
cm using a stadiometer.  
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4.2.4 DEXA measurements 
Whole body composition was measured twice in each patient, once with a 
Lunar DEXA machine (Lunar Prodigy, software version 6.50; Lunar Corporation, 
Madison, Wisconsin, USA) and once with a Hologic DEXA machine (Hologic 
QDR 2000, software version 5.73A; Hologic Inc., Bedford, MA, USA) that are 
situated at different locations in our hospital. The paired measurements were 
performed on the same day, within an interval of 4 hours and the machines were 
used in random order. Patients were scanned wearing light indoor clothing. Scans 
were performed and analyzed by the same operator following manufacturer’s 
instructions, and using standardized cut-offs for regional measurements. The two 
machines were regularly calibrated for quality control purposes according to 
procedures specified by the manufacturer. Figure 4.1 illustrates Lunar DEXA scan 




Figure 4.1 Lunar DEXA scan image of one subject 
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4.2.5 Statistical analysis 
Comparisons of the duplicate Lunar and Hologic body composition 
measurements from individual patients were made by paired t-tests. Trends in 
inter-machine differences were evaluated using the method of Bland and Altman 
(Bland and Altman, 1986) and linear regression analysis. Two-sample t-tests were 
used to compare means for lipodystrophy and non-lipodystrophy subjects 
measured by one machine. The DEXA contribution to composite scores for 
lipodystrophy diagnosis were calculated using previously published conversion 
factors (Carr et al., 2003) and the mean lipodystrophy scores from the two DEXA 
machines were compared by paired t-tests. All P values were two sided and the 
level of statistical significance was considered to be alpha = 0.05. The data 




4.3.1 Patients demographic and clinical characteristics 
The demographic and clinical characteristics of the 24 patients are shown 
in Table 4.1. Those with lipodystrophy were significantly older, had a longer 
duration of HIV infection and a higher CD4 count than those without 
lipodystrophy. Twenty-two of the 24 patients were receiving HAART including a 
protease inhibitor. Of the 12 patients with lipodystrophy, 10 had facial 









Age, years 46.3 ± 14.2 35.3 ± 4.7 0.013 
Male sex, n 8 8 1 
Stage C disease, n 10 7 0.334 
Duration of HIV infection, months 55.3±15.5 39±20.9 0.043 
CD4 count, cells/mL 405±226 214±143 0.024 
Viral load, log10 copies/mL 2.21±1.02 2.90±1.54 0.227 
Viral load < 400 log10copies/mL, n 8 7 0.9 
Duration of ART, m 42.3±16.3 33.9±21.6 0.312 
Current use of HAART, n 12 11 0.9 
Height, cm 163.4±7.0 163.4±8.0 0.861 
Weight, kg 56.1±6.9 59.9±7.5 0.451 
BMI, kg/m2 21.1±2.5 22.4±2.5 0.326 
ART, antiretroviral treatment; BMI, body mass index. Data shown are mean ± SD,  
except for sex, disease stage, viral load below 400 and current use of HAART, which 
are absolute numbers. Means are compared between groups by t-test and by Fisher’s  
exact test.  
 
Table 4.1 Demographic and clinical characteristics of HIV infected patients 
(n=24) 
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4.3.2 Comparison of body composition results between DEXA machines  
The results of body composition measurements obtained with the two 
machines are shown in Table 4.2. Hologic gave significantly higher values than 
Lunar for total body fat (13.0 vs. 11.9 kg, P<0.001), and significantly lower values 
than Lunar for total body lean (41.4 vs. 43.3 kg, P<0.001) and bone mineral mass 
(1.9 vs. 2.3 kg, P<0.001). Total body fat percentage was significantly higher (22.9 
vs. 20.5%, P<0.001) when measured on the Hologic machine compared to Lunar.  
The distribution of body fat between central and peripheral areas also 
showed significant differences between the two machines. Hologic gave 
significantly higher measures of arm fat percent (27.9 vs. 14.5%, P<0.001) and leg 
fat percent (23.4 vs. 17.5%, P<0.001), and significantly lower values than Lunar 
for trunk fat percent (22.3 vs. 24.7%, P<0.001) and trunk-to-limb fat percent ratio 
(0.89 vs. 1.62, P<0.001). The individual differences between trunk-to-limb fat 
percent ratio and leg fat percent measurements obtained by the two machines are 
shown in Figure 4.2 and 4.3. The magnitude of the inter-machine differences for 
measurement of trunk-to-limb fat percent ratio increased as the mean trunk-to-
limb fat percent ratio increased (P=0.003). There was no significant relationship 
between the inter-machine difference and the mean for leg fat percent. The 
determination coefficients (r2) of the linear regressions between leg fat percent and 




  Hologic Lunar  Difference 95% CI P 
Total body mass (kg) 56.3±7.1 57.4±7.2 -2.1 -2.32 to -1.91 <0.001 
Total body fat (kg) 13.0±5.7 11.9±6.0 1.1 0.63 to 1.55  <0.001 
Total body fat (%) 22.9±9.6 20.5±9.9 2.4 1.59 to 3.24  <0.001 
Total lean tissue (kg) 41.4±6.8 43.3±6.8 -1.9 -2.44 to -1.44 <0.001 
Total BMC (kg) 1.9±0.3 2.3±0.3 -0.4 -0.44 to -0.37  <0.001 
      
Limb fat (kg) 5.8±2.5 4.1±2.3 1.7 1.53 to 1.92 <0.001 
Limb fat (%) 24.6±10.3 16.8±9.4 7.8 7.05 to 8.59 <0.001 
Trunk fat (kg) 6.4±3.4 7.4±3.8 -0.9 -1.32 to -0.53 <0.001 
Trunk fat (%) 22.3±11.3 24.7±11.4 -2.5 -3.82 to -1.11 0.001 
Arm fat (kg) 1.7±0.7 0.8±0.5 0.9 0.72 to 1.00 <0.001 
Arm fat (%) 27.9±11.6 14.5±8.8 13.4 11.98 to 14.79 <0.001 
Leg fat (kg) 4.1±1.9 3.2±1.9 0.9 0.70 to 1.03 <0.001 
Leg fat (%) 23.4±10.2 17.5±9.6 5.9 5.09 to 6.70 <0.001 
Trunk limb fat percent ratio  0.89±0.28 1.62±0.47 -0.72 -0.87 to -0.57 <0.001 
Trunk fat % minus limb fat % -2.3±6.2 7.9±5.3 -10.3 -11.54 to -9.01 <0.001 
      
Limb lean tissue (kg) 16.7±3.1 18.8±3.3 -2.1 -2.31 to -1.91 <0.001 
Trunk lean tissue (kg) 21.4±3.7 21.0±3.3 0.4 -0.08 to 1.04 0.09 
Arm lean tissue (kg) 4.2±1.0 4.8±1.0 -0.6 -0.75 to -0.46  <0.001 
Leg lean tissue (kg) 12.5±2.2 14.0±2.4 -1.5 -1.74 to -1.29 <0.001 
BMC, body mineral content; CI, confidence interval; P value was calculated using paired t-test. 
 




Figure 4.2 Lack of agreement between trunk-to-limb fat percent ratios by 
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 : lipodystrophy patients; ∆: Non-lipodystrophy patients. The solid line 
represents the regression line, the dotted line represents mean difference, and the 
broken lines illustrate the 95% confidence limits of the mean difference.
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represents the regression line, the dotted line represents mean difference, and the 




4.3.3 Comparison of two machines for detection of lipodystrophy changes 
The results of comparison of lipodystrophy and non-lipodystrophy patients 
using each machine are shown in Table 4.3. There were no significant differences 
between lipodystrophy and non-lipodystrophy subjects in whole body composition 
when measured by either Lunar or Hologic machines. When measured by Lunar 
DEXA, patients with lipodystrophy had significantly lower leg fat percent (13.5 
vs. 21.6%, P=0.04) and higher trunk to limb fat percent ratio (1.85 vs. 1.38; 
P=0.012) than those without lipodystrophy. When measured by Hologic, patients 
with lipodystrophy had values of leg fat percent (20.1 vs. 26.8%, P=0.11) and 
trunk to limb fat percent ratio (0.95 vs. 0.85, P=0.43) that did not differ 
significantly from those in patients without lipodystrophy.  
The differences in the DEXA contribution to a composite lipodystrophy 
score calculated using published conversion factors are shown in Table 4.4 and 
4.5. The DEXA contribution was significantly lower with Hologic DEXA than 
with Lunar DEXA both for patients with lipodystrophy (-6.30 vs. 2.59, P<0.001; 
mean difference -8.89, range -15.45 to -1.95) and for those without lipodystrophy 
(-10.77 vs. -7.6, P<0.001; mean difference -3.08; range -5.00 to -1.45).  
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Lunar DEXA Hologic DEXA Parameter 
LD (n=12) Non-LD (n=12) Difference P LD (n=12) Non-LD (n=12) Difference P 
Total body mass (kg) 55.3±6.5 59.4±7.5 -4.2 0.160 54.3±6.4 58.4±7.4 -4.1 0.160 
Total body fat (kg) 9.7±6.4 14.1±4.9 -4.4 0.075 11.4±6.1 14.7±4.9 -3.3 0.160 
Total body fat (%) 17.5±11.5 23.5±7.2 -6 0.140 20.9±11.0 25.0±7.7 -4.2 0.294 
Total lean tissue (kg) 43.5±7.9 43.2±5.8 0.3 0.908 41.1±7.4 41.7±6.6 -0.6 0.825 
Total BMC (kg) 2.2±0.3 2.4±0.4 -0.2 0.171 1.8±0.2 2.0±0.3 -0.2 0.139 
         
Limb fat (kg) 3.0±2.4 5.1±1.7 -2.2 0.018 4.7±2.6 6.8±2.0 -2.1 0.040 
Limb fat (%) 13.2±10.6 20.4±6.5 -7.2 0.06 21.3±11.7 27.9±8.0 -6.6 0.123 
Trunk fat (kg) 6.3±4.0 8.4±3.3 -2.1 0.186 5.9±3.7 7.0±3.2 -1.2 0.420 
Trunk fat (%) 21.9±13.4 27.6±8.8 -5.7 0.236 20.8±12.8 23.8±9.8 -3 0.531 
Arm fat (kg) 0.7±0.5 1.0±0.4 -0.3 0.082 1.4±0.7 2.0±0.7 -0.5 0.064 
Arm fat (%) 12.2±10.2 16.9±6.8 -4.6 0.208 24.7±12.5 31.1±10.1 -6.4 0.181 
Leg fat (kg) 2.3±1.9 4.1±1.3 -1.8 0.014 3.3±2.1 4.9±1.5 -1.6 0.043 
Leg fat (%) 13.5±10.8 21.6±6.5 -8.1 0.040 20.1±11.6 26.8±7.5 -6.7 0.108 
Trunk limb fat percent ratio  1.85±0.49 1.38±0.32 0.47 0.012 0.94±0.30 0.85±0.27 0.09 0.426 
Trunk fat % minus limb fat % 8.7±5.0 7.2±5.7 1.54 0.490 -0.5±5.2 -4.2±6.8 3.63 0.159 
         
Limb lean tissue (kg) 18.7±3.7 18.9±3.1 -0.3 0.853 16.6±3.3 16.8±3.1 -0.1 0.934 
Trunk lean tissue (kg) 21.2±3.9 20.7±2.5 0.6 0.685 21.2±4.0 21.7±3.4 -0.5 0.763 
Arm lean tissue (kg) 4.8±1.1 4.8±0.9 0.0 0.964 4.2±1.1 4.2±1.0 0.1 0.869 
Leg lean tissue (kg) 13.9±2.6 14.1±2.3 -0.2 0.811 12.4±2.3 12.6±2.2 -0.2 0.842 
LD, lipodystrophy; BMC, body mineral content; P value was calculated using two-sample t-test.       
 




Hologic DEXA measurement  Lunar DEXA measurement 
Leg fat LD Trunk limb fat LD Total   Leg fat LD Trunk limb fat LD Total  
Score difference Subject 
percent  score  percent ratio score score percent  score  percent ratio score score (Hologic - Lunar) 
P 
LD 7.93 0 1.00 5.00 5.00  4.41 0 2.22 11.10 11.10 -6.1  
LD 14.12 -8 0.89 4.45 -3.55  8.22 0 2.38 11.90 11.90 -15.45  
LD 10.95 -8 0.28 1.40 -6.60  4.33 0 1.23 6.15 6.15 -12.75  
LD 10.80 -8 0.64 3.20 -4.80  4.26 0 1.69 8.45 8.45 -13.25  
LD 44.57 -16 0.81 4.05 -11.95  37.6 -16 1.22 6.10 -9.90 -2.05  
LD 15.62 -14 1.02 5.10 -8.90  8.98 -8 2.10 10.50 2.50 -11.4  
LD 12.59 -8 1.02 5.10 -2.90  6.25 0 2.44 12.20 12.20 -15.1  
LD 20.05 -14 1.54 7.70 -6.30  12.55 -8 2.66 13.30 5.30 -11.6  
LD 31.25 -16 1.08 5.40 -10.60  22.08 -16 1.55 7.75 -8.25 -2.35  
LD 30.78 -16 1.07 5.35 -10.65  23.28 -16 1.54 7.70 -8.30 -2.35  
LD 10.68 -8 0.91 4.55 -3.45  5.99 0 1.77 8.85 8.85 -12.3  
LD 31.41 -16 1.02 5.10 -10.90  24.12 -16 1.41 7.05 -8.95 -1.95  
Total (Mean ± SD, n=12)   -6.30±4.81       2.59±8.89 -8.89 <0.001 
              
Non-LD 27.24 -16 0.65 3.25 -12.75  21.55 -16 1.27 6.35 -9.65 -3.1  
Non-LD 36.26 -16 0.95 4.75 -11.25  28.44 -16 1.32 6.60 -9.40 -1.85  
Non-LD 27.02 -16 0.75 3.75 -12.25  19.8 -14 1.04 5.20 -8.80 -3.45  
Non-LD 38.96 -16 0.69 3.45 -12.55  32.64 -16 1.04 5.20 -10.80 -1.75  
Non-LD 34.99 -16 1.03 5.15 -10.85  28.73 -16 1.32 6.60 -9.40 -1.45  
Non-LD 26.10 -16 1.15 5.75 -10.25  22.02 -16 1.80 9.00 -7.00 -3.25  
Non-LD 20.90 -14 0.83 4.15 -9.85  17.81 -14 1.45 7.25 -6.75 -3.1  
Non-LD 19.32 -14 1.41 7.05 -6.95  15.19 -14 2.06 10.30 -3.70 -3.25  
Non-LD 30.25 -16 0.95 4.75 -11.25  25.69 -16 1.51 7.55 -8.45 -2.8  
Non-LD 13.12 -8 0.75 3.75 -4.25  9.49 -8 1.59 7.95 -0.05 -4.2  
Non-LD 22.32 -16 0.58 2.90 -13.10  21.04 -14 1.16 5.80 -8.20 -4.9  
Non-LD 25.08 -16 0.41 2.05 -13.95  16.34 -14 1.01 5.05 -8.95 -5  
Total (Mean ± SD, n=12) -10.77±2.76    -7.60±2.99 -3.18 <0.001 
DEXA, dual enengy X-ray absortiometry; LD, lipodystrophy; P value was calculated using paired t-test 
Table 4.4 DEXA contribution of LD score by Lunar and Hologic machines in HIV infected patients 
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 4.4 Discussion 
 
4.4.1 Comparison of two machines for detection of lipodystrophy changes 
In this study, we found that body composition measurements by DEXA 
differed markedly between machines from different manufacturers. Differences in 
total body fat between Lunar and Hologic machines have been noted in a number 
of previous studies in healthy individuals and patients with clinical disease, 
although the direction of the differences varied between studies (Kistorp and 
Svendsen, 1997; Modlesky et al., 1996; Pritchard et al., 1993; Tothill et al., 1994). 
In addition to differences in total body composition, we found differences between 
Lunar and Hologic DEXA in the way soft tissue mass was apportioned between 
limb and trunk regions. Compared to Lunar, Hologic DEXA gave higher values of 
limb fat and lower values of trunk fat. This was especially marked in the arms 
where Hologic gave values of fat almost double that of Lunar. Higher limb fat and 
lower trunk fat values with Hologic compared to Lunar DEXA have been 
demonstrated previously in a study in healthy young men (Modlesky et al., 1996) 
and in a study of patients with diabetes (Kistorp and Svendsen, 1997) confirming 
that the differences we found are not unique to our particular machines but rather 
are the result of systematic differences in hardware and software between the two 
manufacturers. Although the principle of the technology is the same, the X-ray 
frequencies used and the way the beam is generated differ between DEXA 
manufacturers (Mazess et al., 1991; Tothill et al., 1994). The raw measurements 
are converted into estimates of soft tissue composition by software and the 
assumptions in the calculations and resulting formulae used are likely to differ, 
especially in the way that values of soft tissue composition are allocated to areas 
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 overlying bone. The equations remain proprietary information and are not publicly 
available, so it is not possible to assess exactly which assumptions may be 
contributing to these differences. DEXA measurements are known to be very 
reproducible, with coefficients of variation of less than 5% for whole body and 
regional soft tissue measurements both in other center (Madsen et al., 1997) and 
our center (see section 2.2.4, page 50). Differences in operators doing the analysis 
can increase the variability of the results from DEXA (Smith et al., 2003), but 
same operator performed and analyzed all our scans. Also, the possible 
differences in reproducibility between Hologic and Lunar could not explain the 
systematic differences in measurements between machines that we have observed.  
 
4.4.2 Differences between Lunar and Hologic DEXA 
Both Lunar and Hologic machines have been validated for measuring 
whole body composition in humans against gold standard methods such as CT, 
MRI, and four-compartment body composition models (Fuller et al., 1999; 
Salamone et al., 2000; Visser et al., 1999; Wang et al., 1996). Validation for 
measurement of regional body composition has been more limited due to the lack 
of gold-standard methods for comparison. In a study in which slabs of lard were 
placed over the body, Hologic DEXA detected 96% of the fat mass placed on the 
limbs, but only 53% of the fat placed on the trunk (Snead et al., 1993). Another 
study indicated that Hologic underestimated trunk fat at lower tissue thicknesses 
(Jebb et al., 1995). Several studies that compared Lunar DEXA trunk fat 
measurements with abdominal CT or additions of lard found that Lunar DEXA 
accurately measured trunk fat (Jensen et al., 1995; Svendsen et al., 1993), 
although one study found an underestimate of abdominal fat (Milliken et al., 
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 1996). As we did not have a gold-standard method with which to compare our 
results, we cannot determine which of the scanners (if either) is giving the “true” 
answer. Our results suggest that Lunar might be better for distinguishing patients 
with lipodystrophy from those without lipodystrophy, assuming that our clinical 
classification of lipodystrophy was correct based on the subject report and 
physician assessment, and that the findings of reduced leg fat percent and 
increased trunk to limb fat percent ratio are representative of lipodystrophy (Carr 
et al., 2003).  
 
4.4.3 Difference in contribution to the lipodystrophy diagnosis score by the 
two DEXA machines 
DEXA measurement of fat is included in a clinical algorithm developed 
for diagnosis of HIV-associated lipodystrophy (Carr et al., 2003). The two DEXA 
parameters included in this algorithm, leg fat percent and trunk to limb fat percent 
ratio, are converted into a contribution to a total lipodystrophy score, along with 
component scores for age, sex, duration of HIV infection, CDC disease stage, 
waist hip circumference ratio, HDL cholesterol, anion gap and the ratio of visceral 
to subcutaneous adipose tissue measured by CT (Carr et al., 2003). We found that 
the differences in DEXA measurements of leg fat percent and trunk to limb fat 
percent ratio with the different machines make a difference to the total DEXA 
contribution to the lipodystrophy score of up to 15.45 points in individual patients 
with lipodystrophy. Although we did not have all the other measurements 
necessary to calculate the full lipodystrophy score according to the algorithm, the 
difference in DEXA score is likely to result in a difference in classification for a 
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 number of patients. A change in the cutoff score by 14 points halved the 
sensitivity of the original model for detection of lipodystrophy (Carr et al., 2003).   
 
4.4.4 Calibration of different machines with standard soft tissue phantom 
DEXA is economical, convenient and gives reproducible measurements 
and is therefore attractive as a diagnostic tool for lipodystrophy. This study has 
illustrated the limitations of applying the technique for this purpose. The results 
should be taken as an illustration of the limitations of DEXA in general, and not as 
an indictment of one particular manufacturer. Changes in software occur regularly 
and these may affect the assumptions used. Even within manufacturers there may 
be differences between machines (Lantz et al., 1999; Paton et al., 1995; Tataranni 
et al., 1996). The main point is that without a method of calibration and 
standardization of results between machines, it would be unwise to rely on the 
absolute values of results for individual patients or groups of patients. Ideally 
there should be a standard soft tissue phantom that could be used to calibrate 
different machines (Genton et al., 2002). Further validation studies for regional 
body composition in lipodystrophy are required before this technique can be 
widely applied for diagnostic purposes in this clinical setting. DEXA may be 
useful in longitudinal studies (provided that the same machine is used for repeated 
measurements) as it has good reproducibility and has been shown to have good 
agreement with other methods for detecting changes in whole body composition 
in patients with HIV infection (Paton et al., 1997). However, additional validation 
studies of DEXA for detecting regional body composition changes over time in 
HIV patients are also needed. 
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 4.5 Summary 
DEXA is regarded as a useful objective method for diagnosis of HIV-
associated lipodystrophy. The objective of this study was to determine whether the 
use of different DEXA machines might affect the diagnosis of lipodystrophy.   
Body composition was measured on two DEXA machines (Lunar and 
Hologic) in 24 HIV-infected patients, 12 of whom had clinically-diagnosed 
lipodystrophy. 
Hologic gave significantly higher values than Lunar DEXA for total body 
fat percent (22.9 vs. 20.5 %, P<0.001), arm fat percent (27.9 vs. 14.5%, P<0.001) 
and leg fat percent (23.4 vs. 17.5%, P<0.001), and significantly lower values than 
Lunar for trunk fat percent (22.3 vs. 24.7%, P<0.001) and trunk to limb fat percent 
ratio (0.89 vs. 1.62, P<0.001). When measured by Lunar, patients with 
lipodystrophy had significantly lower leg fat percent (13.5 vs. 21.6 %, P=0.04) 
and higher trunk to limb fat percent ratio (1.85 vs. 1.38; P=0.012) than those 
without lipodystrophy. When measured by Hologic, patients with lipodystrophy 
had values of leg fat percent (20.1 vs. 26.8 %, P=0.11) and trunk to limb fat 
percent ratio (0.95 vs. 0.85, P=0.43) that did not differ significantly from those 
without lipodystrophy. There was a significant difference in the contribution to a 
composite lipodystrophy score between Lunar and Hologic measurements.  
DEXA machines from different manufacturers gave major differences in 
measurements of body fat content and distribution, and this might affect the 
ability to distinguish patients with lipodystrophy from those without 
lipodystrophy. Further standardization of DEXA technology is needed before 




CHAPTER 5 EVALUATION OF REPRODUCIBILITY AND 
ACCURACY OF 3-DIMENSIONAL LASER SCANNING FOR 
ESTIMATING FACIAL VOLUME CHANGE 
 
5.1 Introduction 
The diagnosis of lipodystrophy is currently based on patient self-
assessment and/or physician assessments (Carr et al., 2003), which are subjective 
and may account, in part, for the variation in prevalence rates (20-80%) reported 
in different cohort studies (Carr et al., 2003; Lichtenstein et al., 2003; Paton et al., 
2002). Furthermore, the subjective method had been shown to be insensitive for 
detecting changes over time (Law et al., 2006). Although peripheral fat changes 
can be measured by DEXA (Carr et al., 2003), the method cannot detect changes 
in facial fat (Brownbill and Ilich, 2005). We found in Chapter 2 and Chapter 3 that 
MRI was an accurate and reliable method and could be used to separate patients 
with lipoatrophy and controls and detect substantial ongoing changes in facial fat 
in patients with facial lipoatrophy, but this has limitations of being expensive and 
inconvenient with scanning and image analysis. To date there is no simple and 
economical method that is accepted for the objective assessment of HIV-related 
facial lipoatrophy.  
Three-dimensional laser scanning (LS) has been used in research and 
clinical practice for generating images of facial contour that may be used for 
planning maxillofacial surgery, measuring craniofacial deformity and planning 
radiotherapy (Ferrario et al., 2003; Soncul and Bamber, 2000; Wilks, 1993; 
Wilson et al., 1997). Laser scanners are easy to use, inexpensive, rapid and non-
invasive (Wilson et al., 1997). This method, with appropriate standardisation of 
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scanning technique and image analysis approach, may have potential as an 
objective tool for the assessment of facial lipoatrophy.  
The aim of this study was to evaluate the accuracy and reproducibility of a 
standardised method for assessing cheek volume changes using LS, with a view to 





5.2.1 Accuracy of the volume simulation method 
The accuracy of the method for estimating volume change was tested 
using a mannequin (Modern Artificial Model, Modern Artificial Model Pte. Ltd., 
Singapore). A series of increasing volumes of plasticine (0, 0.5, 1.0, 1.5, 2.0, 2.5, 
3.0, 3.5, 4.0, 4.5, 5.0ml) (Tack-ITTM, A.W. Faber-Castell (M) Sdn. Bhd. Selangor, 
Malaysia), calculated from known density and weight, were used to simulate 
changes in facial contour. The plasticine was placed on the cheeks of the 
mannequin over a circle of 15mm radius centred over the point 1/3 along a line 
drawn between the labial commissure and tragus in order to place it within the 
area used for volume analysis (see below and Figure 5.1). Repeated scans were 
performed with and without each incremental volume of plasticine.  
 
5.2.2 Reproducibility of the volume change simulation in mannequin and 
healthy subjects  
Reproducibility of the volume change estimates was assessed using 5 
repeated scans with and without a constant 2ml of plasticine attached to the 
mannequin cheek. Reproducibility over time was also tested in 10 healthy subjects 
(5 male, 5 female) recruited from hospital staff with normal facial symmetry and 
with no beard or moustache. Subjects were scanned a total of eight times over the 
course of one week. Five scans were obtained on the first day to test the scan-to-
scan variability, and a single scan was repeated on days two, four, and seven to 
test day-to-day variability. The study was approved by the local hospital Ethics 
Committee.  
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5.2.3 LS procedure 
Laser scans were performed using a commercially available three-
dimensional digitiser laser scanner (VIVID 300, Minolta Co Ltd, Osaka, Japan, 
2000). The laser scanner emits a horizontal stripe light through a cylindrical lens 
to the subjects face and converts the reflected light into distance information. This 
process is repeated by scanning the light stripe vertically along the face, and 
40,000 points of three-dimensional data are collected during a scan time of 0.6s.  
Before scanning, subjects were asked to remove any jewellery from the 
face and ears and to moisten and retract any hair to give full exposure of the 
forehead and ears. They were asked to close their mouth without clenching the 
teeth, and adopt an expressionless face without smiling. Subjects were seated 
upright in a standardized swivel chair positioned 120cm from the laser camera. 
The swivel chair was initially rotated 45° clockwise from the frontal plane to 
expose the left cheek, and the subject was instructed to focus their eyes on a 
marker positioned at an appropriate position on the wall of the room. After 
obtaining the laser image, the procedure was repeated with the swivel chair 
rotated to 45° anticlockwise from the frontal plane to obtain an image of the right 
cheek. An identical procedure was used for the scanning of the mannequin except 
the mannequin was positioned on a box to elevate it within the centre of the 




Figure 5.1 The mannequin with plasticine attached on the cheek area to 















5.2.4 Analysis of paired laser scans  
The three-dimensional scan data was transferred to commercially available 
computer software for analysis (RapidForm2004, INUS Technology Inc., Seoul, 
Korea). A pair of scans of the same side of the face was selected, and the 40,000 
data points in each scan were automatically converted by the software into a 
recognisable image of the face for ease of positioning and identification of 
reference points. The images were cropped to remove the neck region and hair. 
Four reference points (eye lateral canthus, tragus, labial commissure, ala; Figure 
5.2) that are known to be reproducible were selected on each of the two images 
(Ferrario et al., 2003). The more recent image was superimposed over the earlier 
image using the 4 reference points as a guide. A vector was generated between the 
midpoint of the bridge of the nose and the chin, and the superimposed image was 
rotated around this axis to 65° from the frontal view to obtain a standardised 
image position for analysis. A vector was then drawn between the labial 
commissure and the tragus, and a point selected 1/3 of the way along the line from 
the labial commisure end. A circle of radius 25 mm was positioned with its centre 
on this point (Figure 5.3), and the estimated cheek surface volume (CSV) 
difference between the two components of the superimposed image was calculated 
within the area of the circle using a customized algorithm developed by the 
software manufacturer that analyses the distance between the three-dimensional 
data points underlying the two images. The procedure was repeated for the 
corresponding images from the opposite cheek and average of the left and right 
estimated CSV differences was calculated. A single technician performed all the 
laser scans, identified the soft tissue landmarks, performed superimpositions, and 




Figure 5.2 The selected reference points and superimposition of two right-













5.2.5 Statistical analysis 
The accuracy for estimating CSV change was assessed by the method of 
Bland and Altman (Bland and Altman, 1986) and linear regression analysis. 
Reproducibility of the method in the mannequin was determined by calculating 
the coefficient of variation (CV). CV values less than 10% was considered to 
represent good reproducibility (Scott et al., 1989). Reproducibility of the method 
in human subjects was assessed by calculating the intraclass correlation 
coefficient (ICC) for the repeated scans on the first day and for the repeated scans 
over one-week. An ICC score of > 0.75 was taken as excellent reliability (Kramer 
and Feinstein, 1981). All P values were two sided and p<0.05 was considered 
statistically significant. The data analyses were performed with SPSS 11.0 






5.3.1 Accuracy of volume changes 
The CSV changes estimated by LS corresponded closely to the actual 
volume changes across the range of simulated volume changes with a mean 
difference of 0.08 ml (95% CI, -0.36 to 0.20 ml) (Figure 5.4). There was a trend 
towards an underestimation by LS at higher values of volume change, but the 




Figure 5.4 Comparison of estimated volume change by laser scans with real 
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The solid line represents the regression line of the differences in estimated and 
real volumes against the average of the estimated and real volumes. The dotted 
line and the broken lines represent the mean and 95% confidence limits 
respectively of the mean difference between the estimated and real volumes. 
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5.3.2 Reproducibility of volume changes 
Repeated measurements of the 2ml volume change gave a mean value of 





  Left Right Average 
Measurement 1 1.767 1.813 1.79 
Measurement 2 1.974 1.903 1.939 
Measurement 3 2.086 2.09 2.088 
Measurement 4 2.178 1.77 1.974 
Measurement 5 1.864 1.867 1.866 
    
Mean 1.974 1.889 1.931 
SD 0.165 0.124 0.113 
CV% 8.4 6.5 5.8 
SD, standard deviation; CV, coefficient of variance  
 
 
Table 5.1 Reproducibility of plasticine volume (2ml) measured in mannequin 
 124 
5.3.3 Reproducibility of measurements in healthy subjects 
The reproducibility of the selected areas for CSV change estimated within 
the 25mm radius circle varied due to individual differences in facial contour, but 
the variation was small (range 1810 to 1870 mm2). For repeated scans on the same 
day, the scan-to-scan volume differences from the baseline scan ranged from -
0.709 to 0.404 ml. The ICC for the repeated measurements was 0.812 (95% CI: 
0.515 to 0.947) (Table 5.2). For repeated scans over one week, the day-to-day 
volume differences from the baseline scan ranged from -1.760 to 0.817 ml. The 




  Left   Right   Average 
  M2 M3 M4 M5   M2 M3 M4 M5   M2 M3 M4 M5 
Mean -0.14 -0.10 -0.05 -0.19  0.05 -0.04 0.07 -0.03  -0.04 -0.07 0.01 -0.11 
SD 0.46 0.32 0.15 0.42  0.42 0.42 0.40 0.59  0.44 0.37 0.28 0.50 
ICC    0.66     0.88     0.81 
95% CI 0.103 to 0.906      0.679 to 0.966     0.515 to 0.947 
M2, M3, M4, M5, consecutive laser scans at first day, superimposed with M1; SD, standard deviation; 
ICC, intraclass correlation coefficient; CI, confidence interval 
 




 Left  Right  Average 
  D2 D4 D7   D2 D4 D7   D2 D4 D7 
Mean  -0.08 -0.21 0.01  0.02 -0.31 -0.10  -0.03 -0.26 -0.05 
SD 0.56 0.44 0.51  0.55 1.02 0.58  0.50 0.62 0.50 
ICC   0.73    0.66    0.76 
95% CI 0.225 to 0.927   0.001 to 0.907   0.332 to 0.935  
D2, D4, D7, consecutive laser scans at day 2, 4 and 7, superimposed with the 1st scan at 1st day 
SD, standard deviation; ICC, intraclass correlation coefficient; CI, confidence interval 
 




5.4.1 Accuracy of the LS volume estimation method 
We have developed a standardised method for estimating CSV changes in 
the cheek using changes in facial contour measured by LS, and have shown that 
the method was accurate in measuring simulated volume change up to 5ml. The 
magnitude of facial volume change that occurs in HIV-related lipoatrophy patients 
over time has not been specifically quantified in any published study. However, 
based on MRI measurements of facial fat volume that show a mean difference 
between severe lipoatrophy and controls of approximately 15ml in the cheek (see 
section 2.3.2, page 52) and the experience from cosmetic surgery where 
immediate changes are noticeable in individual subject after injection of 2-3ml, 
volume changes are unlikely to exceed the range that we have tested. In most 
cases, volume changes are likely to be very small and technically demanding to 
any technique. LS might be one of the few methods with the precision necessary 
to detect such small changes.  
The method we developed focused on estimating CSV change in a defined 
area of the cheek, as facial appearance suggests that most of the severe changes of 
lipoatrophy occur in the cheek area (Orentreich and Leone, 2004; Strauch et al., 
2004; Talmor et al., 2002). The circular area that we have defined might not fully 
capture all the changes of lipoatrophy in a particular patient, and thus there may 
be an underestimate of the actual volume change. However, it is unlikely that 
changes would occur in other areas without involving the cheek and hence volume 
change in the cheek is likely to be representative of volume changes elsewhere. 
Measurement of facial fat volume has shown a similar extent of fat loss in cheek 
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and temporal areas (see section 2.3.2, page 52). The use of a standardised area 
helps to optimise the reproducibility, which would diminish if a larger and less 
well-defined area were to be used.  
 
5.4.2 Reproducibility of the LS volume estimation method 
In longitudinal studies that attempt to detect small changes, reproducibility 
of measurements is critical. Variability is due to a combination of measurement 
artifact and random biological variation over time. The coefficient of variation of 
5.8% for repeated measurements of simulated CSV change and the intra-class 
correlation coefficients of 0.81 and 0.76 for within day and between day 
measurements of human subjects indicate that the method has good 
reproducibility. These good results are likely due in part to the efforts made to 
standardise the scan conditions, the method of image manipulation for analysis, 
and the area used for calculation of volume change. The relative contribution of 
each of these is not known. The only published study in which LS was applied to 
measurement of lipodystrophy showed slightly greater variability (higher standard 
deviation) of inter-measurement differences than we found in our study, but the 
approach used to standardise scan analysis was not reported in sufficient detail to 
speculate on the reasons for the differences (Benn et al., 2003). Careful 
standardisation of the position in which the subject is scanned may be particularly 
important. One study of a portable LS in healthy subjects found good 
reproducibility (standard deviation for inter-scan differences of 0.2ml) when the 
position of the subject for scanning was carefully standardised, but additional 
errors of up to 7.6ml when the subject position was varied (Harrison et al., 2004).   
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5.4.3 Comparison with other measurement methods for facial fat change 
over time 
MRI and spiral CT can provide accurate and direct measurement of facial 
fat volume in non-HIV patients (Abate et al., 1994; Thomas et al., 1998). We 
found in Chapter 2 and Chapter 3 that the MRI method was reproducible and 
detected the difference in volume between HIV infected lipoatrophy and control 
patients. One study in which single-slice CT was used to measure facial adipose 
tissue area in HIV patients with lipoatrophy showed reasonable reproducibility, 
and even patients with mild lipoatrophy could be distinguished from controls 
(Padilla et al., 2004). However, these imaging methods are of limited use for 
repeated measurements in longitudinal clinical studies because of their 
inconvenience, cost, and (in the case of CT) radiation exposure. Ultrasound 
measurement of subcutaneous malar fat depth has the advantages of convenience, 
relatively low cost and lack of radiation exposure. Although it appeared able to 
detect differences between lipoatrophy patients and controls in a cross sectional 
study (Martinez et al., 2000) and has been used in studies of surgical interventions 
for lipoatrophy (Guaraldi et al., 2004), it was unclear to what extent the results 
were technique dependent and vary between observers and it also did not prove 
useful for measuring HIV-lipoatrophy changes when used in a randomised 
controlled trial (Carey et al., 2004). Measurement of skin fold thickness by 
calipers was shown to be reproducible in one study and had a moderate correlation 
with CT-measured fat area (Padilla et al., 2004). Three-dimensional photography, 
used in one trial of polylactic acid injections, shares the advantages of laser 
scanning, but has not yet been validated for measurement of lipoatrophy (Lafaurie 
et al., 2005). To date, most clinical research on lipoatrophy has used DEXA to 
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measure peripheral fat without direct measurements of facial fat. The close 
correlation we found between DEXA measurements of peripheral fat and the MRI 
measurements of facial fat (see section 2.3.4, page 57), suggests that measurement 
of limb fat by DEXA probably provides a suitable surrogate measurement for 
facial lipoatrophy. 
Similarly, laser scanning also is attractive because of its simplicity, ease of 
use, and that it offers quick and accurate results with no patient contact or 
radiation. The combined cost of the scanner and software, currently exceeding 
US$25,000 with estimated cost of S$75 per scan, may limit widespread use. 
Although scanning conditions need to be carefully standardised (see above), this is 
simple to do and does not require specific training. However, some training would 
be needed for individuals performing scan analysis, but in a research setting the 
raw data could easily be transmitted for centralised analysis. It is important to note 
that the method measures change in surface contour, and volume is extrapolated 
from that. Therefore the results may be affected by other factors that alter facial 
contour, such as dehydration and variation of human facial expression. The 
estimated volume change may comprise changes in muscle as well as fat. 
Furthermore, the performance of the method with the use of facial fillers is 
uncertain as the contour of these may alter over time without true change in 
volume, and the method is not suitable for patients with beards or moustaches. 
Although it is unlikely that this technique is going to be useful in the detection and 
assessment of facial lipoatrophy over short-term follow up in individual patients 
in the clinic setting, with careful standardisation of the method it might prove very 
useful for measuring changes in groups of patients in clinical trials and large 
cohort studies.  
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5.5 Summary 
Facial lipoatrophy is a common complication of HAART. Research into 
causes and treatment of facial lipoatrophy is hindered by the lack of an objective 
measurement tool. The objective of this study was to evaluate the accuracy and 
reproducibility of LS for estimating cheek volume changes.  
Paired laser scans were performed and the images superimposed using 
commercial software. The CSV difference between images was computed within 
a circle of radius 25mm placed in a standardised position over the cheek area. 
Accuracy was tested by scanning before and after known volumes of plasticine 
(0.5 to 5ml) applied to the cheek area of a mannequin to simulate volume change. 
Reproducibility was tested by repeated scanning of the mannequin with and 
without 2ml plasticine, and repeated scanning of ten healthy subjects over the 
course of one week. 
The mean volume difference between actual and estimated volume change 
was small across the range of volumes tested (mean difference 0.08ml, 95% CI –
0.36 to 0.20ml). The coefficient of variation for repeated measurements of 2ml 
volume change was 5.8%. The intra-class correlation coefficient for scan-to-scan 
variability was 0.812 (95% CI: 0.515 to 0.947) and for day-to-day variability was 
0.764 (95% CI: 0.332 to 0.935).  
The conclusion of this study was that LS was an accurate and reproducible 
method for estimating cheek volume changes. It might be useful as objective tool 
for assessment of facial lipoatrophy in clinical research studies.  
 CHAPTER 6  VALIDATION OF LASER SCANNING FOR 
DETECTING FACIAL FAT CHANGES IN PATIENTS 
UNDERGOING FACIAL FAT CHANGE 
 
6.1 Introduction 
Evaluation of lipodystrophy in clinical trials is currently based on patient 
self-assessment and/or physician assessments, although these are subjective and 
have been shown to be insensitive for detecting changes over time (Law et al., 
2006). Although DEXA is often used to measure changes in peripheral 
lipoatrophy in clinical research, this method is not suitable for detecting facial fat 
changes (Brownbill and Ilich, 2005). Facial MRI and CT have been used 
successfully in measuring facial soft tissue volumes and their changes over time 
(see section 2.3.2, page 52 and section 3.3.3, page 77), but these techniques are 
limited by cost, inconvenience and (in the case of CT) radiation exposure 
(Cavalcanti et al., 2004; Padilla et al., 2004). 
Laser scanning had shown to have good accuracy and reproducibility for 
detection of simulated facial changes using a mannequin (see section 5.3.2, page 
114), and good reproducibility over time in stable healthy subjects and HIV-
infected patients in our previous validation studies (see section 5.3.3, page 116) 
and in other studies (Benn et al., 2003; Kau et al., 2005). However, in order to be 
useful in clinical or research settings, the method needs be demonstrated to be 
accurate for the detection of changes occurring over time. In this study we set out 
to validate the technique against MRI-measured facial soft tissue changes.  
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 6.2 Methods 
 
6.2.1 Patients 
The patients enrolled for this study were participating in a study of MRI 
measurement of facial soft-tissue compartment changes occurring in facial 
lipoatrophy, wasting and weight gain that has been reported in Chapter 2 (see 
section 2.3.1, page 51) and Chapter 3 (see section 3.3.1, page 72). Each patient 
was assessed at baseline and after an interval of approximately 12 months. At each 
visit a facial MRI scan was performed using a clinical 1.5T MR system (Signa 
NVi, GE Medical Systems, Wisconsin, MI) as described in section 2.2.3 (page 46) 
and a laser scan was performed as described in section 5.2.3 (page 106) and 
analysed as described below. The study was approved by the Ethics Committee of 
Tan Tock Seng Hospital and all subjects gave written informed consent.  
 
6.2.2 Laser scanning procedure and analysis 
Laser scans were performed with a commercially available 3D digitiser 
laser scanner (VIVID 300, Minolta Co Ltd, Osaka, Japan, 2000), using a 
standardised method that we have described in detail in Chapter 5 (see section 
5.2.3, page 106). The patient was seated in a swivel chair positioned 120cm from 
the laser camera, and rotated to obtain separate images of the right and left cheeks. 




Figure 6.1 The subject taking laser scanning images 
 
The solid arrow represents emitting light stripe; the dotted arrow represents 
reflected light stripe which received by laser scanner 
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 Laser scans were transferred to commercially available computer software 
(RapidForm2004, INUS Technology Inc., Seoul, Korea) for analysis. The 
calculation of CSV change has been described in detail in Chapter 5 (see section 
5.2.4, page 108).  
In addition, we calculated the change in cheek surface point-displacement 
(CPD) using the individual baseline and follow-up scans, an approach that does 
not require superimposition of sequential scans. For this method, an individual 
scan was selected, a vector drawn between the labial commissure and the tragus at 
the point one third of the way along the line from the labial commissure end 
(Point A; the same as the centre point of the circle used to define the surface 
volume changes, as described above), and a plane was created perpendicular to the 
vector at this point. A second line was created between the labial commisure and 
tragus that followed the surface contour of the cheek, and the point of intersection 
of this line with the perpendicular plane as defined above (Point B) was 
determined. The CPD is the measured distance between point A and B (Figure 
6.2). The analysis was performed twice and then repeated using the image of the 
opposite cheek, and the average of these four measurements was taken as the final 
CPD. The change in CPD was calculated from the difference in results from 
baseline and follow up scans. All laser scan analyses were performed by the same 



















AB is the cheek surface point displacement (CPD) 
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 6.2.3 Superficial fat volume measurement by MRI method 
MRI measurement was performed as described in section 2.2.3 (page 46) 
on the same day as laser scans. Tracing and analysis of all soft tissue volumes 
were performed both at baseline and at follow up by the single experienced reader, 
who was blinded to subject grouping. 
 
6.2.4 Statistical analysis 
Associations between laser scan estimates and parameters measured by 
MRI were assessed by Pearson’s correlation coefficients. Intra-group changes in 
CSV and CPD from baseline were assessed by Wilcoxon Signed Ranks Test. All 
P values were two sided and p<0.05 was considered statistically significant. The 
data analyses were performed with SPSS 11.0 software (Chicago, IL). 
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 6.3 Results 
 
6.3.1 Patients 
Twenty-four patients were studied (mean age 44±7 years, mean CD4 
326±300 cells/mm3). Of these, 12 patients had lipoatrophy at baseline and 
continued on ART during follow up (lipoatrophy group). Five patients who did 
not take ART experienced weight loss of more than 10% during follow-up, 
associated with episodes of opportunistic infection (weight loss group). Seven 
patients (five of whom had opportunistic infections at baseline) and all of whom 
received ART during follow-up, gained more than 10% of body weight during 
(weight gain group). The median time between baseline and follow up scans was 
10 months (range 5 to 14 months). The clinical details and MRI results had been 
reported in detail in Chapter 3 (see section 3.3.2, page 73).  
 
6.3.2 Estimated CSV changes by LS and their relationships with MRI cheek 
fat changes  
The median estimated CSV changes were –2.1 (range –4.6 to –0.8) ml, in 
the lipoatrophy group, –1.5 (range –6.8 to –1.3) ml in the weight loss group and 
+3.1 (range –0.2 to +5.4) ml in the weight gain group. The corresponding changes 
in cheek fat measured by MRI were –4.6ml, -3.7ml and +7.0ml in the three groups 
respectively. The relationship between laser scan measured CSV change and MRI 
measured cheek fat are shown in Figure 6.3. In the patients with lipoatrophy there 
was no significant correlation between surface volume change and cheek fat 
change (r=0.34, P=0.28), a trend towards a correlation with buccal fat pad change 
(r=0.52, P=0.08), and no relationship with masseter muscle change (r=-0.20, 
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 P=0.53). In the 12 patients with weight loss or gain, there were significant 
correlations between cheek surface volume change and cheek fat change (r=0.71, 
P=0.01), buccal fat pad change (r=0.77, p=0.004), and masseter muscle change 






 Figure 6.3 Relationship between cheek fat change measured by MRI and CSV change estimated by laser scanning in 
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 6.3.3 CPD changes and their relationships with MRI cheek fat changes  
The median changes in CPD from baseline to follow up were –0.9 (range –
3.5 to +0.6) mm in the lipoatrophy group (P=0.06), –1.7 (range –4.7 to 0.0) mm in 
the weight loss group (P=0.08) and +2.7 (range +0.6 to +6.1) mm in the weight 
gain group (P=0.02). In the lipoatrophy group there were no significant 
correlations between CPD and cheek fat change (r=0.20, P=0.54), nor buccal fat 
pad change (r=0.39, P=0.22), nor masseter muscle change (r=0.40, P=0.20). 
However, in the 12 patients with weight loss or gain, there was a strong 
relationship between CPD and cheek fat change (r=0.74, P=0.006), a trend 
towards a relationship with buccal fat pad change (r=0.52, P=0.09) and a 
significant correlation with masseter muscle change (r=0.66, P=0.019). The 
relationship between laser scan measured CPD change and MRI measured cheek 
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 6.4 Discussion 
 
6.4.1 Surface volume change in patients with facial lipoatrophy 
We found that laser scanning was able to detect changes in surface volume 
in the appropriate direction in a group of 12 patients with progressive lipoatrophy, 
although the median CSV change was about half the median measured change in 
cheek fat volume. In an earlier study, in which changes in cheek fat were 
simulated by applying known volumes of plasticine to a mannequin (see section 
5.3.1, page 112), we found a tendency for laser scanning to underestimate cheek 
changes, although the effect was small. The large underestimate in the present 
study may in part be explained by the location of the changes in facial fat that 
occur in real-life patients. Sequential scans are superimposed based on four 
reference points that lie outside the central circle of measurement and are known 
to be reproducible from scan to scan (Ferrario et al., 2003). However, if these 
reference points are also displaced in the same direction as the central circle of 
measurement, the process of superimposition of scans will in effect minimise the 
estimated central surface volume difference. Although changes occurring in HIV 
lipoatrophy are most obvious in the centre of the cheek, in advanced cases they 
can extend as far as the temples and orbit (James et al., 2002). MRI measurements 
have also shown that fat depletion occurs in other compartments in addition to the 
cheek (see section 2.3.2, page 52). This source of error was not present in our 
mannequin model because the plasticine was only applied in the centre of the 
cheek, and the reference points on the surrounding areas were unchanged (see 
section 5.2.3, page 106). Another study of surface contour measurement that used 
a 3-dimensional imaging approach similar to ours also noted a relatively small 
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 change in mean dermal thickness (2.3mm) in a group of patients given a series of 
injections of polylactic acid into their cheeks for correction of lipoatrophy 
(Lafaurie et al., 2005). Thus there may also be a general tendency for 3-
dimensional laser imaging approaches to underestimate surface volume changes.  
 
6.4.2 Cheek surface contour change and facial fat compartment change 
In the group of patients with lipoatrophy there was no significant 
relationship between the individual measurements of CSV change and the MRI-
measured change in cheek fat volume, although there was a trend towards a 
significant correlation with change in buccal fat pad volume. The lack of 
correlation may reflect the relatively small measured surface volume changes 
(median of 2.3ml per cheek), together with the combined errors associated with 
measuring CSV change (coefficient of variation of 5.8%, see section 5.3.2, page 
114) and cheek fat change (coefficient of variation of 8.3%, see section 2.2.3, 
page 46). The differences between surface contour volume changes and MRI-
measured facial fat volume changes may not necessarily indicate that that laser 
estimates are incorrect as they are, in fact, measuring different things. There may 
be changes in buccal cavity volume, accumulation of fibrous tissue, or alterations 
of the skin such as thickening of nasolabial folds (as well as changes in muscle 
compartments occurring with weight loss or gain) that lead to a dissociation 
between changes in fat volume within the cheek and changes in surface contour 
volume. However, measurements of surface contour volume changes are likely to 
be more closely related to the changes in facial appearance that are the primary 
concern for patients with lipoatrophy. Thus laser scan changes may provide an 
additional dimension of assessment that is perhaps more clinically meaningful 
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 than MRI-measured changes in cheek fat. The small number of patients and 
relatively crude clinical lipoatrophy assessment scale do not permit us to make a 
meaningful comparison of the surface contour changes with patient perceptions of 
lipoatrophy progression, but a future study (see next Chapter) would be of interest 
to determine this.   
 In patients with weight loss or weight gain, the laser scanning method 
again appeared to underestimate the actual MRI measurement of cheek fat by 
about 50%. However, there was a strong relationship (good correlation) between 
the individual measurements of CSV change and MRI measured cheek fat volume 
change. This may reflect the much wider range of measurements seen in this 
group (range –6.8ml to +5.4ml) as well as the changes in facial muscles in the 
same direction as the fat changes that accompany weight loss and weight gain and 
that may amplify the observed CSV changes (muscle compartments do not change 
with pure lipoatrophy, see Chapter 2 and Chapter 3).  
 
6.4.3 CPD as a measurement of facial fat change 
The analysis of laser scans by superimposing paired scans that is required 
for calculation of CSV change is time-consuming and requires considerable 
experience. As an alternative, we assessed a method of analysis based on the CPD. 
This has the advantage of being easier to perform, and gives a result based on 
analysis of individual scans (rather than requiring analysis of superimposed paired 
scans). This method also detected changes in the appropriate direction in patients 
with lipoatrophy, weight loss and weight gain and the correlations with MRI-
measured soft-tissue volumes were similar to those seen with the superimposition 
method.  
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 6.5 Summary 
No established simple objective method for assessing facial lipoatrophy in 
HIV-infected patients is available. The objective of this study was to evaluate the 
accuracy of LS for detecting facial fat changes over time in HIV infected patients.  
Laser scans of the face were performed at baseline and repeated after a 
median of 10 months in 12 patients with lipodystrophy continuing antiretroviral 
therapy, in 5 patients who lost weight and in 7 patients who gained weight (more 
than 10% change). Baseline and follow-up scans were superimposed to estimate 
CSV change using a standardised technique, and CPD were calculated both at 
baseline and follow up. MRI scans of the face were done on the same day as laser 
scans to measure change in superficial cheek fat.  
The median estimated CSV changes were –2.1 (range –4.6 to –0.8) ml, in 
the lipoatrophy group, –1.5 (range –6.8 to –1.3) ml in the weight loss group and 
+3.1 (range –0.2 to +5.4) ml in the weight gain group (median changes in cheek 
fat were –4.6ml, -3.7ml and +7.0ml in the three groups respectively). 
Measurements of CSV change and cheek fat change were not significantly 
associated in lipoatrophy patients (r=0.34, P=0.28), but there was a good 
association in patients who changed weight (r=0.71, P=0.01). Similar results were 
shown for CSV. 
The conclusion were that laser scanning could detect changes in cheek 
surface volume in the appropriate direction, although they were less than and were 
variably related to MRI measured superficial cheek fat volume changes. Laser 
scanning might be useful in clinical research, although the relationship between 
CSV changes and patient perception of lipoatrophy needs to be investigated. CPD 
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 might be a simple, reliable supplement method for measurement of facial fat 
change over time. 
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 CHAPTER 7  LONGITUDINAL CHANGES IN FACIAL 
FAT AND WHOLE BODY FAT IN A COHORT OF PATIENTS 
RECEIVING COMBINATION ANTIRETROVIRAL THERAPY 
 
7.1 Introduction 
Many approaches such as switching to regimens without thymidine 
analogues, especially stavudine (John et al., 2003; Martin et al., 2004; Moyle et al., 
2003), and injection of facial fillers such as polylactic acid (Lafaurie et al., 2005; 
Moyle et al., 2004; Valantin et al., 2003) and silicone (Jones et al., 2004) have 
been shown to be effective or promising. However, assessment of interventions is 
limited by the fact that there is no accepted objective method for assessing facial 
lipoatrophy. Patient self-report and/or physician assessments are subjective and 
insensitive for detecting changes over time (Law et al., 2006) but remain the main 
practice for evaluation of facial lipoatrophy in clinical trials.  
Previous validation studies had shown that laser scanning could detect 
changes in the appropriate direction in patients with lipoatrophy, weight loss and 
weight gain and results were correlated with MRI-measured facial fat changes 
(see Chapter 6). To take this further, the method needs to be evaluated for its 
utility in detecting facial lipoatrophy changes in a large cohort of patients on 
treatment. Therefore, we set out to measure changes in facial fat using laser 
scanning and examine the relationship with clinical and DEXA assessments of 
lipoatrophy in a cohort of patients receiving antiretroviral therapy. 
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 7.2 Methods 
 
7.2.1 Patients 
The study was conducted at the outpatient clinics of the Communicable 
Disease Centre, Tan Tock Seng Hospital, Singapore from June 2003 to April 2005. 
Consecutive male and female patients who were known to have HIV infection 
(determined by positive results of ELISA and Western blot assay), over 18 years of 
age and on HAART treatment more than 12 months were invited to participate in 
the study. Exclusion criteria were wasting (defined as weight loss of more than 
10% of their usual body weight during the past 6 months), concomitant use of 
diuretics, systemic corticosteroids, pregnancy or breast-feeding, wearing a beard 
or having any serious facial deformity. Patients underwent clinical and body 
composition assessment at baseline and after an interval of 12 months (within a 
window of 10 to 15 months). The assessments were timed to coincide with routine 
clinic visits. The protocol was explained to patients before participation and all 
subjects gave written informed consent. The study was approved by the ethics 
committee of Tan Tock Seng Hospital. 
 
7.2.2 Clinical characteristics  
A standard questionnaire about changes in appearance was administered to 
all patients and findings were confirmed by the study physician. Any changes 
were graded as mild, moderate or severe (Carr et al., 2003). Patients were 
classified as having facial lipoatrophy if they had evidence of at least moderate 
facial lipoatrophy (i.e. readily noticeable by patient and physician). Patients were 
classified as having limb lipoatrophy if they had evidence of at least moderate arm 
 149
 or leg lipoatrophy (i.e. readily noticeable by patient and physician) or both.  
Patients were classified as having abdominal fat accumulation if they had 
evidence of at least moderate fat accumulation in the abdominal area (i.e. readily 
noticeable by patient and physician). Patients who had the same facial lipoatrophy 
grade at baseline and follow up were classified as stable facial lipoatrophy. 
Patients who had a greater extent of facial lipoatrophy at follow up compared with 
baseline (i.e. progression from none to mild, moderate or severe; from mild to 
moderate or severe; from moderate to severe) were classified as a facial 
lipoatrophy progression group. Patients who had a reduced extent of facial 
lipoatrophy at the end of follow up compared with baseline were classified as a 
facial lipoatrophy recovery group. The same questionnaire was used and same 
study physician conducted the lipodystrophy assessment at baseline and at the end 
of follow up. Clinical information including the result of the most recent CD4 
count, viral load, and details of the antiretroviral treatment history were abstracted 
from the medical case records. Body weight was measured to the nearest 0.1 kg 
using electronic scales (SECA, Model 7700, Vogel & Halke, Hamburg, Germany) 
and height was measured to the nearest 0.5 cm using a stadiometer.  
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 7.2.3 Laser scanning procedure and analysis 
Laser scans of both cheeks were performed at baseline and about 12 
months later with a commercially available 3D digitiser laser scanner (VIVID 300, 
Minolta Co Ltd, Osaka, Japan, 2000), using a standardised method that we have 
described in detail in Chapter 5 (see section 5.2.3, page 106). Laser scans were 
transferred to commercially available computer software (RapidForm2004, INUS 
Technology Inc., Seoul, Korea) for analysis. The calculation of CSV change and 
and CPD change have been described in detail in Chapter 5 (see section 5.2.4, 
page 108) and Chapter 6 (see section 6.2.2, page 125). All laser scan analyses 
were performed by the same operator who was blinded about the patient’s clinical 
lipoatrophy assessment. 
 
7.2.4 DEXA measurements 
Whole body composition was measured in each patient with a Lunar 
DEXA machine (Lunar Prodigy, software version 6.50; Lunar Corporation, 
Madison, Wisconsin, USA) using the method described in Chapter 2 (see section 
2.2.3, page 46). DEXA measurements were done on the same day as the laser 
scans. All scans were performed and analyzed by the same operator following 
manufacturer’s instructions, and using standardized cut-offs for regional 
measurements.  
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 7.2.5 Statistical analysis 
Baseline and follow-up measurements were compared by paired samples t-
tests or Fisher’s exact test, as appropriate. CSV, CPD and body composition 
parameters among the three groups who had stable, progression or recovery on 
clinical lipoatrophy assessment were compared by ANOVA, with post-hoc 
Scheffe test. Associations between CSV, CPD and limb fat changes over time 
were assessed by Pearson’s correlation coefficients. Multiple regression analyses 
were used to evaluate the factors associated with changes in CSV, CPD, limb fat 
and trunk fat. The factors included in the forwarded selection regression model 
were age, gender, race, HIV duration, CDC disease stage, BMI at baseline, follow 
up time, stavudine, zidovudine, PI, and NNRTI usages during the follow up. All P 
values were two sided and a P value of less than 0.05 was considered to be 
statistically significant. The data analyses were performed with SPSS 13.0 
software (Chicago, IL). 
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 7.3 Results 
 
7.3.1 Demographic and clinical characteristics of study patients 
A total of 199 patients met the inclusion/exclusion criteria and were 
recruited into the study. Of these, 14 patients were lost to clinic follow up, 20 
patients did not attend at the clinic within the specified window period for having 
a follow up scan, 12 attended clinic but refused consent for a second scan. A 
further seven patients attended for study follow-up but had disease complications 
during the follow-up period (Pneumocystis jiroveci pneumonia in three patients, 
lymphoma in two patients, disseminated tuberculosis in one patient and 
disseminated cytomegalovirus infection in one patient) and were therefore 
excluded to avoid confounding the lipoatrophy assessments with concomitant 
wasting. Therefore, 146 patients’ data are presented in this analysis.  
The patients were mostly Chinese males, and the mean age was 44 years. 
The clinical data at baseline and during follow up are shown in Table 7.1. At 
baseline, the mean duration of HIV infection was 57 months and 51 (35%) 
patients had stage C disease. The mean duration of ART at baseline was 42 
months. Seventy-two patients had received stavudine prior to study entry (average 
duration of 21 months), 38 had received zidovudine (average 29 months), 43 had 
received a PI (average 31 months), 91 had received a NNRTI (average 23 months). 
During follow up, most patients were taking an NNRTI-based regimen (stavudine, 
lamivudine and nevirapine in 70, 48%; zidovudine, lamivudine and efavirenz in 





  Baseline Follow up 
Duration of HIV infection, months 56.5±31.8  
Stage C disease, n (%) 51 (34.9%)  
CD4 count, cells/mL 366.2±217.8 420.4±233.4 
Viral load, log10 copies/mL 2.4±1.2 2.3±1.1 
Duration of ART at baseline, months   
   D4T 10.0±16.7  
   AZT 7.6±15.4  
   NNRTI 14.2±13.7  
   PI 9.2±18.5  
ART regimen during follow up, n (%)   
   D4T/3TC/NVP  70 (48.0%) 
   D4T/SAQ/RIT  10 (6.8%) 
   AZT/3TC/EFV  38 (26.0%) 
   IDV/EFV/RIT  10 (6.8%) 
   Others  18 (12.3%) 
   
Height, cm 165.8±7.7  
Weight, kg 60.5±10.6 60.3±10.7 
BMI, kg/m2 22.0±3.5 21.9±3.6 
Data shown are mean ± SD, except for disease stage and HAART regimen during follow 
up, which are absolute numbers. ART, antiretroviral treatment; D4T, stavudine;  
AZT, zidovudine; NNRTI, non-nucloside analogue reverse transcriptase inhibitors;  
PI, protease inhibitor; 3TC, lamivudine; NVP, nevirapine; RIT, ritonavir; SAQ, saquinavir; 
EFV, efavirenz; BMI, body mass index.  
 
Table 7.1 Demographic and clinical characteristics of HIV infected patients 
at baseline and follow up (n=146) 
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 7.3.2 Clinical facial lipoatrophy both at baseline and follow up 
The clinical classification of lipodystrophy at baseline and follow up are 
shown in Table 7.2. At baseline 37% of patients had moderate or severe facial 
lipoatrophy, and this increased to 43% after 1 year of follow-up (change not 
statistically significant). The proportion of patients with limb lipoatrophy and 
central fat accumulation also increased slightly during follow up (not significant). 
Twenty-seven patients were classified as having progression of clinical facial 
lipoatrophy grade, and 17 patients had reduction in clinical facial lipoatrophy 
grade, and the remaining 102 patients had stable facial lipoatrophy assessment 






  Baseline, n (%) Follow up, n (%) P 
Facial lipoatrophy 54 (37.0) 63 (43.2) 0.282 
   Moderate 33 (22.6) 38 (26.0) 0.495 
   Severe 21 (14.4) 25 (17.1) 0.521 
    
Limb lipoatrophy 40 (27.4) 52 (35.6) 0.131 
   Moderate 31 (21.2) 39 (26.7) 0.273 
   Severe 9 (6.2) 13 (8.9) 0.375 
    
Any peripheral lipoatrophy 64 (43.8) 75 (51.4) 0.197 
   Moderate 38 (26.0) 45 (30.8) 0.364 
   Severe 26 (17.8) 30 (20.5) 0.552 
    
Abdominal fat accumulation 39 (26.7) 45 (30.8) 0.438 
   Moderate 20 (13.7) 24 (16.4) 0.513 
   Severe 19 (13.0) 21 (14.4) 0.734 
p was calculated by Chi-square or Fisher’s exact test. 
 
Table 7.2 Clinical classification of lipodystrophy at baseline and follow up 
(n=146) 
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 7.3.3 CSV and CPD at baseline and changes over time 
There was significant positive relationship between CPD by laser scanning 
and limb fat by DEXA (r=0.50, p<0.001) at baseline, whereas there was no 
significant relationship with limb lean (r=0.04, p=0.636). There was also 
significant positive relationship between CPD by laser scanning and trunk fat by 
DEXA (r=0.55, p<0.001) at baseline. The relationship between CPD and limb fat 
at baseline is shown in Figure 7.1. 
The changes over time in laser scanning and body composition are shown 
in Table 7.3 for the whole cohort. The mean overall change in CSV was minimal 
(-0.1±1.9ml), but there were small and significant decreases in mean CPD 






Figure 7.1 Correlation between LS-measured CPD (mm) and DEXA-
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  Baseline Change P 
CSV, ml -* -0.1±1.9 0.523 
CSPD, mm 14.0±3.7 -0.4±1.6 0.009 
    
Total body mass (kg) 59.9±10.6 0.2±2.2 0.276 
Total body fat (kg) 11.7±6.3 -0.1±2.1 0.516 
    
Limb fat (kg) 3.9±2.5 -0.1±0.9 0.042 
Limb fat (%) 15.4±8.8 -0.4±3.0 0.004 
Trunk fat (kg) 7.2±4.0 0.0±1.3 0.982 
Trunk fat (%) 23.1±10.0 -0.2±3.7 0.562 
    
Arm fat (kg) 0.9±0.6 0.0±0.3 0.191 
Arm fat (%) 13.2±8.6 -0.1±3.2 0.666 
Leg fat (kg) 3.1±1.9 0.1±0.7 0.037 
Leg fat (%) 16.0±9.1 -0.5±3.1 0.01 
Trunk limb fat % ratio  1.70±0.64 0.1±0.4 0.126 
CSV, cheek surface volume; CPD cheek surface point-displacement; LS, laser scanning;  
DEXA, Dual energy X-ray absorptiometry. *CSV is a difference in volume obtained by  
superimposing baseline and follow up scans; There is no measurement relating to individual  
(baseline or follow-up) scans. P value was calculated using paired samples t-test except  
for CSV for which the mean change was compared to zero change using the z test. 
 
Table 7.3 CSV and CPD by LS and DEXA body composition results at 
baseline and their respective change over time of all HIV infected patients 
(n=146) 
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 7.3.4 CSV and CPD change over time 
The changes over time in laser scanning and body composition are also 
shown in Table 7.4 with patients classified according to changes in clinical 
lipoatrophy assessment. Neither CSV nor CPD changed in patients who had no 
change in clinical classification of facial lipoatrophy, whereas there was a 
significant decrease in both CSV and CPD in patients who had clinical facial 
lipoatrophy progression (-1.3±1.8ml and -1.9±1.2mm respectively, both p<0.001 
for comparison with stable patients), and an increase in both parameters in those 
with clinical facial lipoatrophy recovery (1.0±1.7ml and 1.5±1.1mm respectively, 
P=0.094 and P<0.001 vs. clinically stable patients). Changes in limb fat by DEXA 
were also in agreement with the clinical classification changes. 
The relationship between changes in LS-measured CSV and DEXA-
measured limb fat is shown in Figure 7.2, and the relationship between LS-
measured CPD and DEXA-measured limb fat is shown in Figure 7.3. There were 
significant correlations between CSV and limb fat change (r=0.32; P<0.001) and 








  LA progression (n=27) LA recovery (n=17) LA stable (n=102) P 
CSV, ml -1.3±1.8* 1.0±1.7 0.0±1.7 <0.001 
CPD, mm -1.9±1.2* 1.5±1.1** -0.2±1.3 <0.001 
     
Total body mass (kg) -1.0±1.7* 1.2±2.7 0.3±2.1 0.003 
Total body fat (kg) -1.4±2.8* 0.8±2.2 0.1±1.7 0.001 
     
Limb fat (kg) -0.8±1.3* 0.4±0.7 0.0±0.7 <0.001 
Limb fat (%) -2.4±4.3* 1.4±2.9 -0.2±2.2 <0.001 
Trunk fat (kg) -0.5±1.6 0.4±1.5 0.1±1.2 0.047 
Trunk fat (%) -1.8±4.5 0.7±4.2 0.1±3.3 0.028 
Arm fat (kg) -0.2±0.4* 0.1±0.2 0.0±0.2 <0.001 
Arm fat (%) -2.2±4.4* 1.3±2.4 0.2±2.7 <0.001 
Leg fat (kg) -0.6±1.0* 0.3±0.7 0.0±0.5 <0.001 
Leg fat (%) -2.4±4.5* 1.4±3.1 -0.3±2.3 <0.001 
Trunk limb fat % ratio  0.08±0.36 -0.04±0.14 0.03±0.29 0.37 
CSV, Cheek surface volume; CPD, cheek surface point displacement; DEXA, Dual energy X-ray absorptiometry; 
LA, facial lipoatrophy. Groups are compared by ANOVA with post-hoc Scheffe tests. 
* p<0.05 vs. LA stable ;  **P<0.01 LA stable ; ¶ P<0.001 LA stable 
 
 
Table 7.4 Changes in CSV and CPD and body composition by DEXA of all subjects over one year follow up with 




Figure 7.2 Correlation between changes in CSV (ml) by laser scanning and 
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Figure 7.3 Correlation between changes in CPD (mm) by laser scanning and 
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 7.3.5 Factors contributed to the facial fat change over time 
Multiple linear regression analysis showed that stavudine use was 
significantly associated with both CSV and CPD change during follow up (Table 
7.5). Likewise, stavudine use was the only factor associated with limb fat change. 
Neither stavudine use nor any other factors were significantly associated with 







  Limb fat change  Trunk fat change 
CSV change, ml 
 
CPD change, mm 
 by DEXA, kg  by DEXA, kg Variables 
β coefficient P  β coefficient P  β coefficient P  β coefficient P 
Age, year -0.12 0.151  -0.06 0.481  -0.09 0.275  0 0.99 
Male sex 0.06 0.520  0.03 0.716  -0.1 0.26  0.09 0.365 
  Chinese race 0.05 0.611  -0.04 0.65  -0.06 0.502  0.06 0.494 
HIV duration, month 0.08 0.341  0.04 0.649  0.09 0.313  0.06 0.493 
Stage C disease 0.06 0.474  -0.04 0.615  -0.11 0.177  -0.08 0.367 
BMI at study entry -0.03 0.721  -0.08 0.355  -0.08 0.375  -0.05 0.56 
Follow up time, month -0.07 0.387  -0.07 0.387  -0.01 0.864  0.02 0.788 
D4T use during follow up -0.32 0.003  -0.25 0.026  -0.24 0.03  0.01 0.95 
AZT use during follow up 0.00 0.978  -0.08 0.465  -0.03 0.762  0 0.995 
PI use during follow up 0.07 0.398  0.05 0.561  0.07 0.363  0.16 0.21 
NNRTI use during follow up -0.05 0.555 -0.02 0.803 -0.03 0.724 -0.03 0.731 
CSV, Cheek surface volume; CPD, cheek surface point displacement. DEXA, Dual energy X-ray absorptiometry; BMI, body  
mass index; d4T, stavudine; AZT, zidovudine; PI, protease inhibitor; NNRTI, non-nucleoside reverse transcriptase inhibitor. 
 
 
Table 7.5 Results of multiple regression analysis assessing associations of factors with the changes in CSV (ml), CPD (mm), limb fat 
(kg) and trunk fat (kg) of HIV infected patients (n=146)
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 7.4 Discussion 
 
7.4.1 LS as a method for measurement of facial fat loss 
This is the first study in which the technique of laser scanning has been 
used to document changes in facial fat in a cohort of patients taking combination 
antiretroviral therapy. We have previously validated the laser scanning method 
using a mannequin model (see Chapter 5) and against MRI facial fat measurement 
in a small group of patients undergoing changes (see Chapter 6). The data from 
the present study provides further evidence of validity in a large group of patients. 
Firstly, we found that the laser scanning method had good agreement with the 
clinical classification, in that groups of patients who had clinical lipoatrophy 
progression or recovery showed significant changes in laser scanning in the 
appropriate direction. Secondly, we found a significant (albeit weak) correlation 
between laser scanning assessment and limb fat change measured by DEXA in the 
overall patient cohort. Thirdly, we found a highly statistically significant 
relationship between laser scan changes and use of stavudine, which is known to 
be the main drug related cause of facial lipoatrophy. This provides further 
independent evidence that the parameters we have measured by laser scan are a 
valid measure of the facial lipoatrophy process. In addition to the results of this 
cohort study and our previous validation studies, Benn et al have shown that laser 
scanning can detect changes in patients undergoing treatment (drug switches or 
facial injections) for lipoatrophy (Benn et al., 2005). They studied 47 patients who 
switched from stavudine (or zidovudine) to tenofovir or abacavir (less 
lipoatrophy-inducing drugs) and 19 patients who had collagen injections into the 
cheeks. The patients who switched drugs had a mean total increase in cheek 
volume by 2.5ml, and the patients who underwent collagen injections into the 
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 cheeks showed mean total cheek volume increase by 3.2ml. Also, there was 
significant correlation between cheek volume change and DEXA limb fat change 
(Benn et al., 2005).  
Although highly statistically significant, the correlation between limb fat 
change by DEXA and laser scan measurements was relatively weak (around 0.3 
for both techniques). A similar strength of association between limb fat and laser 
volume change (r=0.4) was seen in the study of therapeutic interventions 
conducted by Benn et al (Benn et al., 2005). In our study comparing MRI with 
laser volume changes, we again found a relatively weak correlation (r=0.3) 
although this did increase substantially in patients who had more than 10% weight 
change (r=0.7; see section 6.3.2, page 128) The weak correlation coefficient 
between laser scan changes and other objective measurements might reflect the 
errors inherent in both measurements, and might also be because the measured 
processes (facial surface contour change, facial fat compartment change and 
peripheral fat change) do not progress exactly in parallel (see section 6.4.2, page 
133). The measurement of surface contour change by laser scanning may provide 
useful complementary information to DEXA measurements of peripheral fat. 
 
7.4.2 Comparison between CSV and CPD 
In this study we evaluated two approaches to analysing the laser scan data. 
Both CSV and CPD showed similar correlation with DEXA measurement of limb 
fat change. Both methods were able to detect changes in the appropriate direction 
in patients who had lipoatrophy progression or recovery, although a higher 
standard deviation in relation to the mean value for change was obtained with the 
CSV method, perhaps reflecting greater error with this latter measurement making 
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 it less sensitive for detecting changes. On the other hand, the relationship between 
laser scan measurement and stavudine use was stronger with the CSV method, 
suggesting that perhaps it may have greater utility for detecting treatment effects 
in clinical trials. Although the CSV method gives a result for volume change 
which is intuitively more appealing than a simple point displacement distance, the 
volume change does not appear to be an accurate reflection of underlying facial 
volume loss (see section 6.4.2, page 133) and hence it has to be accepted that 
either method of obtaining surface contour change estimation is potentially valid. 
Given that the CSV approach requires analysis of laser scans by superimposing 
paired scans which is time-consuming and requires considerable experience, 
whereas the CPD approach is much simpler and appears to have similar validity, 
the latter approach may represent a reasonable compromise for large studies.  
 
7.4.3 Comparison with other study results 
We detected relatively small changes in lipodystrophy parameters as a 
whole. Overall, the number of patients with facial and/or limb lipoatrophy 
increased by only 11 (7%), mean absolute leg fat showed only minimal change 
(from 3.1kg to 3.0kg) and percentage leg fat decreased from 16.0% to 15.3%. The 
lack of change in the clinical classification is consistent with the report that the 
clinical classification by patient self-assessment and/or physician confirmation is 
crude and does not give a quantitative measurement, especially in patients who 
have already reached the severe end of the spectrum where the clinical 
classification cannot detect further progression (Law et al., 2006). We found a 
small decrease in trunk fat (0.2%) overall, although the number of patients 
reporting abdominal fat gain increased slightly during follow up. This agrees with 
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 the FRAM study results in that there is no evidence of simultaneous central fat 
accumulation accompanying the peripheral fat change (Bacchetti et al., 2005). 
Similar study was also noted lower waist and hip circumferences in HIV-infected 
men compared with HIV-negative controls although some HIV infected patients 
reported more fat accumulation in the abdomen in another large multicenter cross-
sectional study (Palella et al., 2004). All these results demonstrate the relative 
sparing (but not overall increase) of trunk fat compared with limb fat in HIV 
infected patients, consistent with other small earlier studies in HIV infection 
(Kotler et al., 1999; Saint-Marc et al., 2000). 
This study also provided direct confirmation of the association between 
stavudine use and facial lipoatrophy. Previously this association has been shown 
for DEXA measured peripheral lipoatropy (Yang et al., 2005) and clinical 
assessments of facial lipoatrophy (see section 3.3.2, page 73). Although stavudine 
is no longer used in first-line treatment regimens in Western countries, it is still 
being used extensively in many developing countries because generic manufacture 
is relatively economical. Thus facial lipoatrophy is likely to remain an issue for 
many years to come, and the development of a simple objective method for 
assessing such change may be of value in treatment and intervention studies. The 
findings of this study demonstrated that laser scanning might be a useful objective 
method for detecting the lipoatrophy-inducing effects of drugs and for assessing 
the efficacy of therapeutic interventions in future clinical trials. 
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 7.4.4 Limitation of the LS methodology 
Single point CPD could only reflect the facial fat depletion in the centre of 
the cheek, but not in other areas that might be affected by lipoatrophy (see section 
2.3.2, page 52). The LS method including CSV and CPD measures change in 
surface contour, and other factors that alter facial contour, such as dehydration and 
variation of human facial expression, might also affect the results. The measured 
change by LS may comprise changes in facial muscle as well as fat, although with 
careful cohort selection such as ours in which patients with wasting are excluded, 
this should not be a major confounding problem. None of the patients in our 
cohort had facial fillers or other corrective procedures for lipoatrophy and the 
performance of the method in this situation is uncertain.  
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 7.5 Summary 
The aim of this study was to measure changes in facial fat using laser 
scanning and examine the relationship with clinically-assessed lipoatrophy 
changes and DEXA measured body composition changes in a longitudinal cohort 
study of HIV infected patients receiving antiretroviral therapy.  
Consecutive patients taking HAART for at least 12 months were recruited 
from a specialist outpatient HIV clinic. Clinical lipoatrophy assessment, three-
dimensional laser scanning of the face and a whole body DEXA scan was 
performed at baseline and repeated after a mean of 12 months. CSV and CPD 
were calculated from the laser scans using a standardised technique.  
Baseline and follow up assessments were obtained in 146 patients. In 102 
patients whose clinical lipoatrophy grade was stable during follow up, there was 
no change in CSV (0.0±1.7ml). In 27 patients who had clinical lipoatrophy 
progression, CSV decreased by 1.3±1.8ml (p<0.001 vs. stable patients) and in 17 
patients who experienced recovery from facial lipoatrophy CSV increased by 
1.0±1.7ml (p=0.092 vs. stable patients). CSV change was significantly related to 
limb fat change by DEXA in the overall cohort (r=0.32, p<0.001). Multivariate 
regression analysis showed that stavudine use was a significant independent 
predictor of CSV (beta=-0.32, P=0.003). Similar directional changes and 
correlations were obtained with the CPD method.  
Laser scanning could detect facial lipoatrophy changes in a longitudinal 
study, and could clearly detect the effects of individual drugs. Laser scan change 
was only partly related to limb fat changes. This potentially represented an 
objective and reliable method to assess facial fat change in future clinical trials.  
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 CHAPTER 8 DISCUSSION 
 
8.1 Overall conclusion  
The studies presented in this thesis have focused on novel facial fat 
measurement methods and provided some insight into the facial fat changes of 
HIV-infected population in the HAART era. We found that MRI is a sensitive and 
reproducible method for facial fat assessment. Facial fat was reduced by more 
than 50% in patients with lipoatrophy compared with controls, with all areas of 
superficial facial fat (temporal, cheek and peri-orbital) and deep fat (buccal fat pad) 
involved. The magnitude and widespread distribution of fat loss indicated that 
complete restoration of normal appearance is unlikely to be possible by surgical 
correction methods. Thus, focus should be on the early detection and prevention 
of lipoatrophy. Also, the very close relationship between superficial facial fat 
volume and limb fat in the patients with lipoatrophy suggested that measurement 
of limb fat by DEXA might be a suitable surrogate measurement for facial 
lipoatrophy. A subsequent longitudinal study was performed and showed that 
lipoatrophy patients had further superficial facial fat decrease by 20% over one-
year of HAART treatment.  
DEXA measurement is recognized as a gold standard method for body 
composition measurement. However, studies using DEXA have revealed 
considerable inter-machine differences, even among machines from the same 
manufacturer. We performed a study that showed significant inter-machine 
difference in assessing body composition change in HIV-associated patients with 
lipodystrophy of a magnitude that might impact on the assessment of 
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 lipodystrophy in studies conducted at different centres. Thus, a standard soft tissue 
phantom should be used to calibrate different machines for this purpose.  
Laser scanning was shown to be accurate and reproducible method for 
estimating cheek fat volume (CSV) changes by superimposition in a mannequin. 
However, when the method was validated against MRI for its ability to detect 
lipoatrophy changes over time in human subjects, the method performed less well 
(although it was better in detecting changes in patients who had wasting or weight 
gain). As a further refinement, a CPD method of analysis of scan data was 
validated against MRI facial fat volume and changes, and gave similar results. 
This simpler method may be useful in the diagnosis of facial lipoatrophy based on 
a single scan.  
Finally, a longitudinal observational study on facial fat and regional body 
composition change over time was also conducted in a group of HIV-infected 
patients on HAART treatment. LS and DEXA were conducted both at study entry 
and repeated after 12 months of follow up. LS CSV changes and CPD and its 
changes were calculated. Laser scanning could detect facial lipoatrophy changes 
in a longitudinal study, and could clearly detect the effects of individual drugs. 
Laser scan change was only partly related to limb fat changes. This potentially 
represents an objective and reliable method to assess facial fat change in future 
clinical trials. 
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 8.2 General discussion 
 
8.2.1 Change in definition of lipodystrophy  
 
8.2.1.1 Lipoatrophy is linked to lipohypertrophy  
Originally, the definition of lipodystrophy included peripheral lipoatrophy, 
central lipohypertrophy and mixed type. The first international lipodystrophy case 
definition study was led by Dr. Andrew Carr of St. Vincent's Hospital in Sydney, 
Australia. Four hundred and seventeen cases and 371 HIV-infected controls in 32 
study sites were recruited to participate in the study. The study indicated that both 
lipohypertrophy and lipoatrophy were features of lipodystrophy. The two features 
were linked to each other – where there was an increase in visceral fat there would 
most likely be a decrease in subcutaneous fat (and vice versa) (Carr et al., 2003). 
The definition of lipodystrophy generated had 80% sensitivity and specificity, but 
the definition needs complicated and expensive parameters including lab results, 
CT and DEXA measurement results to build up which proved to be too complex 
to be used in clinical practice (Milinkovic and Martinez, 2005).  
 
8.2.1.2 Lipoatrophy is not linked to lipohypertrophy 
Preliminary data reported by Gripshover et al, from the FRAM study, led 
by Dr. Carl Grunfeld of the University of California, San Francisco, called this 
perception that decrease in subcutaneous fat was linked to increase in visceral fat 
into question (Gripshover et al., 2003). In the cross-sectional study, 412 HIV-
positive men and 153 age-matched controls were recruited. Self-report and 
physical examination was used to assess peripheral and central fat redistribution. 
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 However, neither self-report nor physical examination results supported a 
correlation between peripheral fat and central fat in HIV-positive men. Peripheral 
lipoatrophy (38.9% vs. 4.6%, P<0.001) and central lipoatrophy (7.8% vs. 2.6%, 
P<0.031) were reported more frequently in HIV-positive men than did controls. 
To the surprise of the researchers, central lipohypertrophy (40.3% vs. 56.2%, 
P<0.001) was also less frequently reported in HIV infected subjects. Further more, 
peripheral lipoatrophy was associated with central lipoatrophy (odds ratio [OR]: 
18.3; CI: 5.5-61.2; P<0.001) but did not correlate with central lipohypertrophy 
(OR: 0.70; CI: 0.45-1.07; P=0.100) in the group of HIV infected patients.  
The following report from the FRAM study with even more subjects 
consolidated the same query about the connection between lipoatrophy and 
lipohypertrophy (Bacchetti et al., 2005). The FRAM study reported data from both 
825 HIV-positive man and 350 HIV positive women, and 338 HIV-negative 
people. Again, they found that lipoatrophy was much more common in the HIV-
positive patients than in the HIV-negative study participants. Clinical lipoatrophy 
was also documented in approximately 38% of the HIV-positive men compared to 
approximately 4% of the HIV-negative men and in 28% of the HIV-positive 
women compared to 4% of the HIV-negative women. At the same time, even 
though HIV-positive people experienced lipohypertrophy, this phenomenon was 
actually more common in the HIV-negative men than in the HIV-positive men. 
Approximately 40% of the HIV-positive men compared to approximately 56% of 
the HIV-negative men experienced lipohypertrophy. As for women, 
approximately 62% of the HIV-positive women compared to 63% of the HIV-
negative women experienced lipohypertrophy. Other study also agreed that 
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 lipoatrophy was the hallmark of body fat changes in HIV-infected people (Kotler, 
2002).  
All these data suggest that lipoatrophy and lipohypertrophy might not be 
linked, and lipoatrophy might be a unique complication caused by HIV and/or 
HIV medications, whereas lipohypertrophy might not be. A single pathogenic 
mechanism linking peripheral lipoatrophy and central lipohypertrophy might not 
exist. Our group had also longitudinally followed up a group of 29 HIV infected 
patients nested to a randomized controlled clinical trial containing stavudine 
immediate release versus extended release formulation. Body composition was 
measured by DEXA 6-monthly for 18 months. Stavudine extended release 
formulation was not found to decrease the side effect of peripheral lipoatrophy, as 
the limb fat decreased equally in both groups. Interestingly, patients in both arms 
also showed decreased but not increased trunk fat (see Chapter 7). These results 
were in line with the FRAM study results, that lipoatrophy is the predominant 
feature of lipodystrophy in this group of Asian HIV infected population.  
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 8.2.2 Methods for facial fat measurements  
 
8.2.2.1 Clinical assessment by questionnaire 
The current practice in clinical research for the assessment of HAART-
related facial lipoatrophy is by questionnaire to record patients’ self-report of 
facial wasting. Patient classed as facial lipoatrophy has at least moderate or severe 
feature of lipoatrophy arising (readily noticeable by patient or physician, score of 
2) since the diagnosis of HIV infection, and that has been independently 
confirmed by physical examination to be moderate or severe (Carr et al., 2003; 
Lichtenstein et al., 2001). However, the questionnaire method had been shown to 
be subjective and insensitive for detecting facial fat changes over time (Law et al., 
2006). 
 
8.2.2.2 CT and MRI measurement 
CT and MRI may be the most accurate and useful method of measuring 
facial fat (Sjostrom et al., 1986; Tokunaga et al., 1983). In a study of 13 cadaver 
heads that were examined with spiral CT, good reproducibilities in head soft 
tissue measurement were reported as for interobserver and intraobserver 
measurements or between imaging and physical measurements in both 3-
dimentional CT protocols (Cavalcanti et al., 2004). MRI measurement 
methodology had also used in the assessment of changes in autologous fat grafting 
over time in a facial lipoatrophy patient with satisfactory result (Goehde et al., 
2005). In another study of 53 patients with facial defect, Horl et al reported facial 
fat change over time by repeated MRI measurements with good reproducibility 
(Horl et al., 1991). Furthermore, single sliced CT scan (at the level of upper lip) of 
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 measurement of adipose tissue area in 61 HIV infected patients were found to be 
able to separate patients with and without facial lipoatrophy. Good correlation 
between clinical assessment of facial wasting and adipose tissue area. The method 
also presented with good inter-observer and intra-observer reproducibility (Padilla 
et al., 2004). The main limitation of CT and MRI measurement is their high cost 
and the radiation involved with CT scan. 
 
8.2.2.3 Sonography measurement 
High resolution real-time ultrasound allows good delineation of normal 
anatomy, especially when they are thick and contain fat (Derchi et al., 1987). 
Sonography has the advantage of low cost, noninvasiveness, availability, and 
reproducibility, as well as its acceptability among patients. It is also technically 
less demanding and free of ionising radiation, make it an ideal tool for diagnosis of 
lipodystrophy and for early identification of subcutaneous fat thickness reduction 
and visceral fat increase (Gulizia et al., 2005). This methodology might be a more 
practical than CT scanning and DEXA for measurement of facial fat change.  
Sonography has been used to assess subcutaneous fat thickness at the 
brachial, crural and malar levels in different studies (Asensi et al., 2004; Gulizia et 
al., 2005; Martinez et al., 2000; Milinkovic et al., 2003). In a study of 60 HIV 
infected patients and 60 HIV negative controls in which 43 patients had 
lipodystrophy, Martinez et al found that sonographic assessment of subcutaneous 
malar and brachial fat in patients with lipodystrophy was more sensitive and 
specific than that of intra-abdominal fat in the diagnosis of abnormal fat 
distribution (Martinez et al., 2000). In another study in which 74 patients were 
studied, perirenal fat diameter by sonography at baseline could separate HAART- 
 178
 naive from HAART-treated patients (P<0.001). Furthermore, the same method 
was the best predictor of lipodystrophic changes after 12 months of follow-up 
(hazard ratio, 7.34; 95% CI, 1.18-45.49; P=0.032). In addition, HAART-
experienced patients in whom lipodystrophy improved had thinner baseline 
perirenal fat than those in whom lipodystrophy did not improve (P=0.04). A 
perirenal fat diameter of >2.6 mm at baseline or >4.9 mm during receipt of 
HAART suggested lipodystrophy predisposition. Echographically measured 
perirenal fat diameter is associated with lipodystrophy and could be used as an 
early predictor of this syndrome in treatment-naive patients starting HAART 
(Asensi et al., 2004). Furthermore, good correlation was also reported between 
sonography and CT or DEXA subcutaneous fat measurements in other study 
(Gulizia et al., 2005; Milinkovic et al., 2003).  
Sonography had also been used for measurement of subcutaneous fat in 
healthy HIV negative subjects. In a cross sectional study of 37 healthy subjects, 
Liu et al found that mesenteric fat thickness measured by sonography showed 
good relationship with most cardiovascular factors. The mesenteric fat thickness 
was the major explanatory variable (30-65%) for most cardiovascular factors such 
as increased triglycerides, total cholesterol, low density lipoprotein and 
hemoglobin A1c, and reduced low density lipoprotein. Good intra-operator and 
inter-operator reproducibility in measurement of mesenteric fat thickness were 
also demonstrated (Liu et al., 2003). Also, good correlation between the findings 
of sonography and CT scanning has been demonstrated for the measurement of 
visceral fat in HIV negative patients (Cucchi et al., 1997).  
However, contradictory results were also reported. In a study of 56 HIV 
infected patients receiving antiretroviral therapy, subcutaneous fat thickness over 
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 the malar bone was measured by ultrasound at weeks 0, 24 and 48. Carey et al 
found changes in facial fat assessed by sonography did not correlate significantly 
with more established objective measures of lipoatrophy severity. The author 
suggested that the measurement of malar fat using sonography was not 
recommended (Carey et al., 2005). The conclusion was questioned in that the 
measurement method they used for the facial fat thickness was problematic, and 
other confounding factors such as gender and body mass index was not adjusted 
(Gulizia et al., 2005; Martinez et al., 2006). Also, the correlation between facial 
fat thickness by sonography and limb fat change by DEXA was also not 
necessarily appropriate as DEXA could not give any information about the fat 
distribution in the head, thus facial lipoatrophy (Gulizia et al., 2005). 
 
8.2.2.4 LS measurement  
LS has been used in research and clinical practice for generating images of 
facial contour that may be used for planning maxillofacial surgery, measuring 
craniofacial deformity and planning radiotherapy (Ferrario et al., 2003; Soncul 
and Bamber, 2000; Wilks, 1993; Wilson et al., 1997). Laser scanners are easy to 
use, inexpensive and non-invasive (Wilson et al., 1997). Previously, LS had been 
tested to be clinically reproducible within a short period of three days in a group 
of school children (Kau et al., 2005). Benn et al tested 17 HIV infected patients 
with various degrees of facial lipoatrophy, LS showed good reproducibility for 
repeated scan within the three days (Benn et al., 2003). Then the group applied the 
method to a sub-study in 47 individuals recruited to RAVE; an open-label 
randomized study in 105 patients on zidovudine or stavudine who substituted 
either tenofovir 300mg QD or abacavir 300mg BID for the thymidine analogue. 
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 Another group of 19 HIV infected patients underwent collagen injections into the 
cheeks were also tested. Over 48 weeks follow-up, there were mean total increase 
in cheek volume of 2.8 and 2.2 in patients at tenofovir and abacavir arms 
respectively, whereas there was no change (<0.1ml) at the forehead area where is 
no fat. The patients who underwent collagen injections into the cheeks showed 
mean total cheek volume increase by 3.2ml. Also, there was significant positive 
relationship between cheek volume change and DEXA limb fat change (Benn et 
al., 2005). Our group had also tested the LS method with a mannequin and 10 
healthy subjects, LS was shown as an accurate and reproducible method in 
assessing facial fat change (see Chapter 5). However, further testing in 12 HIV 
infected patients with facial lipoatrophy on combination ART treatment over one 
year against gold standard MRI superficial fat measurement, there was poor 
relationship between LS volume estimation and superficial fat change by MRI, 
whereas there was good correlation in patients with more than 10% weight 
changes (see Chapter 6). As mentioned earlier, the possible reason might be that 
the two methods measure different things, LS measures facial surface contour 
change, whereas MRI measures only fat compartment changes. Yet, the facial 
contour change is of more clinical importance for lipoatrophic patients.  
 
8.2.3 Treatment of facial lipoatrophy  
Currently, study have found no beneficial effect on lipodystrophy with diet 
adjustment and physical exercise and recombinant human growth hormone (rhGH) 
(Milinkovic and Martinez, 2005). Although switching from a thymidine analogue 
does confer an increase in peripheral fat, the effect is relatively modest and slow 
(Milinkovic and Martinez, 2005; Zhong et al., 2005). As no effective and quick 
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 solution for lipoatrophy is available, there is a growing demand for interventions 
with immediate results. This explains why the advances in the field of plastic and 
reparatory surgery are such attractive treatment options in the treatment of facial 
atrophy. 
 
8.2.3.1 Autologous fat transplantation and silicone oil injection 
Autologous fat transplantation had been attempted as one strategy to 
correct facial lipoatrophy. In a study of 15 patients, Levan et al reported 
satisfactory correction of facial lipoatrophy in HIV-infected patients on HAART 
by injection of autologous fatty tissue. The satisfactory correction lasted for at 
least 6 months (Levan et al., 2002). However, 4 out of 41 HIV-infected patients 
with facial lipoatrophy who underwent autologous fat transplantation were 
reported with disfiguring facial lipohypertrophy at the graft site (Guaraldi et al., 
2005). Also, lipoatrophy occurs in the abdominal and buttock area during the 
process of facial lipoatrophy, most patients lack adequate donor fat reserves. 
Furthermore, transferred fat often continues to dwindle, and corrections often fade 
over 6-12 months (Jones, 2005).  
Injection of silicone oil has been used as another option. In a study of 77 
patients received injections of highly purified 1000-cSt silicone oil, facial 
contours restored in all patients, and the treatment was well tolerated. But the long 
term safety and efficacy remain to be proven (Caye et al., 2003; Jones et al., 2004).  
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 8.2.3.2 Poly-L-Lactic Acid (PLLA) 
In a recently published review, Barton reviewed 4 published articles for 
using PLLA to correct facial lipoatrophy (Barton et al., 2006). PLLA is the only 
Federal Drug Administration (FDA) approved method for treatment of 
lipoatrophy. All 4 studies were single-centre trials. The first study observed 50 
patients with 4-5 sets of PLLA injection at 2 weeks apart, and total cutaneous 
thickness by facial sonography and quality of life were used to assess the 
correction effects. Baseline median facial fat thickness=0 (range, 0.0-2.1 mm). 
The total cutaneous thickness increased steadily over the 96 weeks following up 
(5.1mm, 6.4mm, 7.2mm, 7.2mm, and 6.8mm at week 6, 24, 48, 72, and 96 
respectively) with an evident aesthetic and quality of life improvement (Valantin 
et al., 2003). However, the fact that measurements were made below the malar 
bone without using a specific landmark, and that there were no objective measures 
for LA severity flawed the interpretation of the study results (Carey et al., 2005). 
Moyle et al randomized 30 patients to immediate (weeks 0, 2 and 4) or delayed 
(weeks 12, 14 and 16) PLLA injection, PLLA given as three bilateral injections 2 
weeks apart into the deep dermis overlying the buccal fat pad. Assessments 
included buccal skin thickness by ultrasound, visual analogue scales, the Hospital 
Anxiety and Depression Scale (HADS) and assessment using photographs at 
weeks 0, 12 and 24. The mean change in cheek area skin thickness was about 5 
mm. Patient visual analogue assessments, photographic assessments, and anxiety 
and depression scores improved with treatment. At week 12, immediate-treatment 
patients had significantly better visual analogue scores (7 vs. 1, P<0.001) and 
lower anxiety scores (6 vs. 9, P=0.056) than delayed-treatment patients. Benefits 
on visual analogue and HADS scores persisted until week 24 (Moyle et al., 2004). 
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 The improvements in visual analogue scores for facial appearance were sustained 
from baseline to the recall visit after 18 months follow up in both randomization 
groups (P<0.05 and P<0.001). Trends in improvement in HADS scores were also 
noted, with patients in the delayed group experiencing significant improvements 
in depressive symptoms (P<0.05). The author suggested that Physical and 
psychological benefits of PLLA are sustained over at least 18 months (Moyle et 
al., 2006).  
Another two studies included APEX002 study and Blue Pacific study 
(Engelhard and Knies, 2002; Mest and Humble, 2004). In the APEX002 study, 99 
patients with facial lipoatrophy were participated in the study. Patients were given 
1-6 treatment sessions and 4-6 week apart, and the majority receiving 3-4 sessions. 
Cheek lipoatrophy score rated by the investigators decreased from 3.58 from 
baseline to 1.51 prior to final treatment and further decreased to 0.87 and 0.81 at 
month 6 and month 12 respectively. In the Blue Pacific study, 99 patients were 
also given 1-6 treatment sessions and 3 weeks apart. Callipers were used to 
quantify baccal skin thickness. At the final treatment visit, mean skin thickness 
increased by 57.8% from baseline. The increase sustained by 53.5% and 54.9% at 
month 6 and month 12 from baseline respectively.  
 
8.3 Future studies arising from this work 
 
8.3.1 Further refinement of the LS methods 
The studies described in this thesis had largely focused upon assessing the 
novel LS methodology in measurement of facial fat change over time. Two 
methods, CSV and CPD, had been developed, and validated against gold standard 
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 MRI method in HIV infected patients with lipoatrophy and with significant weight 
changes including weight gain and weight loss. Although LS method was accurate 
and reliable in mannequin and could separate patients with facial lipoatrophy 
progression from patients with stable lipoatrophy and reversion, the volume 
change estimated by LS underestimated the facial fat change by almost 50%. Also, 
facial fat changes assessed by both methods showed poor correlation with 
superficial fat changes by gold standard MRI method in lipoatrophy patients. 
Given that the poor relationship might be due to that LS assesses the facial 
contour change, which is more closely related to the changes in facial appearance 
that are the primary concern for patients with lipoatrophy, whereas MRI measures 
fat compartment changes, the current methods deserve further refinement before 
LS can be better used in clinical trials.  
The LS methods used in this study could be improved by increasing the 
measurement area in cheek area and decreasing the variation in measurement error 
with the latest version of laser scanner and analyzing software. Also, the temporal 
area might be included as the measurement area. The increased measurement area 
should enable us to get more information regarding the facial fat change 
assessment. Another strategy for improving the methodology might be involving 
the one point displacement distance. Currently, only one point CPD measurement 
was used to present data, which may be more variable. The sum of CPDs 
measured at different points along the line between the ala and the tragus may be 
more reflective of real facial fat changes. However, the new method needs to be 
validated before it can be used in any of the future clinical trials. 
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 8.3.2 Cohort studies with longer follow up period 
The study results in this thesis showed good relationship between MRI 
superficial fat change and change in volume estimation and cheek surface point 
displacement by LS only in patients with significant weight gain and loss (>10%), 
but not in lipoatrophy patients. Although the accompanying muscle compartment 
change also contributed to the facial contour change, a longer follow up period 
might enable us to catch more severe change in facial contour and get a better 
relationship in lipoatrophy patients.  
 
8.3.3 Applications in clinical trials for NRTI switching strategy or surgical 
intervention  
As a strategy to further test the usefulness of the LS methods in clinical 
research and practice, further application of the novel LS methods in clinical trials 
for reversing lipoatrophy by switching from lipoatrophic NRTI to other less toxic 
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APPENDIX 3 CLINICAL LIPODYSTROPHY ASSESSMENT AND 
CLASSIFICATION 
(A) Subject Assessment of Body Shape  
TICK the most appropriate box for current severity:  
Mild  -- noticeable only when specifically sought 
Moderate -- readily obvious to the clinician or patient 
Severe -- obvious to a casual observer  
 
 Nil Mild Moderate Severe 
1. Is there any fat loss in your face?     
2. Is there any fat gain in your face?     
3. Is there any fat loss in the front or sides of your neck?     
4. Is there any fat gain in the front or sides of your neck?     
5. Is there any fat loss in the back or base of your neck?     
6. Is there any fat gain in the back or base of your neck?     
7. Is there any fat loss on your arms?     
8. Is there any fat gain on your arms?     
9. Has the size of your breasts decreased?     
10. Has the size of your breasts increased?     
11. Has the size of your waist decreased?     
12. Has the size of your waist increased?     
13. Has the amount of fat on your buttocks decreased?     
14. Has the amount of fat on your buttocks increased?     
15. Has the amount of fat on your legs decreased?     
16. Has the amount of fat on your legs increased?     
17. Since you were diagnosed with HIV, have the veins in 
your arms and/or legs become more prominent? 
    
18. Since you were diagnosed with HIV, have the veins in 
your arms and/or legs become less prominent? 
    
19. Since you were diagnosed with HIV, have you developed 
any fat lumps (lipomata)? 
If yes, site of lipomata: ___________________________ 
    
 
 249
(B) Physician Assessment of Patient’s Clinical Features  
 
TICK the most appropriate box for current severity:  
Mild  -- noticeable only when specifically sought 
Moderate -- readily obvious to the clinician or patient 
Severe -- obvious to a casual observer  
 
 Nil Mild Moderate Severe 
1. Is there any fat wasting in the face?     
2. Is there any fat accumulation in the face?     
3. Is there any fat wasting in the neck (except 
dorsocervical area)? 
    
4. Is there any fat accumulation in the neck (except 
dorsocervical area)? 
    
5. Is there any fat wasting in the dorsocervical area?     
6. Is there any fat accumulation in the dorsocervical area?     
7. Is there any fat wasting in the arms?     
8. Is there any fat accumulation in the arms?     
9. Is there any fat wasting in the breasts?     
10. Is there any fat accumulation in the breasts?     
11. Is there any fat wasting in the abdomen?     
12. Is there any fat accumulation in the abdomen?     
13. Is there any fat wasting in the buttocks?     
14. Is there any fat accumulation in the buttocks?     
15. Is there any fat wasting in the legs?     
16. Is there any fat accumulation in the legs?     
17. Does the subject have more prominent non-varicose 
normal veins in the arms and/or legs? 
    
18. Does the subject have less prominent non-varicose 
normal veins in the arms and/or legs? 
    
19. Does the patient have any lipomata? 
    If yes, site of lipomata: ___________________________ 







Background: The volume and anatomical distribution of
facial fat depleti n in HIV related lipoatrophy have not
been properly quantified. We aimed to determine the
extent and distribution of facial fat loss in HIV-infected
patients with lipoatrophy and whether this differs from
wasting.
Design: We studied HIV-infected patients with clinically
defined moderate to severe lipoatrophy without wasting
(n=15), clinically defined wasting (>10% weight loss and
recent opportunistic infection) with no previous reported
lipodystrophy (n=15), and controls without lipodystrophy
or wasting (n=15). Facial MRI scans were performed, and
areas of fat were manually traced bilaterally in all indi-
vidual image slices and summed to calculate volume in
anatomically defined regions of interest.
Results: Patients with lipoatrophy had lower fat volumes
in the temporal region (8.9 ±9.4 vs 20.5 ±7.2ml;
P<0.001), cheek region (25.6 ±24.9 vs 55.5 ±15.0 ml;
P<0.001), periorbital region (1.9 ±1.0 vs 2.7 ±1.0 ml;
P=0.09) and buccal fat pad (13.4 ±9.4 vs 21.8 ±9.8 ml;
P=0.030) compared with controls. Patients with wasting
had temporal, cheek, periorbital and buccal fat pad
volumes (10.4 ±6.7 ml, 34.0 ±14.8 ml, 1.4 ±1.1 ml and
13.1 ±4.6 ml respectively) that were lower than controls
(all P<0.01) but similar to lipoatrophy patients (all
P>0.5).
Conclusions: Facial fat depletion in lipoatrophy is
substantial (approximately 50% volume loss) and
involves superficial and deep fat (buccal fat pad). The
distribution and volume of fat change is similar to that
seen in wasting. Given the extent of the changes,
complete surgical correction is unlikely to be possible and
hence emphasis should be placed on prevention of
lipoatrophy.
Facial fat volume in HIV-infected patients with
lipoatrophy
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Lipodystrophy is a common complication of the treat-
ment of HIV disease. It is usually characterized by
atrophy of fat in the face, arms and legs and sometimes
by fat accumulation in central areas. These changes 
are often accompanied by hyperlipidaemia and insulin
resistance [1]. Facial lipoatrophy is the most dis-
tressing manifestation for patients, and the resulting
stigma and psychological morbidity may affect adher-
ence to treatment [2,3]. Although the aetiology of
lipoatrophy is uncertain, it may be related to mito-
chondrial toxicity caused by nucleoside analogue
medication [4].
In spite of its importance to patients, and the efforts
that have been made in developing treatments, there
have been few studies that have properly quantified the
extent and location of facial fat depletion in HIV
related lipoatrophy. It has been suggested by some
authors that there is widespread loss of fat in the
buccal, parotid and pre-auricular fat pads [5,6],
although these conclusions have been based on clinical
observation only.
We set out to quantify the volume and anatomical
location of facial fat in patients with lipoatrophy using
volumetric magnetic resonance imaging (MRI) scan-
ning and to compare the pattern of soft tissue depletion
with that seen in patients with wasting.
Methods
Study patients
We recruited 45 male HIV infected patients (confirmed
by ELISA and Western blot assay) from the outpatient
clinics of the Communicable Disease Centre, Tan Tock
Seng Hospital, the national referral centre for HIV
infection in Singapore. Patients were classified and
recruited into lipoatrophy, wasting and control groups
as described below. Patients with lipoatrophy were
required to have evidence of at least moderate facial
lipoatrophy (that is, readily noticeable by patient or
physician) [1] reported both by patient and study
physician, and to have been on antiretroviral therapy
for at least 1 year. In order to distinguish from wasting,
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they were required to be free from opportunistic infec-
tion for at least 1 year, to have a body weight at least
90% of their usual weight at time of study and not to
have experienced recent weight loss (defined as more
than 5% over the previous 6 months).
Patients with wasting were required to have experi-
enced an opportunistic infection within the previous 
6 months that was associated with >10% weight loss,
and to have a body weight that was less than 90% 
of their usual body weight at the time of study. To
further distinguish from lipoatrophy, wasting patients
were also required to have received less than 12 months
of antiretroviral therapy and not to have previous
report of lipodystrophy prior to the opportunistic
infection.
Control patients were required to have no report 
of lipodystrophy (facial or other body region) by
patient or physician, to be free from opportunistic
infection for at least 1 year, to have a body weight 
at least 90% of their usual weight at time of study and
not to have experienced recent weight loss (defined as
more than 5% over the previous 6 months). Duration
of antiretroviral therapy was not specified for this
group.
Exclusion criteria for recruitment to all groups were
concomitant use of diuretics, systemic corticosteroids,
pregnancy or breast-feeding, any serious facial injury,
and any of the standard contraindications for MRI
scanning. All patients gave written informed consent
and the protocol was approved by the Ethics
Committee of Tan Tock Seng Hospital.
Clinical characteristics 
A standard questionnaire about changes in appearance
was administered to all patients, and any changes were
classified as mild, moderate or severe [1]. Clinical
information including the result of the most recent
CD4 count, viral load and details of the antiretroviral
treatment history were abstracted from the medical
case records. Body weight was measured to the nearest
0.1 kg using electronic scales (SECA, Model 7700,
Vogel & Halke, Hamburg, Germany) and height was
measured to the nearest 0.5 cm using a stadiometer.
MRI measurement 
MRI was performed on a clinical 1.5T MR system
(Signa NVi, GE Medical Systems, Wisconsin, MI, USA)
using a standard quadrature head coil. Patients were
positioned in the magnet in a supine position, with
arms relaxed by their side. The entire head volume was
scanned using contiguous axial 1.5 mm thick slices
with no interslice gap. High resolution spoiled gradient
recalled echo (SPGR) 3D T1-weighted MR images were
obtained with parameters of TR/TE/flip angle
8.9/4.2/15˚; field of view 240×190 mm; matrix
256×256; number of excitation 2; scan time 5 min
4 sec.
MR images were transferred to a SUN Sparc 10
workstation (SUN Microsystems, Mountain View, CA,
USA) for analysis using in-house MRreg v.1.6.2 
software [7]. Each fat or muscle region of interest
(ROI) was manually traced using a mouse-driven
cursor. Different contrast settings optimized for facial
fat and muscle were used in the display panels. The
regions of interest were temporal fat and cheek fat
(separated at zygomatic arch level), periorbital fat, the
buccal fat pad, orbital fat, and the masseter and tempo-
ralis muscles (Figure 1). All constituent tissues within
the ROI were assessed bilaterally. The volume of ROI
per slice was calculated by counting the 3D pixels
(voxels) within a traced area, multiplying the selected
area by the slice thickness in mm. The volumetric func-
tion of the MRreg software summed the selected slice
volumes to compute a total volume. Superficial fat
volume was defined as the sum of the temporal, cheek
and periorbital fat compartments. Total facial fat was
defined as the sum of all the measured fat compartment
volumes. 
In addition to the above volume analysis, the fat and
muscle areas were recorded for a standard single slice.
The position of this slice was located at 2.4 cm (16
cuts) below the maximum prominence of the zygomatic
level, placing it approximately in the center of the
cheek for most patients.
Tracing and analysis of soft tissue volumes was
performed for all the patients by an experienced reader
blinded to the patients’ grouping. The entire image
analysis per patient took approximately 1 h to
perform. Reproducibility of the measurements was
evaluated by performing repeat analysis of 10
randomly selected scans. The coefficient of variations
of repeated measurements were 4.3%, 6.8%, 8.3%,
9.2%, 7.5%, 4.0%, 6.8%, 7.9% and 5.5% for total
facial fat, temporal fat, cheek fat, periorbital fat, buccal
fat pad, orbital fat, superficial fat, temporalis muscle
and masseter muscle respectively.
Dual energy X-ray absorptiometry (DXA) measurement
Whole body composition was measured in each patient
with a Lunar DXA machine (Lunar Prodigy, software
version 6.50; Lunar Corporation, Madison, Wisconsin,
USA). Patients were scanned wearing light indoor
clothing. Scans were performed and analysed by the
same operator (blinded to subject grouping) following
manufacturer’s instructions, and using standardized
cut-offs for regional measurements. The machine was
regularly calibrated for quality control purposes
according to procedures specified by the manufacturer.
The measurements were performed on the same day as
the MRI measurement.
Y Yang et al.




MRI facial fat and muscle volumes and single sliced fat
or muscle areas were compared among the three groups
of patients by ANOVA, with post-hoc Scheffe test.
Pearson’s correlation coefficients were calculated to
show the relationship between MRI volumes and DXA
measurements, and between MRI volumes and single
slice MRI areas. All P values were two sided and
P<0.05 was considered statistically significant. The
data analyses were performed with SPSS 11.0 software
(Chicago, IL, USA).
Results
The demographic, clinical characteristics and body
composition results of the 45 patients (all Asian,
predominantly Chinese) are shown in Table 1. All 15
patients with lipoatrophy reported facial, arm, and leg
Antiviral Therapy 10:4 577





Figure 1. T-1 weighted MRI scans to show facial fat and muscle in three HIV-infected patients
Panel A, Control: 48-year-old man without lipodystrophy or wasting. Panel B, Lipoatrophy: severe facial fat loss following 4 years of HAART, in a 40-year-old man
who did not have opportunistic infections or weight loss. Image shows total absence of superficial facial fat, with reduced buccal fat and preserved masseter and
temporalis muscles. Panel C, Wasting: a 38-year-old man who had not taken ART and had experienced 30% loss of body weight accompanying an episode of pneu-






atrophy, and two had central adiposity. All were taking
highly active antiretroviral therapy (HAART) at the
time of the study, and the mean duration of antiretro-
viral therapy was almost 5 years. None had received
any facial implant or injections to correct the facial
atrophy. The mean body mass index (BMI) was in the
normal range, total lean tissue was no different from
controls, but total fat and limb fat were lower than
controls. Patients with wasting all had advanced HIV
disease and the mean CD4 count was 84 cells. Only
three were receiving antiretroviral therapy. The BMI in
the wasting patients was significantly lower than
controls, as were total lean tissue, total body fat and
limb fat.
The MRI measurements of facial fat and muscle
volumes in the three groups of patients are shown in
Y Yang et al.
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Table 1. Demographic, clinical and body composition data of HIV infected patients (n=45)
Controls (n=15) Lipoatrophy (n=15) Wasting (n=15) P
Age, years 40.4 ±7.6 41.6 ±5.9 42.3 ±7.1 0.741
Chinese, n 15 12 10 0.056
HIV duration, months 42.7 ±33.4 80.5 ±29.2* 41.4 ±40.2† 0.004
Stage C disease, n 6 7 15 0.001
CD4 lymphocytes, cells/mm3 386.3 ±184.7 522.7 ±292.5* 84.3 ±106.4*† <0.001
Viral load, log10 copies/ml 3.57 ±1.47 2.75 ±1.48 5.00 ±0.00† 0.012
Viral load <400 log10 copies/ml, n 4/12 10/15 0/2 <0.001
ART duration, months 18.5 ±25.7 58.1 ±21.8* 2.0 ±3.5† <0.001
Current use of HAART, n 7 15 3 <0.001
D4T/3TC/NVP 3 10 2 0.003
D4T/SAQ/RIT 2 3 0 0.207
Others 2 2 1 0.799
Height, cm 167.1 ±7.4 168.2 ±6.0 167.3 ±7.6 0.908
Weight, kg 68.3 ±10.5 63.5 ±10.5* 52.1 ±10.8*† <0.001
BMI, kg/m2 24.5 ±3.9 22.4 ±2.8* 18.6 ±3.4*† <0.001
Total fat by DXA, kg 16.9 ±5.1 9.8 ±5.9* 9.0 ±6.8* 0.001
Limb fat by DXA, kg 6.1 ±1.8 2.9 ±2.0* 3.6 ±3.0* 0.001
Total lean by DXA, kg 49.1 ±6.4 51.2 ±5.6 40.1 ±5.0*† <0.001
ART, antiretroviral treatment; BMI, body mass index. DXA, dual energy X-ray absorptiometry. Data shown are mean ±SD, except for Chinese race, disease stage, viral
load <400 log10 copies/ml, current use of highly active antiretroviral therapy (HAART) and HAART regimens, which are absolute numbers. Means are compared among
groups by one-way ANOVA followed by post hoc Scheffe tests and proportions are compared by Fisher’s exact test. P is for overall differences among the three
groups. *P<0.05 vs controls by post-hoc Scheffe tests, †P<0.05 vs lipoatrophy by post-hoc Scheffe tests. d4T, staduvine; 3TC, lamivudine; NVP, nevirapine; RIT, riton-
avir; SAQ, saquinavir.
Table 2. Comparison of MRI-measured facial soft tissue volumes and single-slice cheek fat and muscle area between controls
and patients with lipoatrophy and wasting
Controls (n=15) Lipoatrophy (n=15) Wasting (n=15) P
Temporal fat, ml 20.5 ±7.2 8.9 ±9.4* 10.4 ±6.7* <0.001
Cheek fat, ml 55.5 ±15.0 25.6 ±24.9* 34.0 ±14.8* <0.001
Periorbital fat, ml 2.7 ±1.0 1.9 ±1.0 1.4 ±1.1* 0.006
Buccal fat pad, ml 21.8 ±9.8 13.4 ±9.4* 13.1 ±4.6* 0.009
Orbital fat, ml 16.5 ±4.9 16.1 ±7.2 14.3 ±4.1 0.510
Total superficial facial fat, ml 78.7 ±20.7 36.3 ±34.1* 45.8 ±20.8* <0.001
Total facial fat, ml 116.9 ±30.3 65.8 ±48.1* 73.2 ±26.0* <0.001
Temporalis muscle, ml 60.3 ±13.4 59.8 ±12.2 45.3 ±11.1*† 0.001
Masseter muscle, ml 49.1 ±12.4 47.8 ±9.7 35.6 ±6.8*† 0.001
Single slice cheek fat area, cm2 11.1 ±2.2 4.8 ±4.6* 6.9 ±3.0* <0.001
Single slice cheek muscle area, cm2 9.2 ±1.9 8.8 ±1.6 7.0 ±2.2*† 0.006
Volumes are sum of left and right sides. Total superficial facial fat is the sum of temporal fat, cheek fat, and periorbital fat. Single-slice is positioned at 2.4 cm below
zygomatic arch level. Groups are compared by ANOVA with post-hoc Scheffe tests. P is for overall differences among the three groups. *P<0.05 vs controls by post-
hoc Scheffe tests, †P<0.05 vs lipoatrophy by post-hoc Scheffe tests. MRI, magnetic resonance imaging.
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Table 2. Patients with lipoatrophy had lower fat volume
in the temporal region (8.9 ±9.4 vs 20.5 ±7.2 ml;
P<0.001), cheek region (25.6 ±24.9 vs 55.5 ±15.0 ml;
P<0.001), periorbital region (1.9 ±1.0 vs 2.7 ±1.0 ml;
P=0.09) and buccal fat pad (13.4 ±9.4 vs 21.8 ±9.8 ml;
P=0.03) compared with controls. Patients with wasting
had temporal, cheek, periorbital and buccal 
fat pad volumes (10.4 ±6.7 ml, 34.0 ±14.8 ml,
1.4 ±1.1 ml, and 13.1 ±4.6 ml respectively) that were
lower than controls (all P<0.01), but did not differ
from those of lipoatrophy patients (all P>0.5). Orbital
fat showed no significant difference between control,
lipoatrophy and wasting patients (Table 2). There was
no difference between lipoatrophy and control patients
in the volume of the masseter muscle (47.8 ±9.7 vs
49.1 ±12.4 ml) or the temporalis muscle (59.8 ±12.2 vs
60.3 ±13.4 ml). However, patients with wasting had
masseter and temporalis muscle volumes (35.6 ±6.8 ml
and 45.3 ±11.1 ml) that were significantly lower than
both controls and lipoatrophy patients (all P<0.05).
The relationship between superficial facial fat
volume measured by MRI and limb fat measured by
DXA is shown in Figure 2 (for all patients) and Figure
3 (for lipoatrophy patients only). There was a high and
statistically significant correlation between superficial
facial fat and limb fat for the overall group of 45
patients (r=0.78, P<0.001) and the relationship was
even closer between these two parameters when the
analysis was performed on just the patients with lipoa-
trophy (r=0.91, P<0.001).
Comparison of the three groups for fat and muscle
area obtained from the single cheek slice measurement
revealed significant differences among the groups in the
same direction and to the same extent as was seen with
the full face volume measurements (Table 2).
Furthermore, the fat area from the single cheek slice
was strongly correlated with superficial facial fat
volume (r=0.92, P<0.001) for all patients and (r=0.95,
P<0.001) for just patients with lipoatrophy.
Discussion
This is the first study to quantify objectively the extent
and anatomical distribution of facial fat depletion in
patients with HIV-related lipoatrophy. We found that
facial fat was reduced by more than 50% in patients
with lipoatrophy compared with controls, with all
areas of superficial facial fat (temporal, cheek and peri-
orbital) affected. The very close relationship (high
correlation coefficient) between volume of superficial
facial fat and limb fat measurements in the patients
with lipoatrophy suggested that superficial facial fat
depletion occurred in proportion to a generalized
process of peripheral lipoatrophy. The mean difference
in superficial facial fat between lipoatrophy and
controls was greater than 20 ml on each side, which is a
surprisingly large amount given that volume change of
only a few ml of facial fat is necessary to bring about a
noticeable change in facial appearance [8,9]. Although
improvements in appearance of facial lipoatrophy have
been obtained with the use of submalar silicone
implants [10] and injections of polylactic acid [8,9], the
magnitude and widespread distribution of fat loss we
have observed in this study indicate that complete
restoration of normal appearance is unlikely to be
possible by surgical correction methods. The focus
should therefore remain on strategies for the early
detection and prevention of severe facial lipoatrophy.
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Figure 2. Correlation between superficial facial fat volume
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Figure 3. Correlation between superficial facial fat volume
(ml) and limb fat (kg) in patients with lipoatrophy (n=15)
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The buccal fat pad is located deep in the cheek, and
it has been unclear previously whether this was affected
in the process of HIV-related facial lipoatrophy. The
buccal fat pad is a specialized type of fat termed syssar-
cosis, a type of fat that enhances intermuscular motion,
and it has a distinct appearance from the subcutaneous
fat of the cheek [11]. The buccal fat pad appears to be
less metabolically active than other fat, with less
numerous vesicles and smaller mitochondria, and has
been previously noted to be preserved even in very
cachectic patients [12]. Thus, given its unique nature, it
is conceivable that the buccal fat pad might be spared
by the process of lipodystrophy. Indeed, the only
previous study that has formally attempted an evalua-
tion of the buccal fat pad (by visual inspection prior to
surgery) concluded that it was not affected by lipoat-
rophy [10]. However, our study has clearly demon-
strated that the buccal fat pad is significantly depleted
in lipoatrophy, although the extent of depletion (to
60% of controls) appears less than that of superficial
fat depletion (to 45% of controls). In four patients the
buccal fat pad was reduced to extremely low values
(0.6–5.7 ml), well below the lowest value (8.6 ml) seen
in patients with wasting. The function of the buccal fat
pad is to assist the muscles of mastication, although
whether there are any functional consequences of such
extreme depletion is unclear. However, orbital fat (a
deep fat compartment) was relatively well preserved in
patients with lipoatrophy (as well as those with
wasting) which is consistent with the observation that
orbital fat is the last area of fat to be lost in patients
with severe emaciation due to anorexia nervosa [13].
Loss of facial fat in lipoatrophy and wasting gives
rise to a cachectic appearance that is stigmatizing and
makes it difficult for patients to hide the presence of
their underlying medical condition. One of the aims of
this study was to examine whether the pattern of facial
fat loss in lipodystrophy was distinct from the pattern
seen in wasting. This is a plausible hypothesis, given
the likely different aetiology of fat depletion in these
two processes. Whereas lipodystrophy is thought to be
due to mitochondrial toxicity, wasting is caused by
restriction of energy intake leading to reduction of fat
as well as lean tissue to meet energy requirements [14].
In fact we found that the distribution and extent of fat
depletion did not differ between lipoatrophy and
wasting patients. In contrast to patients with lipoat-
rophy, wasting patients had a significant reduction in
facial muscle volume that may make a further contri-
bution to their cachectic appearance. The pattern of
loss of fat tissue with preservation of muscle tissue in
the face might prove helpful in the diagnosis of lipody-
strophy. The differences between measured muscle
volumes in the two groups also suggest that the 
stringent inclusion criteria we used were effective in 
separating wasting and lipoatrophy patients, although
in clinical practice the two conditions may sometimes
overlap.
Although facial lipoatrophy is probably the most
important component of the ‘lipodystrophy syndrome’
for patients, it has been difficult to investigate in clin-
ical studies due to the lack of an appropriate and objec-
tive measurement method. The MRI analysis method
we used in this study is precise (that is, gives repro-
ducible measurements, with a coefficient of variation of
6.8% for analysis of superficial facial fat volume).
Given the large magnitude of the differences seen in
lipoatrophy in relation to the measurement precision,
the method is clearly suitable for detecting lipoatrophy
changes in small groups of patients. Analysis of scans
could easily be centralized to preserve precision in a
clinical trial setting. The major disadvantages of MRI
are the cost and inconvenience of scanning and
analysis. As a potential approach to reduce the scan-
ning and analysis time, we also evaluated the use of a
single slice scan to measure fat area in the cheek. We
found this to be reproducible and able to detect the soft
tissue differences among the groups, and therefore this
approach may be of some practical use. Spiral CT can
also provide a good measure of facial soft-tissue
volumes [15] but shares the disadvantages with MRI of
cost and inconvenience with the added disadvantage of
radiation exposure which would limit its use in longi-
tudinal studies. A single-slice CT approach has been
shown to be reproducible and to be able to differentiate
patients with lipoatrophy from controls [16].
Ultrasound measurement of subcutaneous malar fat
depth has the advantages of convenience, relatively low
cost and lack of radiation exposure. Although it
appeared able to detect differences between lipoat-
rophy patients and controls in a cross sectional study
[17] and has been used in studies of surgical interven-
tions for lipoatrophy [18], it did not prove useful for
measuring HIV-lipoatrophy changes when used in a
randomized controlled trial [19]. Laser scanning has
been shown to be an accurate and reproducible method
for measuring changes, and has the advantages of being
relatively quick and inexpensive, with no radiation
exposure so may be suitable for repeated use in patients
on longitudinal follow up in large scale clinical studies
[20,21]. However, the method assesses changes in
contour, and does not specifically measure change in
fat. Three-dimensional photography, used in one trial
of polylactic acid injections, shares the advantages of
laser scanning, but has not yet been validated for
measurement of lipoatrophy [9]. To date, most clinical
research on lipoatrophy has used DXA to measure
peripheral fat without direct measurements of facial
fat. The close correlation we found between DXA
measurements of peripheral fat and the MRI 
Y Yang et al.
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measurements of facial fat, suggests that measurement
of limb fat by DXA probably provides a suitable surro-
gate measurement for facial lipoatrophy.
Facial lipoatrophy is likely to increase in importance
as the use of stavudine-containing combined formula-
tion pills becomes more widespread in expanded access
programs. This study has provided definitive informa-
tion about the nature of the facial fat changes which
should encourage more objective approaches to study
this condition.
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Background: Dual-energy X-ray absorptiometry (DXA) is
regarded as a useful objective method for diagnosis of
HIV-associated lipodystrophy (LD). 
Objective: To determine whether the use of different DXA
machines may affect the diagnosis of LD. 
Methods: Body composition in 24 HIV-infected patients,
12 of whom had clinically diagnosed LD, was measured
on two DXA machines (Lunar and Hologic). 
Results: Hologic gave significantly higher values than
Lunar DXA for total body fat percent (22.9 vs 20.5%,
P<0.001), arm fat percent (27.9 vs 14.5%, P<0.001) and
leg fat percent (23.4 vs 17.5%, P<0.001), and signifi-
cantly lower values than Lunar for trunk fat percent
(22.3 vs 24.7%, P<0.001) and trunk-to-limb fat percent
ratio (0.89 vs 1.62, P<0.001). When measured by Lunar,
patients with LD had significantly lower leg fat percent
(13.5 vs 21.6%, P=0.04) and higher trunk-to-limb fat
percent ratio (1.85 vs 1.38; P=0.012) than those without
LD. When measured by Hologic, patients with LD had
values of leg fat percent (20.1 vs 26.8%, P=0.11) and
trunk-to-limb fat percent ratio (0.95 vs 0.85, P=0.43)
that did not differ significantly from those without LD.
There was a significant difference in the contribution to
a composite LD score between Lunar and Hologic
measurements. 
Conclusion: DXA machines from different manufacturers
give major differences in measurements of body fat
content and distribution, and this may affect the ability
to distinguish patients with LD from those without LD.
Further standardization of DXA technology is needed
before widespread application in the clinical diagnosis
of LD.
Comparison of dual-energy X-ray absorptiometry
machines for measuring fat distribution changes of
HIV-associated lipodystrophy 
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Lipodystrophy (LD) is a common complication of the
treatment of HIV disease. It is usually characterized by
wasting of fat in the face, arms and legs and sometimes
by fat accumulation in central areas. Hyperlipidaemia
and insulin resistance may also occur [1]. Substantial
variations in the prevalence (20–80%), incidence,
severity and risk factors for LD have been reported,
which are likely to arise in part due to differences in
diagnostic criteria for LD [1–6]. 
Dual-energy X-ray absorptiometry (DXA) has been
advocated as a useful objective tool in the diagnosis
and evaluation of LD [1]. The technique can detect
differences in fat distribution between LD and non-LD
patients, and DXA measurements of leg fat percent and
trunk-to-limb fat percent ratio made a significant
contribution to a diagnostic model for a case definition
of LD [1,2]. However, it is known that DXA results
vary with manufacturers, as well as with hardware and
software versions used [7–9]. Studies using DXA
instruments at various clinical research centres
revealed considerable inter-machine differences [10],
even among machines from the same manufacturer
[11–13]. LD is probably the first situation in which
DXA soft tissue measurements have been applied as a
clinical diagnostic tool. However, the impact of inter-
machine differences on the assessment and diagnosis of
LD has not been assessed. The aim of this study was to
compare measurements of fat distribution between two
different DXA machines and to determine the impact
of differences on LD diagnosis.
Methods
Patients
Twenty-four HIV-infected patients (confirmed by
ELISA and Western Blot assay) were recruited from the
outpatient clinics of the Communicable Disease
Centre, Tan Tock Seng Hospital, the national referral
centre for HIV infection in Singapore. Subjects were
required to have LD (12 subjects, see below for details
Introduction
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of diagnosis) or no LD (12 subjects). Exclusion criteria
were wasting (defined as weight loss of more than 10%
of their usual body weight during the past 6 months),
concomitant use of diuretics, systemic corticosteroids,
pregnancy or breast-feeding. All subjects gave written
informed consent and the protocol was approved by
the Ethics Committee of Tan Tock Seng Hospital. 
Methods
A standard questionnaire was given to all subjects. The
questionnaire asked about any loss of fat or accumula-
tion of fat in the face, neck, dorso-cervical spine, arms,
breasts, abdomen, buttocks or legs, as well as the pres-
ence, site and number of any lipomata (focal
accumulation of fat). The degree of lipoatrophy, diffuse
fat accumulation or lipomatosis at every site on the
body was rated as absent (score of 0), mild (noticeable
on close inspection, score of 1), moderate (readily
noticeable by patient or physician, score of 2) or severe
(readily noticeable to a casual observer, score of 3).
Positive findings were confirmed by a study physician.
We classified patients as LD if they had at least one
confirmed moderate or severe feature of lipoatrophy,
diffuse fat accumulation or lipomatosis that had arisen
since the diagnosis of HIV infection [1]. 
Medical records were reviewed and clinical infor-
mation was abstracted including CD4 counts, viral
load and antiretroviral treatment history. Body weight
was measured to the nearest 0.1 kg using electronic
scales (SECA, Model 7700, Vogel & Halke, Hamburg,
Germany) and height was assessed to the nearest
0.5 cm using a stadiometer. 
Whole body composition was measured twice in
each patient, once with a Lunar DXA machine (Lunar
Prodigy, software version 6.50; Lunar Corporation,
Madison, Wis., USA) and once with a Hologic DXA
machine (Hologic QDR 2000, software version 5.73A;
Hologic Inc., Bedford, Mass., USA), which are situated
at different locations in our hospital. The paired
measurements were performed on the same day within
an interval of 4 h, and the machines were used in
random order. Patients were scanned wearing light
indoor clothing. Scans were performed and analysed
by the same operator following manufacturer’s instruc-
tions, using standardized cutoffs for regional
measurements. The two machines were regularly cali-
brated for quality control purposes according to
procedures specified by the manufacturer. 
Statistical analysis
Comparisons of the duplicate Lunar and Hologic body
composition measurements from individual patients
was made by paired t-tests. Trends in inter-machine
differences were evaluated using Bland & Altman’s
method [14] and linear regression analysis. Two-sample
t-tests were used to compare means for LD and non-
LD subjects measured by one machine. The DXA
contributions to composite scores for LD diagnosis
were calculated using previously published conversion
factors [1] and the mean LD scores from the two DXA
machines were compared with paired t-tests. All P
values were two-sided and the level of statistical signif-
icance was considered to be α=0.05. The data analyses




The demographic and clinical characteristics of the 24
patients are shown in Table 1. Those with LD were
significantly older, had a longer duration of HIV infec-
tion and a higher CD4 count than those without LD.
Twenty-two of the 24 patients were receiving highly
active antiretroviral therapy (HAART) including a
protease inhibitor. Of the 12 patients with LD, 10 had
facial lipoatrophy, nine had arm and/or leg lipoatrophy
and two had central adiposity. 
Comparison of body composition results between
DXA machines
The results of body composition measurements obtained
with the two machines are shown in Table 2. Hologic
gave significantly higher values than Lunar for total
body fat (13.0 vs 11.9 kg, P<0.001), and significantly
lower values than Lunar for total body lean (41.4 vs
43.3 kg, P<0.001) and bone mineral mass (1.9 vs 2.3 kg,
P<0.001). Total body fat percent was significantly
higher (22.9 vs 20.5%, P<0.001) when measured on the
Hologic machine compared with the Lunar machine. 
The distribution of body fat between central and
peripheral areas also showed significant differences
with the two machines. Hologic gave significantly
higher measures of arm fat percent (27.9 vs 14.5%,
P<0.001) and leg fat percent (23.4 vs 17.5%,
P<0.001), and significantly lower values than Lunar
for trunk fat percent (22.3 vs 24.7%, P<0.001) and
trunk-to-limb fat percent ratio (0.89 vs 1.62, P<0.001).
The individual differences between trunk-to-limb fat
percent ratio measurements obtained by the two
machines are shown in Figure 1. The magnitude of the
inter-machine differences for measurement of trunk-to-
limb fat percent ratio increased as the mean
trunk-to-limb fat percent ratio increased (P=0.003).
There was no significant relationship between the
inter-machine difference and the mean for leg fat
percent. The determination coefficients (r2) of the
linear regressions between leg fat percent and trunk-to-
limb fat percent ratio by the two DXA machines were
0.97 and 0.44, respectively. 
Y Yang et al.
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Comparison of the two machines for detection of LD
changes
The results of comparison of LD and non-LD patients
using each machine are shown in Table 3. There were
no significant differences between LD and non-LD
subjects in whole body composition when measured by
either Lunar or Hologic machines. When measured by
Lunar DXA, patients with LD had significantly lower
percent (13.5 vs 21.6%, P=0.04) and higher trunk-to-
limb fat percent ratio (1.85 vs 1.38; P=0.012) than
those without LD. When measured by Hologic,
patients with LD had values of leg fat percent (20.1 vs
26.8%, P=0.11) and trunk-to-limb fat percent ratio
(0.95 vs 0.85, P=0.43) that did not differ significantly
from those in patients without LD. 
The differences in the DXA contribution to a
composite LD score calculated using published conver-
sion factors are shown in Table 4. The DXA
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Table 2. Body composition results of all subjects by Lunar and Hologic DXA (n=24)
Hologic Lunar Difference 95% CI P
Total body mass, kg 56.3 ±7.1 57.4 ±7.2 –2.1 –2.32 to –1.91 <0.001
Total body fat, kg 13.0 ±5.7 11.9 ±6.0 1.1 0.63 to 1.55 <0.001
Total body fat, % 22.9 ±9.6 20.5 ±9.9 2.4 1.59 to 3.24 <0.001
Total lean tissue, kg 41.4 ±6.8 43.3 ±6.8 –1.9 –2.44 to –1.44 <0.001
Total BMC, kg 1.9 ±0.3 2.3 ±0.3 –0.4 –0.44 to –0.37 <0.001
Limb fat, kg 5.8 ±2.5 4.1 ±2.3 1.7 1.53 to 1.92 <0.001
Limb fat, % 24.6 ±10.3 16.8 ±9.4 7.8 7.05 to 8.59 <0.001
Trunk fat, kg 6.4 ±3.4 7.4 ±3.8 –0.9 –1.32 to –0.53 <0.001
Trunk fat, % 22.3 ±11.3 24.7 ±11.4 –2.5 –3.82 to –1.11 0.001
Arm fat, kg 1.7 ±0.7 0.8 ±0.5 0.9 0.72 to 1.00 <0.001
Arm fat, % 27.9 ±11.6 14.5 ±8.8 13.4 11.98 to 14.79 <0.001
Leg fat, kg 4.1 ±1.9 3.2 ±1.9 0.9 0.70 to 1.03 <0.001
Leg fat, % 23.4 ±10.2 17.5 ±9.6 5.9 5.09 to 6.70 <0.001
Trunk-to-limb fat percent ratio 0.89 ±0.28 1.62 ±0.47 –0.72 –0.87 to –0.57 <0.001
Trunk fat % minus limb fat % –2.3 ±6.2 7.9 ±5.3 –10.3 –11.54 to –9.01 <0.001
Limb lean tissue, kg 16.7 ±3.1 18.8 ±3.3 –2.1 –2.31 to –1.91 <0.001
Trunk lean tissue, kg 21.4 ±3.7 21.0 ±3.3 0.4 –0.08 to 1.04 0.090
Arm lean tissue, kg 4.2 ±1.0 4.8 ±1.0 –0.6 –0.75 to –0.46 <0.001
Leg lean tissue, kg 12.5 ±2.2 14.0 ±2.4 –1.5 –1.74 to –1.29 <0.001
BMC, body mineral content; CI, confidence interval; P value was calculated using paired t–test.
Table 1. Demographic and clinical characteristics of HIV-infected patients (n=24)
LD (n=12) Non-LD (n=12) P
Age, years 46.3 ±14.2 35.3 ±4.7 0.013
Male sex, n 8 8 1
Stage C disease, n 10 7 0.334
Duration of HIV infection, months 55.3 ±15.5 39 ±20.9 0.043
CD4 count, cells/ml 405 ±226 214 ±143 0.024
Viral load, log10 copies/ml 2.21 ±1.02 2.90 ±1.54 0.227
Viral load <400 log10 copies/ml, n 8 7 0.9
Duration of ART, months 42.3 ±16.3 33.9 ±21.6 0.312
Current use of HAART, n 12 11 0.9
Height, cm 163.4 ±7.0 163.4 ±8.0 0.861
Weight, kg 56.1 ±6.9 59.9 ±7.5 0.451
BMI, kg/m2 21.1 ±2.5 22.4 ±2.5 0.326
LD, lipodystrophy; ART, antiretroviral treatment; BMI, body mass index. Data shown are mean ±SD, except for sex, disease stage, viral load <400 log10 copies/ml and
current use of highly active antiretroviral therapy (HAART), which are absolute numbers. Means are compared between groups by t-test and by Fisher’s exact test. 
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Figure 1. Lack of agreement between measurement of trunk-to-limb fat percent ratio by Lunar and Hologic DXA machines   
, LD patients; , Non-LD patients. The solid line represents the regression line, the dotted line represents mean difference and the broken lines illustrate the 95%

































Table 3. Body composition between LD and non-LD HIV-infected patients by Lunar and Hologic DXA
Parameter Lunar DXA Hologic DXA
LD (n=12) Non-LD (n=12) Difference P LD (n=12) Non-LD (n=12) Difference P
Total body mass, kg 55.3 ±6.5 59.4 ±7.5 –4.2 0.160 54.3 ±6.4 58.4 ±7.4 –4.1 0.160
Total body fat, kg 9.7 ±6.4 14.1 ±4.9 –4.4 0.075 11.4 ±6.1 14.7 ±4.9 –3.3 0.160
Total body fat, % 17.5 ±11.5 23.5 ±7.2 –6.0 0.140 20.9 ±11.0 25.0 ±7.7 –4.2 0.294
Total lean tissue, kg 43.5 ±7.9 43.2 ±5.8 0.3 0.908 41.1 ±7.4 41.7 ±6.6 –0.6 0.825
Total BMC, kg 2.2 ±0.3 2.4 ±0.4 –0.2 0.171 1.8 ±0.2 2.0 ±0.3 –0.2 0.139
Limb fat, kg 3.0 ±2.4 5.1 ±1.7 –2.2 0.018 4.7 ±2.6 6.8 ±2.0 –2.1 0.040
Limb fat, % 13.2 ±10.6 20.4 ±6.5 –7.2 0.06 21.3 ±11.7 27.9 ±8.0 –6.6 0.123
Trunk fat, kg 6.3 ±4.0 8.4 ±3.3 –2.1 0.186 5.9 ±3.7 7.0 ±3.2 –1.2 0.420
Trunk fat, % 21.9 ±13.4 27.6 ±8.8 –5.7 0.236 20.8 ±12.8 23.8 ±9.8 –3.0 0.531
Arm fat, kg 0.7 ±0.5 1.0 ±0.4 –0.3 0.082 1.4 ±0.7 2.0 ±0.7 –0.5 0.064
Arm fat, % 12.2 ±10.2 16.9 ±6.8 –4.6 0.208 24.7 ±12.5 31.1 ±10.1 –6.4 0.181
Leg fat, kg 2.3 ±1.9 4.1 ±1.3 –1.8 0.014 3.3 ±2.1 4.9 ±1.5 –1.6 0.043
Leg fat, % 13.5 ±10.8 21.6 ±6.5 –8.1 0.040 20.1 ±11.6 26.8 ±7.5 –6.7 0.108
Trunk-to-limb fat percent ratio 1.85 ±0.49 1.38 ±0.32 0.47 0.012 0.94 ±0.30 0.85 ±0.27 0.09 0.426
Trunk fat % minus limb fat % 8.7 ±5.0 7.2 ±5.7 1.54 0.490 –0.5 ±5.2 –4.2 ±6.8 3.63 0.159
Limb lean tissue, kg 18.7 ±3.7 18.9 ±3.1 –0.3 0.853 16.6 ±3.3 16.8 ±3.1 –0.1 0.934
Trunk lean tissue, kg 21.2 ±3.9 20.7 ±2.5 0.6 0.685 21.2 ±4.0 21.7 ±3.4 –0.5 0.763
Arm lean tissue, kg 4.8 ±1.1 4.8 ±0.9 0.0 0.964 4.2 ±1.1 4.2 ±1.0 0.1 0.869
Leg lean tissue, kg 13.9 ±2.6 14.1 ±2.3 –0.2 0.811 12.4 ±2.3 12.6 ±2.2 –0.2 0.842
LD, lipodystrophy; BMC, body mineral content; P value was calculated using two–sample t–test.
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contribution was significantly lower with Hologic
DXA than with Lunar DXA both for patients with LD
(–6.30 vs 2.59, P<0.001; mean difference –8.89, range:
–15.45 to –1.95) and for those without LD (–10.77 vs
–7.6, P<0.001; mean difference –3.08; range: –5.00
to –1.45). 
Discussion
We found that body composition measurements by
DXA differed markedly between machines from
different manufacturers. Differences in total body fat
values between Lunar and Hologic machines have been
noted in a number of previous studies in healthy indi-
viduals and patients with clinical disease, although the
direction of the differences varied between studies
[7–9,15]. In addition to differences in total body
composition, we found differences between Lunar and
Hologic DXA in the way soft tissue mass was appor-
tioned between limb and trunk regions. Compared
with Lunar, Hologic DXA gave higher values of limb
fat and lower values of trunk fat. This was especially
marked in the arms, where Hologic gave values of fat
almost double those of Lunar. Higher limb fat and
lower trunk fat values with Hologic compared with
Lunar DXA have been previously demonstrated in a
study in healthy young men [15] and in a study of
patients with diabetes [9], confirming that the differ-
ences we found are not unique to our particular
machines but rather are the result of systematic differ-
ences in hardware and software between the two
manufacturers. 
Although the principle of the technology is the
same, the X-ray frequencies used and the way the
beam is generated differ between DXA manufacturers
[7,16]. The raw measurements are converted into esti-
mates of soft tissue composition by software and the
assumptions in the calculations and resulting formulae
used are likely to differ, especially in the way that
values of soft tissue composition are allocated to areas
overlying bone. The equations remain proprietary
information and are not publicly available, so it is not
possible to assess exactly which assumptions may be
contributing to these differences. DXA measurements
are known to be very reproducible, with coefficients of
variation of less than 5% for whole body and regional
soft tissue measurements [17]. Differences in operators
carrying out the analysis can increase the variability of
the results from DXA [18], but the same operator
performed and analysed all our scans. Although we
did not formally assess measurement reproducibility in
this study, differences in reproducibility between
Hologic and Lunar could not explain the systematic
differences in measurements between machines that we
have observed. 
Both Lunar and Hologic machines have been vali-
dated for measuring whole body composition in
humans against gold-standard methods such as
computerized tomography (CT), magnetic resonance
imaging and four-compartment body composition
models [19–22]. Validation for measurement of
regional body composition has been more limited due
to the lack of gold-standard methods for comparison.
In a study in which slabs of lard were placed over the
body, Hologic DXA detected 96% of the fat mass
placed on the limbs, but only 53% of the fat placed on
the trunk [23]. Another study indicated that Hologic
underestimated trunk fat at lower tissue thicknesses
[24]. Several studies that compared Lunar DXA trunk
fat measurements with abdominal CT or additions of
lard found that Lunar DXA accurately measured trunk
fat [25,26], although one study found an underesti-
mate of abdominal fat [27]. As we did not have a
gold-standard method with which to compare our
results, we cannot determine which of the scanners (if
either) is giving the ‘true’ answer. Our results suggest
that Lunar might be better for distinguishing patients
with LD from those without LD, assuming that our
clinical classification of LD was correct based on the
subject report and physician assessment, and that the
findings of reduced leg fat percent and increased trunk-
to-limb fat percent ratio are representative of LD [1]. 
DXA measurement of fat is included in a clinical
algorithm developed for diagnosis of HIV-associated
LD [1]. The two DXA parameters included in this
algorithm, leg fat percent and trunk-to-limb fat percent
ratio, are converted into a contribution to a total LD
score, along with component scores for age, sex, dura-
tion of HIV infection, CDC disease stage, waist–hip
circumference ratio, HDL cholesterol, anion gap and
the ratio of visceral to subcutaneous adipose tissue
measured by CT [1]. We found that the differences in
DXA measurements of leg fat percent and trunk-to-
limb fat percent ratio with the different machines make
a difference to the total DXA contribution to the LD
score of up to 15.45 points in individual patients with
LD. Although we did not have all the other measure-
ments necessary to calculate the full LD score
according to the algorithm, the difference in DXA
score is likely to result in a difference in classification
for a number of patients. A change in the cutoff score
by 14 points halved the sensitivity of the original
model for detection of LD [1]. 
DXA is economical, convenient and gives repro-
ducible measurements and is therefore attractive as a
diagnostic tool for LD. However, this study has illus-
trated the limitations of applying the technique for this
purpose. The results should be taken as an illustration
of the limitations of DXA in general, and not as an
indictment of one particular manufacturer. Changes in
Y Yang et al.
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software occur regularly and these may affect the
assumptions used. Even within manufacturers, there
may be differences between machines [11–13].The
main point is that without a method of calibration and
standardization of results between machines, it would
be unwise to rely on the absolute values of results for
individual patients or groups of patients. Ideally, there
should be a standard soft tissue phantom that could be
used to calibrate different machines [28]. Further vali-
dation studies for regional body composition in LD are
required before this technique can be widely applied
for diagnostic purposes in this clinical setting. DXA
may be useful in longitudinal studies (provided that the
same machine is used for repeated measurements) as it
has good reproducibility and has been shown to have
good agreement with other methods for detecting
changes in whole body composition in patients with
HIV infection [29]. However, additional validation
studies of DXA for detecting regional body composi-
tion changes over time in HIV patients are also needed. 
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ORIGINAL RESEARCH
Laser scanning as a tool for assessment of HIV-related
facial lipoatrophy: evaluation of accuracy and
reproducibility
Y Yang and NI Paton
Infectious Disease Research Centre (IDRC), Department of Infectious Diseases, Tan Tock Seng Hospital, Singapore
Background
Facial lipoatrophy (LA) is a common complication of highly active antiretroviral therapy (HAART).
Research into causes and treatment of facial LA is hindered by the lack of an objective measurement
tool.
Objective
To evaluate the accuracy and reproducibility of three-dimensional laser scanning (LS) for estimating
cheek volume changes.
Methods
Paired laser scans were performed and the images superimposed using commercial software. The
volume difference between images was computed within a circle of radius 25 mm placed in a
standardized position over the cheek area. Accuracy was tested by scanning before and after
known volumes of plasticine (0.5–5 mL) were applied to the cheek area of a mannequin to
simulate volume change. Reproducibility was tested by repeated scanning of the mannequin with
and without 2 mL of plasticine, and repeated scanning of 10 healthy subjects over the
course of 1 week.
Results
The mean difference between actual and estimated volume change was small across the range of
volumes tested [mean difference 0.08 mL; 95% confidence interval (CI)–0.36 to 0.20 mL). The
coefficient of variation for repeated measurements of 2-mL volume change was 5.8%. The intraclass
correlation coefficient for scan-to-scan variability was 0.812 (95% CI 0.515–0.947) and for
day-to-day variability it was 0.764 (95% CI 0.332–0.935).
Conclusions
LS is an accurate and reproducible method for estimating cheek volume changes. It may be useful as
an objective tool for assessment of facial LA in clinical research studies.
Keywords: accuracy, HIV, laser scanning, lipoatrophy, reproducibility
Received: 11 November 2004, accepted 12 April 2005
Introduction
Lipodystrophy is a common side effect of treatment with
highly active antiretroviral therapy (HAART) in HIV-
infected patients. Lipodystrophy is characterized by per-
ipheral fat atrophy, facial lipoatrophy (LA), central fat
accumulation, or a mixed pattern of fat atrophy and
accumulation [1]. Facial LA is probably the most important
manifestation of lipodystrophy as it is often disfiguring and
may cause psychosocial symptoms (e.g. social stigmatiza-
tion and low self-esteem) [2,3], and may also result in
compromised adherence to antiretroviral therapy [4,5].
The diagnosis of lipodystrophy is currently based on
patient self-assessment and/or physician assessments [1].
These methods are subjective and may account, in part, for
the variation in prevalence rates (20–80%) reported in
different cohort studies [1,2,6]. Although peripheral
fat changes can be measured by dual-energy X-ray
Correspondence: Dr Nicholas I Paton, MRC Clinical Trials Unit, 222 Euston
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absorptiometry [1], the method cannot detect changes in
facial fat. To date there is no accepted method for the
objective assessment of HIV-related facial LA.
Three-dimensional laser scanning (LS) has been used in
research and clinical practice for generating images of
facial contour that may be used for planning maxillofacial
surgery, measuring craniofacial deformity and planning
radiotherapy [7–10]. Laser scanners are easy to use,
inexpensive, rapid and noninvasive [7]. This method, with
appropriate standardization of scanning technique and
image analysis approach, may have potential as an
objective tool for the assessment of facial LA.
The aim of this study was to evaluate the accuracy and
reproducibility of a standardized method for assessing
cheek volume changes using LS, with a view to future
application in studies of HIV-related lipodystrophy.
Methods
Volume simulation and human subject reproducibility
The accuracy of the method for estimating volume change
was tested using a mannequin (Modern Artificial Model,
Modern Artificial Model Pte. Ltd., Singapore). A series of
increasing volumes of plasticine (0, 0.5, 1.0, 1.5, 2.0, 2.5,
3.0, 3.5, 4.0, 4.5 and 5.0 mL, TACK-ITt; A. W. Faber-
Castell [M] Sdn. Bhd., Selangor, Malaysia), calculated from
known density and weight, was used to simulate changes in
facial contour. The plasticine was placed on the cheeks of
the mannequin over a circle of 15-mm radius centred over
the point one-third of the way along a line drawn between
the labial commissure and tragus in order to place it within
the area used for volume analysis (see below and Fig. 1).
Repeated scans were performed with and without each
incremental volume of plasticine.
Reproducibility of the volume change estimates was
assessed using five repeated scans with and without a
constant 2 mL of plasticine attached to the mannequin
cheek. Reproducibility over time was also tested in 10
healthy subjects (five male and five female) recruited from
hospital staff with normal facial symmetry and with no
beard or moustache. Subjects were scanned a total of eight
times over the course of 1 week. Five scans were obtained
on the first day to test the scan-to-scan variability, and a
single scan was repeated on days 2, 4, and 7 to test day-
to-day variability. The study was approved by the local
hospital Ethics Committee.
Laser scan procedure
Laser scans were performed using a commercially available
three-dimensional digitizer laser scanner (VIVID 300;
Minolta Co Ltd, Osaka, Japan). This emits a horizontal
stripe light through a cylindrical lens to the subject’s face
and converts the reflected light into distance information.
This process is repeated by scanning the light stripe
vertically along the face, and 40 000 points of three-
dimensional data are collected during a scan time of 0.6 s.
Before scanning, subjects were asked to remove any
jewellery from the face and ears and to moisten and retract
any hair to give full exposure of the forehead and ears.
They were asked to close their mouth without clenching the
teeth, and adopt an expressionless face without smiling.
Subjects were seated upright in a standardized swivel chair
positioned 120 cm from the laser camera. The swivel chair
was initially rotated 451 clockwise from the frontal plane to
expose the left cheek, and the subject was instructed to
focus their eyes on a marker positioned at an appropriate
position on the wall of the room. After obtaining the laser
image, the procedure was repeated with the swivel chair
rotated to 451 anticlockwise from the frontal plane to
obtain an image of the right cheek. An identical procedure
was used for the scanning of the mannequin, except that
the mannequin was positioned on a box to elevate it within
the centre of the scanning gantry.
Analysis of paired laser scans
The three-dimensional scan data were transferred to
commercially available computer software for analysis
(RAPIDFORM2004; INUS Technology Inc., Seoul, Korea). A
pair of scans of the same side of the face was selected, and
the 40 000 data points in each scan were automatically
converted by the software into a recognizable image of the
face for ease of positioning and identification of reference
points. The images were cropped to remove the neck region
and hair. Four reference points (eye lateral canthus, tragus,
Vertical axis




Fig. 1 Position and size of the plasticine and selected area on the
mannequin cheek area.
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labial commissure and ala) that are known to be
reproducible were selected on each of the two images [8].
The more recent image was superimposed over the earlier
image using the four reference points as a guide. A vector
was generated between the midpoint of the bridge of the
nose and the chin, and the superimposed image was rotated
around this axis to 651 from the frontal view to obtain a
standardized image position for analysis. A vector was then
drawn between the labial commissure and the tragus, and a
point selected one-third of the way along the line from the
labial commissure end. A circle of radius 25 mm was
positioned with its centre on this point (Fig. 1), and the
volume difference between the two components of
the superimposed image was calculated within the area
of the circle using a customized algorithm developed by the
software manufacturer that analyses the distance between
the three-dimensional data points underlying the two
images. The procedure was repeated for the corresponding
images from the opposite cheek and the average of the left
and right cheek volume differences was calculated. A
single technician performed all the laser scans, identified
the soft tissue landmarks, and performed superimpositions
and volume change calculations.
Statistical analysis
The accuracy for estimating volume change was assessed
by the method of Bland and Altman [11] and linear
regression analysis. The reproducibility of the method in
the mannequin was determined by calculating the coeffi-
cient of variation (CV). CV values less than 10% were
considered to represent good reproducibility [12]. The
reproducibility of the method in human subjects was
assessed by calculating the intraclass correlation coeffi-
cient (ICC) for the repeated scans on the first day and for
the repeated scans over 1 week. An ICC score of 0.75
was taken as representing excellent reliability [13]. All
P-values were two-sided and Po0.05 was considered
statistically significant. The data analyses were performed
with SPSS 11.0 software (SPSS, Chicago, IL, USA).
Results
Accuracy of volume changes
The volume change estimated by LS corresponded closely
to the actual volume change across the range of simulated
volume changes, with a mean difference of 0.08 mL [95%
confidence interval (CI) 0.36 to 0.20 mL] (Fig. 2). There
was a trend towards an underestimation by LS at higher
values of volume change, but the effect was small
(regression slope b5 0.04; P5 0.134).
Reproducibility of volume changes
Repeated measurements of the 2-mL volume change gave a
mean value of 1.93 mL. The CV was 5.8%.
Reproducibility of measurements in healthy subjects
The reproducibility of the selected areas for volume change
estimated within the 25-mm radius circle varied as a result
of individual differences in facial contour, but the variation
was small (range 1810–1870 mm2). For repeated scans on
the same day, the scan-to-scan volume differences from the
baseline scan ranged from  0.709 to 0.404 mL. The ICC
for the repeated measurements was 0.812 (95% CI 0.515–
0.947). For repeated scans over 1 week, the day-to-day
volume differences from the baseline scan ranged from
 1.760 to 0.817 mL. The ICC was 0.764 (95% CI 0.332–
0.935).
Discussion
We have developed a standardized method for estimating
volume changes in the cheek using changes in facial
contour measured by LS, and have shown that the method
was accurate in measuring simulated volume change up to
5 mL. The magnitude of facial volume change that occurs
in HIV-related LA patients over time has not been
specifically quantified in any published study. However,
based on magnetic resonance imaging (MRI) measurements
of facial fat volume that show a mean difference between
patients with severe LA and controls of approximately
15 mL in the cheek [14], and the experience from cosmetic
surgery where immediate changes are noticeable in
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Fig. 2 Comparison of estimated volume change by laser scans with
real volume of plasticine added to the mannequin cheek (mL). The
solid line represents the regression line of the differences in
estimated and real volumes against the average of the estimated and
real volumes. The dotted line and the broken lines represent the
mean and 95% confidence limits respectively of the mean difference
between the estimated and real volumes.
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changes are unlikely to exceed the range that we have
tested. In most cases, volume changes are likely to be very
small and technically demanding to any technique. LS may
be one of the few methods with the precision necessary to
detect such small changes.
The method we developed focused on estimating volume
change in a defined area of the cheek, as facial appearance
suggests that most of the severe changes of LA occur in the
cheek area [4,15,16]. The circular area that we have defined
might not fully capture all the changes of LA in a particular
patient, and thus there may be an underestimate of the actual
volume change. However, it is unlikely that changes would
occur in other areas without involving the cheek and hence
volume change in the cheek is likely to be representative of
volume changes elsewhere. Measurement of facial fat
volume has shown a similar extent of fat loss in cheek and
temporal areas [14]. The use of a standardized area helps to
optimize the reproducibility, which would diminish if a
larger and less well-defined area were to be used.
In longitudinal studies that attempt to detect small
changes, reproducibility of measurements is critical.
Variability is a result of a combination of measurement
artefact and random biological variation over time. The
coefficient of variation of 5.8% for repeated measurements
of simulated volume change and the intraclass correlation
coefficients of 0.81 and 0.76 for within-day and between-
day measurements of human subjects indicate that the
method has good reproducibility. These good results are
probably attributable in part to the efforts made to
standardize the scan conditions, the method of image
manipulation for analysis, and the area used for calculation
of volume change. The relative contribution of each of
these is not known. The only published study in which LS
was applied to measurement of lipodystrophy showed
slightly greater variability (higher standard deviation) of
intermeasurement differences than we found in our study,
but the approach used to standardize scan analysis was not
reported in sufficient detail to allow speculation on the
reasons for the differences [17]. Careful standardization of
the position in which the subject is scanned may be
particularly important. One study of a portable LS in
healthy subjects found good reproducibility (standard
deviation for interscan differences of 0.2 mL) when the
position of the subject for scanning was carefully
standardized, but additional errors of up to 7.6 mL when
the subject position was varied [18].
MRI and spiral computer tomography (CT) can provide
accurate and direct measurement of facial fat volume in
non-HIV-infected patients [19,20]. A study in which
volume of facial fat was measured by MRI in HIV-infected
patients demonstrated that the method was reproducible
and detected the difference in volume between LA and
control patients [14]. One study in which single-slice CT
was used to measure facial adipose tissue area in HIV-
infected patients with LA showed reasonable reproduci-
bility, and that even patients with mild LA could be
distinguished from controls [21]. However, these imaging
methods are of limited use for repeated measurements in
longitudinal clinical studies because of their inconveni-
ence, cost and (in the case of CT) radiation exposure.
Sonographic measurement of facial fat at a single point on
the cheek has also been shown to be reproducible and able
to detect reduced facial fat in patients with LA [22]. The
advantages of sonography are that it is rapid, safe and
relatively economical, although it is unclear to what extent
the results are technique dependent and vary between
observers. Similarly, LS also is attractive because of its
simplicity and ease of use, and because it offers quick and
accurate results with no patient contact or radiation. The
combined cost of the scanner and software, currently
exceeding US$25 000, may limit widespread use. Although
scanning conditions need to be carefully standardized (see
above), this is simple to do and does not require specific
training. However, some training would be needed for
individuals performing scan analysis, but in a research
setting the raw data could easily be transmitted for
centralized analysis. It is important to note that the method
measures change in surface contour, and volume is
extrapolated from that. Therefore the results may be
affected by other factors that alter facial contour, such as
dehydration and variation of human facial expression. The
estimated volume change may comprise changes in muscle
as well as fat. Furthermore, the performance of the method
with the use of facial fillers is uncertain as the contour of
these may alter over time without true change in volume,
and the method is not suitable for patients with beards or
moustaches. Although it is unlikely that this technique is
going to be useful in the detection and assessment of facial
LA over short-term follow-up in individual patients in the
clinic setting, with careful standardization of the method it
may prove very useful for measuring changes in groups of
patients in clinical trials and large cohort studies.
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L ipodystrophy is a common complication ofthe treatment of HIV disease. It is usuallycharacterized by lipoatrophy in the face,
arms, and legs and sometimes by fat accumulation
in central areas.1 The disfigurement of facial
lipoatrophy may lower patients’ self-esteem,
discourage some patients from continuing their
antiretroviral therapy, or lead them to seek surgical
correction.2,3 Studies have found that regimens
containing stavudine are associated with a greater
risk of lipodystrophy than regimens containing
other nucleoside reverse transcriptase inhibitors
(NRTIs),4–7 and replacing stavudine with abacavir,
zidovudine, or tenofovir resulted in improvement
in stavudine-induced lipodystrophy.6–9 It has been
suggested that lipoatrophy and other delayed side-
effects of stavudine such as peripheral neuropathy
may occur as a result of inhibition of DNA
polymerase γ, which is involved in mitochondrial
DNA synthesis,10,11 or may result from other
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processes such as disruption of expression of lipid
metabolism genes and increased rates of adipocyte
apoptosis.6,12–14
Stavudine extended release formulation
(stavudine ER) was designed to allow once-daily
dosing and thereby improve adherence to therapy.
Studies have shown that stavudine ER has compa-
rable efficacy, tolerability, and safety to the
stavudine immediate release (IR) formulation.15,16
The ER formulation is continuously released
throughout the gastrointestinal tract, resulting in
Background: Lipoatrophy is a frequent complication of chronic stavudine therapy.
Stavudine extended release formulation (stavudine ER) gives lower peak and higher
trough levels than the immediate release formulation (stavudine IR), and we
hypothesized that the lower peak might result in less lipoatrophy. Objective: To
compare the rate of peripheral lipoatrophy between patients taking stavudine ER
and stavudine IR. Method: Body composition was measured by dual energy X-ray
absorptiometry (DEXA) every 6 months for 18 months in 29 patients taking either
stavudine ER or IR as part of a randomized controlled clinical trial. Results: DEXA fat
measurements did not differ between the ER and IR groups at baseline, after a
median of 32 months on stavudine-containing treatment. Over the 18 months of
follow-up in the whole cohort limb fat decreased by a mean of 0.29 ± 0.50 kg (p =
.01) and leg fat percent decreased by a mean of 1.23% ± 1.92% (p = .001), whereas
trunk fat and trunk-to-limb fat percent ratio did not change significantly. There was
no significant difference between the ER and IR groups in the rate of change of any
of the fat parameters. At study completion, the proportion of patients with clinical
lipodystrophy was similar in the stavudine ER and stavudine IR groups (67% and
64%, respectively; p = .893). Conclusion: Stavudine ER does not appear to cause
less peripheral lipoatrophy. Key words: extended release, immediate release,
lipodystrophy, stavudine
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lower peak levels (approximately half that of IR)
and higher trough levels (2–3 times higher than IR)
and a similar area under the curve.10 It is possible
that lower peak levels might be associated with less
inhibition of DNA polymerase γ or less adipocyte
apoptosis and lowered incidence and severity of
the associated toxicities. Clinical studies have sug-
gested that that the risk of peripheral neuropathy is
dose-dependent17,18 and that the risk of peripheral
neuropathy may be less in patients taking
stavudine ER.19 Initial data based on spontaneous
clinical reports have also suggested that the inci-
dence of lipoatrophy may be lower in patients tak-
ing stavudine ER.19
The aim of this study was to test the hypothesis
that stavudine ER is associated with less
lipoatrophy than stavudine IR using objective mea-




Patients were recruited from a cohort of patents
attending Tan Tock Seng Hospital, Singapore, who
were participating in a randomized controlled
clinical trial of stavudine IR versus ER formulation
(BMS AI455-99 followed by rollover study BMS
AI455-110). AI455-099 and AI455-110 were multi-
national, randomized, placebo-controlled studies
in treatment-naïve HIV-infected patients to com-
pare the efficacy and safety between stavudine ER
and IR formulation in combination with
lamivudine and efavirenz. The patients at this site
had all commenced therapy between September
2000 and August 2001. All patients who remained
on their randomized allocation of study therapy in
May 2003 were offered enrollment in this lipodys-
trophy study. Patients were required to give addi-
tional written informed consent for participation in
the lipodystrophy study, and the protocol was ap-
proved by the Ethics Committee of Tan Tock Seng
Hospital.
Study Method
Clinical features of lipodystrophy were assessed
at lipodystrophy study entry and 18 months later
using a standard patient-completed questionnaire
supplemented by physician assessment. The physi-
cian was independent of the clinical trial and was
unaware of the patient’s stavudine formulation.
Patients were classified as having lipodystrophy if
they reported at least one feature of peripheral fat
loss or central fat accumulation that was confirmed
by the physician as being of at least moderate se-
verity (i.e., readily noticeable).1
Whole body composition was measured in each
patient at lipodystrophy study entry and at subse-
quent 6-month intervals to 18 months using a Lu-
nar DEXA machine (Lunar Prodigy, software ver-
sion 6.50; Lunar Corporation, Madison, Wisconsin,
USA). Patients were scanned wearing light indoor
clothing. Scans were performed and analyzed by
the same operator following manufacturer’s in-
structions and using standardized cutoffs for re-
gional measurements. The machine was regularly
calibrated for quality control purposes according
to procedures specified by the manufacturer. The
coefficient of variation of DEXA fat measurements
at our center is 1.8%, 3.1%, and 3.2% for limb fat,
trunk fat, and total fat, respectively (previously
established by repeated measurements of three
healthy and five HIV-infected volunteers).
Statistical Analyses
Body composition parameters were compared
between the two groups at study entry by two
sample t tests, and the proportion of patients with
clinical lipodystrophy was compared between the
two groups by Fisher’s exact test. Changes in body
fat and the effects of stavudine formulations over
the 18 months of follow-up were assessed by re-
peated measurement analysis of variance. All p val-
ues were two sided, and a p value of less than .05
was considered to be statistically significant. The
data analyses were performed with SPSS 13.0 soft-
ware (Chicago, Illinois, USA).
RESULTS
Of the 38 patients who had been originally en-
rolled in BMS AI455-099 at this site, eight (four on
ER, four on IR) had been withdrawn prior to com-
mencement of the lipodystrophy study. The rea-
sons for withdrawal were unrelated to lipodystro-
phy (pregnancy in two patients, tuberculosis in one
patient, treatment failure due to drug resistance in
one patient, inadequate compliance in one patient,
and lost to follow-up in three patients), and none of
the patients who were withdrawn were considered
EFFECT OF STAVUDINE ER AND IR ON LIPODYSTROPHY • YANG ET AL. 339
to have evidence of lipodystrophy by the study
investigators at the time of withdrawal. All 30 pa-
tients who were still taking study drug (15 on ER,
15 on IR) consented to participate in the lipodystro-
phy study, and 29 of them continued to take study
medication and had serial DEXA scans throughout
the subsequent 18 months of follow-up. One pa-
tient taking IR stopped antiviral treatment and de-
faulted follow-up after 12 months and is not in-
cluded in the analysis. The clinical trial had been
unblinded prior to the start of the lipodystrophy
study, but all patients continued to take (as open-
label) the formulation of stavudine to which they
had originally been randomized. The mean time on
this treatment was 32 months at the time of entry to
the lipodystrophy study.
The demographic and clinical characteristics
were similar between the two groups at lipodystro-
phy study entry. Overall, 77% of the patients were
of Chinese race (the remainder being Indian or
Malay), and 76% were male. CD4 counts were
greater than 300 cells/mm3 and viral load was less
than 400 copies/mL in all patients. Total and re-
gional measurements of body fat did not differ
between the two groups at entry to the lipodystro-
phy study (see Table 1). The mean values of leg fat
percent (14.9% and 14.2% for ER and IR groups,
respectively) and trunk-to-limb fat percent ratio
(1.96 and 1.83 for ER and IR groups, respectively)
were similar to mean values for patients with mod-
erate to severe lipodystrophy measured at our cen-
ter and those reported in other studies.1,20 Six pa-
tients (43%) in the ER group (peripheral fat loss 6,
mixed 2) and 8 patients (53%) in the IR group (pe-
Table 1. Demographic, clinical characteristics, and DEXA fat measurement of all patients at the time of
study entry and fat changes over 18 months follow-up
ER (n = 15) IR (n = 14) p p
At the time of study entry
Age, years 042.5 ± 10.8 42.4 ± 8.80 .969
Male sex, n 10 11 .682
Stage C disease, n 01 01 .617
Duration of HIV infection, months 047.8 ± 14.8 50.3 ± 24.8 .745
CD4 count, cells/mL 534.0 ± 129.2 571.6 ± 222.7 .579
Viral load >50 copies/mL, n 03 01 .169
Duration of ART, months 030.5 ± 3.60 32.4 ± 4.60 .216
Height, cm 166.7 ± 7.10 165.6 ± 8.700 .709
Weight, kg 0059.3 ± 7.700 61.6 ± 6.60 .389
BMI, kg/m2 0021.3 ± 2.400 22.6 ± 2.60 .202
Total fat, kg 010.99 ± 5.890 11.03 ± 5.340 .982
Limb fat, kg 003.49 ± 2.600 3.57 ± 2.23 .933
Trunk fat, kg 007.02 ± 3.280 6.99 ± 3.08 .976
Leg fat % 014.95 ± 10.71 14.20 ± 9.120 .841
Trunk-to-limb fat % ratio 001.96 ± 0.760 1.83 ± 0.45 .582
p p
Fat change at 18 months  (time trend)  (drug groups)
Total fat, kg −0.57 ± 1.29 −0.32  ± 1.72 .341 .845
Limb fat, kg −0.38 ± 0.45 −0.19  ± 0.55 .010 .353
Trunk fat, kg −0.16 ± 0.98 −0.13  ± 1.22 .823 .952
Leg fat % −1.67 ± 1.87 −0.76  ± 1.94 .001 .246
Trunk-to-limb fat % ratio −0.11 ± 0.31 −0.05  ± 0.26 .159 .446
Note: Means between ER and IR patients at study entry were compared by 2 sample t tests and proportions were compared by
Fisher’s exact text. P (time trend) is for the trend of body composition changes over 18 months follow-up assessed using repeated
measurement analysis. ER = stavudine extended release; IR = stavudine immediate release; ART = antiretroviral therapy; BMI = body
mass index.
340 HIV CLINICAL TRIALS • 6/6 • NOV-DEC 2005
ripheral fat loss 8, mixed 4) had clinical evidence of
lipodystrophy at study entry (p = .573).
Over the 18 months of follow-up in the whole
cohort, limb fat decreased by a mean of 0.29 ± 0.50 kg
(p = .01), and leg fat percent decreased by a mean of
1.23% ± 1.92% (p = .001), whereas trunk fat and
trunk-to-limb fat percent ratio did not change sig-
nificantly (see Table 1 and Figure 1). There was no
significant difference between the ER and IR groups
in the rate of change of any of the fat parameters
(data not shown). At the end of follow-up, a total of
10 patients (67%) in the ER group (peripheral fat loss
10, mixed 3) and 9 patients (64%) in the IR group
(peripheral fat loss 9, mixed 4) had clinical lipodys-
trophy of at least moderate grade (p = .893).
DISCUSSION
The findings of this study do not support the
hypothesis that stavudine ER is associated with
less lipoatrophy than stavudine IR. Mean values of
DEXA parameters were similar at study entry (af-
ter 32 months of stavudine treatment). Although
there was clear evidence of ongoing peripheral fat
loss during the 18 months of follow-up, the rate of
change was similar in the two groups. The DEXA
measurements and the proportion of patients with
a clinical assessment of lipoatrophy of at least mod-
erate degree was similar in the two groups of pa-
tients at the end of the study, after approximately 4
years on treatment with either ER or IR formula-
tion. Our findings contrast with data from the over-
all study population of 934 patients participating in
BMS AI455-110, which suggested that the inci-
dence of lipoatrophy was lower in the ER com-
pared to the IR group (8% vs. 14%, respectively; p =
.004) after a median follow-up of 114 weeks.19,21
However, those estimates were based on spontane-
ous reporting of events (rather than systematic
evaluation for the presence or absence of lipodys-
Figure 1. Changes in leg fat % over 18 months of follow-up in patients treated with stavudine ER and stavudine IR.
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trophy) and did not include independent clinical
assessment and objective DEXA measurements
and may therefore have underestimated the fre-
quency of lipodystrophy or have been affected by
between-group bias. The proportion of patients
with lipodystrophy that we observed is consistent
with that noted in earlier studies, that is, 63% of
patients taking stavudine after a median duration
of 14 months.5,22 Although stavudine ER will not be
made commercially available,23 our results remain
of more general interest in understanding the
pathogenesis of lipoatrophy. The fact that we did
not see a difference between the groups in this
study suggests that the aetiology of lipoatrophy is
unrelated to either peak or trough levels of
stavudine, since these clearly differ between for-
mulations and would have been expected to mani-
fest in between-group differences in patients after
sustained therapy for several years. It remains pos-
sible that reducing the area under the curve and
total exposure to stavudine by using a lower over-
all dose might be associated with less lipoatrophy,
but this may run the risk of inadequate treatment
and development of resistance.
We were not able to perform DEXA scans prior
to the start of antiretroviral therapy in these pa-
tients and are therefore unable to determine
whether there was a difference between groups
during the first 2 years of treatment or in time to
onset of lipoatrophy. Lipoatrophy commences in
the first year following initiation of antiretroviral
therapy,24 and indeed the DEXA fat parameters
in our patients at study entry were similar to
those in patients with moderate to severe lipod-
ystrophy, suggesting that substantial changes
had already occurred.1,20 However, given that the
proportion of patients with clinical lipoatrophy
and DEXA-measured fat values were similar at
study entry in the two groups, it is unlikely that
there were major differences between ER and IR
in the rate of fat loss in the early period following
antiretroviral therapy initiation. Furthermore, as
therapy is required indefinitely, minor differ-
ences between the effects of the formulations in
the first few years would be of little relevance to
the success and acceptability of long-term
therapy. A strength of our study is that patients
were randomly allocated to treatment groups
and retained their allocation throughout follow-
up, and the rate of loss to follow-up was rela-
tively low. The study was performed at a single
site, with a single DEXA machine, and scans were
analyzed by the same operator, thereby avoiding
the confounding differences that may occur in
multicenter studies.25 The study provides objective
DEXA data after a relatively long period of treat-
ment with study drug, which is somewhat unusual
for clinical trials.
Aside from the issues of stavudine formulation,
our results are important for demonstrating that
lipoatrophy is common in a cohort of Asian pa-
tients taking a stavudine-containing regime and
that the process continues even after more than 4
years of therapy. Although stavudine is no longer
favored in first-line regimens in Western countries,
it is being used increasingly in many developing
countries because generic manufacture is relatively
economical and it is available as a convenient fixed
dose combination with lamivudine and
nevirapine. This combination is being advocated
by WHO as part of the “3 by 5 initiative.”26 Our
study is the first to quantify the extensive and on-
going fat loss that occurs with long-term use of
stavudine in a group of Asian patients. It highlights
the adverse consequences and potential for severe
stigmatization that may be seen in the future with
the widespread adoption of stavudine-containing
regimens in developing countries where there are
limited options for second-line therapy or treat-
ment changes to avoid or ameliorate toxicity.
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